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Clinicopathological studies suggest that Alzheimer’s disease (AD) pathology 
begins to appear ~10-20 years before the resulting cognitive impairment draws medical 
attention. Biomarkers that can detect AD pathology in its early stages and predict 
dementia onset and progression would, therefore, be invaluable for patient care and 
efficient clinical trial design. To discover such biomarkers, we measured AD-associated 
changes in the cerebrospinal fluid (CSF) using an unbiased proteomics approach (two-
dimensional difference gel electrophoresis with liquid chromatography tandem mass 
spectrometry). From this, we identified 47 proteins that differed in abundance between 
cognitively normal (Clinical Dementia Rating [CDR] 0) and mildly demented (CDR 1) 
subjects. To validate these findings, we measured a subset of the identified candidate 
biomarkers by enzyme linked immunosorbent assay (ELISA); promising candidates in 
this discovery cohort (N=47) were further evaluated by ELISA in a larger validation CSF 
cohort (N=292) that contained an additional very mildly demented (CDR 0.5) group. 
Levels of four novel biomarkers were significantly altered in AD, and Receiver-operating 
characteristic (ROC) analyses using a stepwise logistic regression model identified 
optimal panels containing these markers that distinguished CDR 0 from CDR>0 (tau, 
YKL-40, NCAM) and CDR 1 from CDR<1 (tau, chromogranin-A, carnosinase-I). Plasma 
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levels of the most promising marker, YKL-40, were also found to be increased in CDR 
0.5 and 1 groups and to correlate with CSF levels. Importantly, the CSF YKL-40/Aβ42 
ratio predicted risk of developing cognitive impairment (CDR 0 to CDR>0 conversion) as 
well as the best CSF biomarkers identified to date, tau/Aβ42 and p-tau181/Aβ42. 
Additionally, YKL-40 immunoreactivity was observed within astrocytes near a subset of 
amyloid plaques, implicating YKL-40 in the neuroinflammatory response to Aβ 
deposition. Utilizing an alternative, targeted proteomics approach to identify novel 
biomarkers, 333 CSF samples were evaluated for levels of 190 analytes using a 
multiplexed Luminex platform. The mean concentrations of 37 analytes were found to 
differ between CDR 0 and CDR>0 participants. ROC and statistical machine learning 
algorithms identified novel biomarker panels that improved upon the ability of the current 
best biomarkers to discriminate very mildly demented from cognitively normal 
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Chapter 1. Introduction and Perspective 
 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder estimated 
to affect 5.3 million Americans (1). Although the course of AD can be heterogeneous 
among individuals, there are many common symptoms. The initial symptom is often a 
problem remembering recently learned information, which is frequently mistaken or 
dismissed as a normal effect of aging. Disease progression is characterized by a gradual 
decline in memory, orientation, comprehension, and judgment, and in advanced stages, 
a loss of control over bodily functions. The mean life expectancy following diagnosis is 
approximately 5 years (2, 3). For most individuals with “late-onset” AD, symptoms first 
begin after age 65; however, the onset is generally gradual and insidious, leading to a 
delay between symptom onset and diagnosis of approximately 3 years (4). It has been 
reported that episodic memory deficits may be detectable by clinical testing up to six 
years before diagnosis (5). While the majority of AD cases are late-onset, an estimated 
200,000 Americans have “early-onset” AD, when symptoms present before age 65 (1). 
Many of these cases are familial (FAD), caused by autosomal dominant mutations in one 
of three genes: amyloid precursor protein (APP) gene on chromosome 21 (6), presenilin 
1 (PSEN1) gene on chromosome 14 (7), and presenilin 2 (PSEN2) gene on 
chromosome 1 (8). Studies of the proteins encoded by these genes has furthered our 
understanding of the molecular mechanisms contributing to AD.  A hallmark 
neuropathological feature of AD is the accumulation of extracellular amyloid plaques 
consisting primarily of amyloid-beta (Aβ). Aβ is a 38-43 amino acid peptide that is 
generated by sequential cleavage of APP by β-secretase and γ-secretase; PSEN1 and 
PSEN2 encode components of the γ-secretase enzyme complex (9). PSEN1 mutations 
account for the majority of FAD cases, and most PSEN1, PSEN2, and APP mutations 
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are thought to affect APP processing such that Aβ production, and specifically the more 
amyloidogenic form, Aβ42, is increased. Additionally, individuals with Down Syndrome 
(trisomy 21) have three copies of APP, resulting in increased Aβ production and early-
onset AD neuropathology (10). These findings, as well as evidence that Aβ is the 
primary component of plaques and that cerebrospinal fluid (CSF) Aβ42 levels are altered 
in AD, point to a critical role for Aβ in AD pathogenesis. The ‘amyloid cascade 
hypothesis’ holds that increased Aβ production and accumulation, whether early in life 
from genetic causes or later in life in sporadic cases, leads to Aβ oligomerization, 
aggregation, and deposition in plaques, eventually resulting in synaptic and neuronal 
injury, glial activation, and ultimately dementia (11). This hypothesis has garnered much 
support, however, additional work is needed to fill in missing details and perceived 
weaknesses in the theory, in particular, improved understanding of the relationship 
between amyloid and neurofibrillary tangle pathology and neurodegeneration (discussed 
more in depth below), and the identity of the specific Aβ species that drives 
neurotoxicity. 
For late-onset AD, the chromosome 19 gene encoding apolipoprotein E (APOE) 
has been the most extensively investigated, and until recently the only consistently 
replicated, genetic risk factor for AD (12). ApoE has three isoforms, ε2, ε3, and ε4, that 
differ by cysteine-arginine interchanges at position 112 and 158 (13). The ApoE ε4 allele 
has been shown to be a risk factor for late-onset familial and sporadic AD (14), as well 
as early-onset sporadic cases (15, 16). This risk is dose dependent, with homozygotes 
at increased risk of disease and demonstrating earlier age of onset than heterozygotes 
or those not carrying an ε4 allele (12, 14, 17). Conversely, it appears that the ε2 allele 
may have a protective effect against the development of late-onset AD (18, 19), and 
confer a reduced risk of cognitive decline among cognitively normal elderly (20-22). 
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Furthermore, ε2 carriers may have less amyloid and tangle pathology (23-26) than non-
carriers. Additionally, ApoE has been found to bind Aβ and to co-localize with cerebral 
amyloid deposits in AD and cerebral amyloid angiopathy (CAA) (27, 28). Although the 
ApoE ε4 allele is a well validated risk factor for late-onset AD, there are likely other 
genetic or environmental factors involved in determining risk, as ε4 is neither necessary 
nor sufficient for disease. Indeed, recent genome wide association studies utilizing many 
thousands of individuals have identified apolipoprotein J (CLU) and phosphatidylinositol 
binding clathrin assembly protein (PICALM) (29-31) as late-onset AD susceptibility loci. 
The mechanisms underlying these associations remain to be determined. 
In addition to amyloid plaques, a second neuropathological hallmark of AD is the 
accumulation of intracellular neurofibrillary tangles composed primarily of 
hyperphosphorylated tau (p-tau). Abnormal tau deposition is seen in other conditions as 
well, including frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), 
and corticobasal degeneration (CBD), and while no AD-causing mutations have been 
identified in the tau gene (MAPT), tau mutations have been linked with FTD with 
parkinsonism, suggesting that tau dysfunction can cause neurodegeneration (32, 33). 
The tau protein is known to bind and stabilize microtubules, and the abnormal 
phosphorylation of tau that occurs in AD is thought to lead to microtubule disassembly, 
disruption of intracellular trafficking, and ultimately neuronal dysfunction (34-36). 
Additionally, abnormal tau aggregates into insoluble paired helical filaments (PHFs) 
which are hypothesized to further compromise neuronal function by occluding axons and 
dendrites (35). Whether phosphorylation of tau drives PHF formation (by preventing tau 
binding to microtubules and thus increasing the availability of unbound tau to aggregate) 
or whether the converse is true, is unknown. Additionally, understanding of the 
regulation of tau phosphorylation is largely incomplete. Importantly, the mechanistic 
relationships between Aβ, tau, and brain degeneration remain unclear. According to the 
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amyloid cascade hypothesis, Aβ is the primary driver of AD pathogenesis, with tau 
hyperphosphorylation and neurofibrillary tangle formation downstream events. 
Unresolved details of the amyloid cascade hypothesis, along with the relatively 
disappointing results of clinical trials with amyloid-reducing therapeutic agents, have, in 
part, lent support to a ‘tau hypothesis’ of AD neurodegeneration; additionally, proponents 
point to mutations in tau that can cause FTD with parkinsonism, a dementing illness 
lacking amyloid pathology, as demonstrating that tau dysregulation alone is sufficient to 
cause neurodegenerative disease. Some in the field have proposed a “dual pathway” 
model postulating that Aβ and tau pathologies are two distinct processes linked by a 
common upstream driver, rather than representing a linear cascade (37). What this 
upstream driver or the signaling pathways between amyloid and tau pathologies may be 
are unknown. A ‘modified’ amyloid cascade hypothesis such that Aβ accumulation 
initiates the disease process, but a secondary event (i.e. tau dysfunction) is necessary 
for subsequent neurodegeneration is also possible, and is supported by a number of 
animal studies of AD (38-41). 
The pattern and chronology of plaque and tangle formation have been well 
studied, and their associations with clinical symptoms have been investigated in an 
attempt to clarify these unresolved relationships. While various findings have 
strengthened one hypothesized model of AD neurodegeneration or another, no model 
has yet been conclusively proven. For example, individuals with APP mutations 
eventually develop plaques and tangles, appearing to suggest that Aβ dysregulation 
causes or leads to tangle formation. Studies by Braak and Braak have suggested that 
neurofibrillary tangles, initially appearing in the limbic system and later spreading to the 
cortex, appear before plaques, which first appear in the frontal cortex and later spread to 
other regions (42, 43). However, subsequent clinicopathologic studies have strongly 
suggested that amyloid plaques, followed by neurofibrillary tangles, begin to accumulate 
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~10-15 years prior to cognitive decline, and that synaptic and neuronal loss best 
correlate with symptom onset (44, 45). A number of studies have shown that dementia 
severity better correlates with the number of neurofibrillary tangles than the amount of 
plaque deposition (46-50), leading some to hypothesize that neurofibrillary tangles are 
the key factor in the development of dementing symptoms. More recently, however, it 
has been suggested that neurofibrillary tangles and amyloid plaques are not the 
neurotoxic agents, but rather the final pathological hallmarks of the disease. Instead, 
oligomers of Aβ (51-53) or tau forms intermediate between normally phosphorylated 
protein and hyperphosphorylated fibrils are thought to represent the neurotoxic species 
(54). It should also be noted that AD pathophysiology does not consist solely of plaque 
and tangle formation, and that microglia and reactive astrocytes can be found 
surrounding plaques (55), implicating neuroinflammatory processes in the pathogenesis 
of AD as well. Whether neuroinflammation is a cause or result of AD is still a matter of 
debate. The interplay between amyloid, tau, and neurodegeneration is an area that 
clearly warrants further study, as the mechanisms of neurodegeneration in AD will have 
important consequences on the time course of biomarker changes that reflect these 
pathologies, as well as ultimately the choice of therapeutic targets.  
 
 
The need for biomarkers of AD 
Reports that the number of AD deaths increased by 46% from 2000-2006, and 
that the number of affected is projected to nearly triple by 2050 have made the ability to 
accurately and reliably diagnose AD in its earliest stages a public health priority (56). 
Currently, the diagnosis of ‘possible’ or ‘probable’ AD is based on clinical assessment 
using the criteria of the National Institute of Neurological and Communicative Diseases 
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and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
and Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV-TR) (57), 
with definitive diagnosis only at autopsy, or rarely, by biopsy. Although the antemortem 
clinical diagnosis of AD is quite accurate in specialized centers, diagnostic accuracy is 
much lower in non-specialized settings, and, in particular, sensitivity at milder disease 
stages can be limited (58-63). Thus, measures to increase diagnostic sensitivity and 
specificity will be extremely important for improving early detection, and consequently 
early intervention. Biomarkers may be useful in this regard, facilitating a more accurate 
and earlier diagnosis, which is particularly difficult given that there are no signs or 
symptoms unique to AD. The Biomarkers Definitions Working Group of the National 
Institutes of Health defines a biomarker as “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (64).  
Importantly, biomarkers may allow for the identification of individuals with 
preclinical AD (those with AD neuropathology but do not yet display clinical symptoms) 
(44, 45, 65-67). Identifying individuals in the preclinical stage is particularly critical, as 
this group will likely have the greatest chance of benefit from targeted therapeutics. 
Biomarkers may be instrumental not only in the diagnosis of disease cases, but may aid 
in following disease progression and response to treatment as well. In these capacities, 
biomarkers will be crucial for the design and evaluation of clinical trials of disease-
modifying therapies by helping to reduce sample size, reduce trial duration, and evaluate 
treatment efficacy. Finally, biomarkers are key in advancing our understanding of the 
pathophysiology of AD, which in turn has important implications for patient diagnosis and 
treatment. 
Recognizing the potential utility of biomarkers and the significant scientific 
advances in the AD field over the last two decades, recent efforts have aimed at revising 
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the current diagnostic criteria, which, although widely used, have not been modified 
since their publication in 1984. This effort, led by scientific workgroups convened by the 
National Institute on Aging and the Alzheimer’s Association, seeks to update diagnostic 
criteria for “Alzheimer’s dementia (AD)” and “mild cognitive impairment (MCI),” and 
proposes a new diagnostic category of “preclinical AD.” As such, the proposed 
guidelines for dementia diagnosis are largely unchanged (cognitive and behavioral 
symptoms with a progressive decline), with amendments refining “probable” and 
“possible” AD categories to reflect advances in our understanding of other dementing 
illnesses, the genetics of AD, and biomarkers. To increase the confidence of AD 
diagnosis, biomarkers such as CSF Aβ42, tau, p-tau, and imaging measures of brain 
amyloid, metabolism, and atrophy (discussed more in depth in the relevant sections 
below) are included in the proposed criteria; however, as there are not yet standardized 
practices to measure and evaluate these biomarkers, and formal cut-offs have not been 
identified, biomarkers will not be required for clinical diagnosis, and are mainly intended 
for use in research settings.  
The proposal also includes revised criteria for the diagnosis of MCI, or the 
symptomatic pre-dementia phase of AD. This stage is analogous to a Clinical Dementia 
Rating (CDR) of 0.5 in the CDR scale developed at Washington University to rate 
cognitive and functional performance (68-70).  Using informant-based clinical 
assessment, this scale rates  individuals as cognitively normal (CDR 0), very mildly 
impaired (CDR 0.5), mildly demented (CDR 1), moderately demented (CDR 2), or 
severely demented (CDR 3) (68). The overall CDR score is based on scores in six 
functional domains (memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care); these six subscores can be combined 
into a “sum of boxes” score. Under the newly proposed diagnostic criteria (similar to the 
old criteria),the clinical diagnosis of MCI is based on impairment in one or more cognitive 
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domains, but an absence of dementia, and a maintenance of independence of function 
in daily life. The domains in which the cognitive impairment can occur have been 
widened to include, in addition to memory, executive functioning, language, visuospatial 
skills, and attentional control. Additionally, as with the proposed AD criteria, biomarker 
measurements are also included to increase the confidence of diagnosis, although they 
are intended primarily for research purposes. A major focus of MCI research has been 
the identification of individuals who will progress to AD from those who will not, as this 
stage allows for an opportunity for medical intervention to perhaps prevent or postpone 
disease progression. Annual conversion rates from MCI to AD are approximately 15% in 
clinic groups, with somewhat lower rates reported for community-recruited groups (71); 
this difference has been attributed to an increased baseline functional impairment of 
clinic versus community MCI groups, as measured by the CDR sum of boxes, which 
most strongly associated with future progression to AD (71). As many here at 
Washington University use the CDR scale, it is important to note that some individuals 
receiving a CDR of 0.5 are insufficiently impaired to meet MCI criteria, and can be 
considered “pre-MCI” (70). A study of these pre-MCI individuals reported a median 
survival time of ~8 years, approximately twice as long as that of the CDR 0.5 individuals 
that met MCI criteria (~4 years, comparable to annual rates of progression of MCI to AD 
of ~15%) (70). These pre-MCI and MCI subjects were followed longitudinally, and 91% 
and 90%, respectively, of those that came to autopsy had a neuropathological diagnosis 
of AD. These results, along with others, strongly suggest that MCI usually represents 
early-stage AD, and that an even earlier stage of AD, pre-MCI, can be identified (69, 70). 
Criteria for a new diagnostic category, preclinical AD, are also among the 
changes recommended by the working group. These preclinical criteria are intended for 
use only in research settings at this point, to determine the measures that will best 
define the preclinical stage. This ‘pre-symptomatic stage’ of AD, during which amyloid 
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plaques and neurofibrillary tangles being to appear, is estimated to be ~10-15 years in 
duration (44, 66, 72), thus providing a lengthy and crucial period for intervention with 
disease modifying therapies. Although AD was first described approximately 100 years 
ago, there are currently no treatments to prevent or delay disease onset or halt disease 
progression. While over 100 compounds have been tested as potential therapeutics, 
only five medications are Food and Drug Administration-approved for AD, all of which 
provide only modest symptomatic benefit of short duration (memantine, donepezil, 
galantamine, rivastigmine, and tacrine) (73). The largely disappointing clinical trial 
results are thought to be due, in part, to the focus of many trials on already symptomatic 
study subjects. It is likely that therapies applied earlier in the disease process 
(preclinically) will have the greatest opportunity for disease modification, and indeed, 
animal studies of AD have suggested that therapies may have limited benefit once 
neurodegeneration has begun. The hope is that the application of these new preclinical 
criteria, which rely on biomarkers for diagnosis, will facilitate characterization of the 
sequences of events and the biological players of preclinical AD, and allow for the 
development of standardized biomarkers panels or biomarker modalities to enhance our 
ability to identify preclinical individuals and predict clinical course. Ultimately these 
findings will have important consequences on drug development and the enrollment and 
end-point monitoring of clinical trials.  
The road to biomarker discovery has not been a simple one, however. The 
identification of reliable biomarkers has been hindered by the fact that patient 
classification relies on clinical diagnosis which is not always accurate, especially at early 
stages of the disease. Requiring postmortem confirmation of disease diagnosis has 
been impractical for biomarker studies. Moreover, control groups are likely to contain 
individuals with preclinical AD, resulting in the observation of overlapping biomarkers 
values between clinical groups. Limited patient sample size and lack of adjustment for 
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covariates such as age, gender, ethnicity, and APOE genotype have restricted the 
application of results from some studies to the general population. In addition, protocols 
for sample collection, preparation, and analysis often vary widely between labs, thus 
contributing additional methodological variability. Adopting standardized protocols for 
clinical assessment, sample analysis, and statistical evaluation would help overcome 
many of these shortcomings. Because of these concerns regarding biomarker discovery, 
it is essential that new candidate biomarkers are validated in independent cohorts by 
multiple groups, a practice not uniformly applied, and even when carried out, often fails 
to replicate initial findings. Given the multifactorial nature of the disease, it is unlikely that 
a single biomarker will meet the needs for clinical diagnosis, while a panel of biomarkers 
may offer improved sensitivity, specificity, and positive and negative predictive values. 
These limitations not withstanding, many potential biomarkers have been identified, the 
most promising of which are discussed below. Furthermore, to appropriately evaluate a 
newly discovered candidate biomarker, its performance must be considered in the 
context of existing biomarkers, and, more broadly, the current standing of the AD 
biomarker field.  
 
The State of the AD Biomarker Field: Fluid Biomarkers 
 
APP   
The postmortem pathological diagnosis of an AD brain relies on the presence of 
amyloid plaques and neurofibrillary tangles. These amyloid plaques are composed of 
Aβ, a proteolytic fragment of APP. If altered proteolytic processing of APP underlies AD, 
then measures of APP or its derivatives may serve as diagnostic markers. Indeed, early 
studies (74-76) observed increased levels of APP and/or its secreted forms in the CSF 
of AD individuals. However, later studies have reported decreased (77-79) or unchanged 
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(80) levels. Several studies of AD patients have shown reduced CSF levels of sAPPα, 
the soluble product released following α-secretase cleavage of APP (79, 81, 82). These 
inconsistent findings between studies do not currently support a consensus of CSF APP 
being a useful biomarker for AD.  
 
Aβ  
 APP is expressed in all tissues and undergoes cleavage by β-secretase to 
release the ectodomain (sAPP-β) and subsequent cleavage by γ-secretase to release 
Aβ peptides of 38-43 amino acids (83). Because Aβ42 is the dominant component of the 
plaques seen in AD (84), many groups have investigated the use of Aβ42, as well as the 
other Aβ species, as a diagnostic tool. The amount of total Aβ in CSF is not well 
correlated with the diagnosis of AD (85-87). The majority of studies have demonstrated a 
decrease in CSF Aβ42 in AD patients (88-112); however, there have been a few reports 
of increased (113) or unchanged (114, 115) CSF Aβ42. These discrepancies are likely 
due to differing methods for assaying samples and varying sizes and selection criteria of 
patient groups, as well as the inclusion of subjects at different points along the disease 
spectrum.  
A number of studies have investigated CSF Aβ42 levels in conjunction with those 
of CSF tau, the primary protein component of neurofibrillary tangles. In perhaps the most 
comprehensive analysis of Aβ42 and tau levels to date, Sunderland et al. (2003) 
assayed 131 AD patients and 72 controls, and performed a meta-analysis of 17 studies 
of CSF Aβ42 levels and 34 studies of CSF tau levels. In their own patient cohort, they 
observed significantly lower mean levels of CSF Aβ42 and higher mean levels of CSF 
tau in AD compared to controls, but with significant overlap between the clinical groups. 
The results of the meta-analysis mimicked their findings, with an effect size, or difference 
in levels between AD and controls, of 1.53 for Aβ42 and 1.31 for tau. Several interesting 
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correlations were observed, with tau correlating with the age of the controls but not of 
the AD individuals, with gender for the AD group only, and with CDR and Mini Mental 
State Examination (MMSE) scores, but not duration of illness. While the meta-analysis 
did not reveal correlations between CSF Aβ42 and any score of dementia severity, age, 
or duration of illness, there have been studies reporting a negative correlation between 
Aβ42 and dementia severity (91, 113, 116) and APOE ε4 dosage (91). 
In addition to distinguishing AD from non-demented subjects, decreased levels of 
CSF Aβ42 have been shown to be predictive of future dementia in MCI patients (109, 
117-124). Additionally, significantly decreased CSF Aβ42 has been observed in patients 
with very mild dementia (MMSE score of 25-28 or CDR 0.5) (99, 107). 
In the evaluation of a candidate biomarker, it is important to consider whether the 
particular marker makes sense in the context of the disease pathophysiology. Mouse 
models of AD have shown that CSF Aβ levels are related to the amount of plaque in the 
brain (125), and human studies have shown that increased neocortical and hippocampal 
plaque burden and cerebral amyloid angiopathy is highly associated with decreased 
Aβ42 in postmortem CSF (126). These finding were furthered by Fagan and colleagues 
(107, 127) who reported an inverse relationship between CSF Aβ42 and in vivo plaque 
load using the amyloid imaging agent Pittsburgh Compound B (PIB) in living humans, 
supporting the authors’ claim that plaques can function as “sinks” or “traps” of Aβ42, thus 
decreasing the amount of Aβ42 clearing the brain to the CSF. Other groups have 
likewise proposed this hypothesis (88, 116). Recent studies have shown that low CSF 
Aβ42 levels can identify PIB-positive individuals with excellent sensitivity and specificity 
(128). 
One possible limitation of Aβ42 for AD diagnosis is that decreased CSF levels 
have also been reported in FTD (93, 96, 129), Creutzfeldt-Jakob disease (CJD) (95, 105, 
110), Gerstmann-Straussler-Scheinker syndrome (105), amyotrophic lateral sclerosis 
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(102), multiple system atrophy (130), and dementia with Lewy bodies (DLB) (97, 105, 
112). While a number of studies have shown that CSF Aβ40 is unchanged in AD (98, 
106, 107, 115, 131), the ratio of Aβ42 to Aβ40, rather than either marker alone, has 
been shown to better distinguish AD subjects from controls or other dementias and to 
identify incipient AD in MCI subjects (92, 106, 122, 131). The ratios of other markers 
such as tau/Aβ (114), tau/Aβ42 (104, 107, 114, 132), and p-tau181/Aβ42 (107, 133) 
have similarly been used, and the CSF tau/Aβ42 ratio has been shown to predict future 
dementia in non-demented cohorts (107, 132).  
While CSF is thought to more closely reflect what is happening in the brain, CSF 
is not as routinely obtained as blood. However, there has been little consensus among 
studies as to the relationship between plasma/serum Aβ and AD. Although increased 
plasma Aβ40 (98) and decreased plasma Aβ42 (134) have been reported in AD, most 
groups have reported no difference in plasma/serum Aβ levels between sporadic AD and 
controls (Aβ40 and Aβ42 (135-137), Aβ42 (98, 112)). In contrast, plasma Aβ42 has been 
found to be increased (137, 138) and Aβ40 decreased (137) in individuals with 
autosomal dominant, disease-causing mutations (FAD). Based on the findings of an 
early study showing that plasma Aβ42 is elevated in presymptomatic FAD mutation 
carriers (138), a recent study investigated the levels of Aβ42 in asymptomatic first-
degree relatives of individuals with sporadic AD (139). As compared to controls, plasma 
Aβ42 was found to be elevated in these subjects, irrespective of APOE ε4 or FAD 
mutations. The difference between the Aβ42 levels of the sporadic AD relatives and the 
controls was small, however (14.2±0.6 and 12.3±0.7 pM, respectively). It will be 
interesting to see in longitudinal studies whether these relatives with increased plasma 
Aβ42 will go on to develop AD dementia.  
Interestingly, several longitudinal studies have found that baseline plasma Aβ42 
levels were significantly higher in those cognitively normal individuals who later 
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progressed to AD as compared to those who did not (140, 141). Additionally, Aβ42 
levels were observed to decrease over time in these individuals, suggesting that while 
plasma Aβ42 does not appear to be a suitable diagnostic marker for AD, it may be a 
marker for progression (141). Similarly, a case-cohort study originating from the 
prospective Rotterdam study found that increased plasma Aβ40 at baseline was 
associated with an increased risk of AD as well as vascular dementia (VD) (142). 
In a recent study however, any association between plasma Aβ40 or Aβ42 levels 
and progression from a normal to demented state was lost after adjusting for covariates 
such as age, cognitive status, cerebrovascular disease, APOE genotype, and kidney 
function (143). A longitudinal study of MCI patients similarly found no correlation 
between plasma Aβ species and progression to AD (124). This lack of association 
between plasma Aβ and AD is further supported by studies demonstrating that plasma 
Aβ40 and Aβ42 levels do not reflect brain Aβ or plaque levels (127, 144) and that there 
is no correlation between plasma and CSF Aβ42 or Aβ40 (112, 145). 
A number of anti-amyloid clinical trials have aimed at slowing or stopping the 
progression of AD by decreasing the production of Aβ42, increasing its clearance, or 
reducing its aggregation. Based on animal findings that immunization with Aβ42 resulted 
in a reduction of brain amyloid plaques (146-148), a phase II clinical trial (AN1792, Elan 
Pharmaceuticals) was undertaken to study its effects in humans. While this trial was cut 
short because of an increased incidence of meningoencephalitis (6%), a six-year follow 
up of a subset of the patients from the earlier phase I trial revealed a positive effect on 
Aβ load and plaque removal, but no effect on cognitive function, clinical outcomes, or 
long-term survival (149). These findings would appear to cast doubt on the role of Aβ as 
a culprit in the cognitive decline characteristic of AD. The lack of correlation between 
amyloid load and dementia severity in clinicopathologic studies would also support this 
assertion (46, 48). It may be, however, that the immunizations were given too late in the 
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disease course, as the subjects already had mild to moderate dementia at the time of 
treatment. Studies have shown that brain accumulation of Aβ probably begins 10-20 
years before clinical manifestations of the disease (150) and can be imaged with a 
variety of compounds that can be visualized by PET (see below), and that this 
accumulation may drive the further accumulation of tau aggregates within vulnerable 
neurons (151). If the phase I demented patients already had substantial tau aggregation, 
it may be that the reduction of Aβ could not reverse the tau-associated pathology and 
consequent cognitive impairment once the disease had progressed too far. However, 
this does not mean that Aβ is not promising as a candidate biomarker of AD. A repertoire 
of biomarkers that can serve as surrogates of underlying disease pathology would be 
crucial to our diagnosing of AD and following its progression and response to treatment. 
While it has been shown that CSF Aβ42 reflects the presence of brain amyloid, the 
results from the Aβ42 immunization trial suggests that tau is likely a better marker to 
follow for clinical disease progression and clinical outcomes. However, since Aβ load in 
the brain does not correlate with dementia severity (46, 48), and some degree of tangle 
pathology can exist in older individuals in the absence of dementia (152-154), accurate 
diagnosis and prognosis of AD will most likely require a combination of these pathology-
related biomarkers. 
 
Tau and p-tau 
The other pathognomic feature of AD brains, neurofibrillary tangles, is composed 
primarily of tau, a microtubule-associated protein which has similarly been extensively 
investigated as a biomarker. Many studies have demonstrated that CSF tau is increased 
in AD patients (88, 91, 92, 96, 97, 100-102, 107, 114, 131, 155-181). 
In AD, tau undergoes abnormal hyperphosphorylation at many sites, and enzyme 
linked immunosorbent assays (ELISAs) have been developed to recognize various 
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phosphorylated epitopes such as threonine 181 and 231 and serine 199, 235, 396, and 
404 (119). As a result of this aberrant phosphorylation, tau is likely unable to bind and 
stabilize microtubules, possibly leading to axon degeneration (34). Thus, one possibility 
is that the increase in tau seen in AD CSF is due to the release of tau from degenerating 
neurons and its subsequent diffusion into the CSF (34). With the disturbance of the tau-
microtubule binding equilibrium, there is a resulting increase in the cytosolic unbound 
levels of tau as well, and consequently an increased likelihood of protein misfolding and 
subsequent aggregation as neuropil threads in dystrophic neurites and as neurofibrillary 
tangles (182). While these observations suggest possible reasons for the increases in 
CSF tau level in AD, it is still unclear what is really happening in the human disease 
process. 
Given that increased levels of CSF tau can be seen in other neurodegenerative 
disorders, in particular FTD, stroke, corticobasal degeneration, and CJD (179), studies 
have begun looking specifically at phosphorylated forms of tau as diagnostic markers for 
AD.  Hampel et al., (2004) compared the accuracy of CSF p-tau231, p-tau181, and p-
tau199 in discriminating AD from FTD, LBD, VD, and normal controls. They found that all 
three proteins were significantly increased in AD as compared to the other groups; 
however, the discriminative power of each differed, with p-tau231 providing for the 
greatest discrimination between AD and non-AD, AD and controls, and AD and FTD 
(183). The combined use of the three p-tau markers did not provide further 
discrimination. Several studies have similarly shown that p-tau231 and p-tau199 can 
discriminate AD from other neurological disorders with sensitivities and specificities in 
the 80%-90% range (179, 184, 185).  
While Aβ42 and tau are specific markers of AD pathogenesis, a recent study has 
investigated the utility of a marker of neuronal death in the diagnosis of AD (186). 
Visinin-like protein 1 (VLP-1), a cytoplasmic calcium sensor protein that is thought to 
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leak from damaged or dying neurons, was found to be significantly increased in the CSF 
of AD subjects compared to controls (186). Although VLP-1 is not specific to AD and 
indeed was originally studied in ischemic stroke subjects (187), the combined use of 
Aβ42, tau, p-tau, and VLP-1 resulted in increased diagnostic accuracy over any marker 
individually. Several studies have shown little correlation between amyloid plaque load 
and dementia severity (46, 48), thus VLP-1, in representing the end-result of the disease 
process, may provide a better reflection of the degree of dementia. In this preliminary 
study, only VLP-1 and none of the other markers were found to correlate with MMSE 
(186). Clearly additional study of this molecule as a potential biomarker of cell death in 
AD is warranted. 
 
Isoprostanes 
Growing evidence suggests that oxidative damage may be important in the 
pathogenesis of AD. Isoprostanes, the end-products of lipid peroxidation, and in 
particular F2-isoprostanes, have been found to be increased in the frontal and temporal 
cortex of AD compared to control and FTD brains, suggesting a specificity for AD (188, 
189). Studies have shown F2-isoprostanes to be increased in postmortem ventricular 
CSF obtained from autopsy-verified AD cases (188, 190, 191), as well as in antemortem 
CSF from individuals diagnosed with AD dementia (192-196). CSF F2-isoprostanes 
have been shown to correlate with brain weight, degree of cortical atrophy, and Braak 
stage (191), as well as with dementia severity (193). Several longitudinal studies have 
shown that over one and two year periods, CSF F2-isoprostanes increase in MCI and 
AD patients (197, 198), and that baseline measurements could distinguish individuals 
that progress to MCI or AD from stable patients with 100% accuracy (199). Moreover, 
the addition of isoprostane measurements to conventional memory testing or to 
quantitative MRI measurements resulted in increased diagnostic and prognostic power 
18 
 
Chapter 1. Introduction and Perspective 
(199), although confirmation awaits investigation in a larger number of subjects. 
Preclinical FAD mutation carriers have been shown to have increased CSF F2-
isoprostanes as well, indicating this marker may be suitable for both sporadic and 
familial AD (200). Using a combined analysis of CSF Aβ42, tau, and F2-isoprostanes, 
Montine et al., (2001) were able to diagnose AD with a sensitivity of 84% and specificity 
of 89%, while Grossman et al., (2005) were able to classify 88.5% of patients in 
accordance with their clinical or autopsy diagnosis using this same panel of markers 
(194, 196).  
Results have been less consistent in regard to peripheral F2-isoprostanes, with 
reports of increased (193, 195) or unchanged (201-203) plasma levels in AD subjects. 
Similarly, urinary F2-isoprostanes have been reported to be increased (193, 195, 204) or 
unchanged (203, 205). The discrepancies concerning peripheral F2-isoprostanes may 
be due to differences in patient selection criteria between studies, as smoking and other 
conditions associated with oxidative stress, such as cardiovascular disease and 
diabetes, can significantly alter isoprostane levels (206).  
 
Inflammatory markers 
In addition to the classical pathological features of amyloid plaques and 
neurofibrillary tangles, AD brains display characteristics of inflammatory processes 
(207). One well investigated potential inflammatory marker of AD is α1-antichymotrypsin 
(ACT), a serine protease inhibitor that is a colocalized with Aβ in senile/neuritic plaques 
(208-210). Early studies of ACT yielded inconsistent results, however, with reports of 
increased ACT in AD serum (211-214) or CSF (211, 215), along with reports of 
unchanged ACT in AD serum (216-218) or CSF (216-218). Four recent studies, 
however, have attempted to put this controversy to rest by measuring ACT levels in 
large groups of subjects or by including additional controls. In a study of 196 subjects, 
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Licastro et al., (2000) observed increased plasma ACT in AD, and found that levels 
inversely correlated with cognitive performance (219). DeKosky et al., (2003) carried out 
a large study of 516 individuals, with AD subjects stratified by dementia severity, and 
similarly found that plasma and CSF ACT were increased, and that levels were 
negatively correlated with dementia severity. This study excluded those with systemic 
inflammatory diseases or those taking anti-inflammatory medications in an attempt to 
achieve as homogeneous a study population as possible. Additionally, plasma ACT was 
significantly increased in women compared to men, perhaps further explaining why 
previous studies which did not control for gender yielded inconsistent results (220). In a 
700+ subject case-cohort study within the Rotterdam Study, Engelhart et al., (2004) 
found that increased plasma ACT was associated with increased risk of dementia, AD, 
and VD (221). A proteomics approach, using gel electrophoresis and mass 
spectrometry, identified CSF ACT as being increased in AD versus control subjects, and 
findings were confirmed by ELISA validation in an independent sample set (222). CSF 
ACT has also been found to be elevated in DLB, suggesting that it may be ineffective in 
distinguishing between these types of dementia (223). 
The results of cytokine studies in AD have been highly inconsistent between 
groups. For example, in AD patients, CSF interleukin-6 (IL-6) has been found to be 
increased (224-227), decreased (228), or unchanged (218, 229-233). Plasma/serum IL-6 
results have similarly been mixed (218, 219, 233-236). Additionally, whereas one report 
was able to discriminate VD from AD by CSF IL-6 levels (237), another found no 
difference in levels between VD and AD (225). These inconsistencies have been 
mimicked in studies of IL-6 receptor, Gp130, IL-1β, TNF-α, and Hp 2-1 (238). Moreover, 
most studies have either found no concentration differences or have yielded inconsistent 
results for additional cytokines such as IL-4, IL-8, IL-10, interferon-gamma, complement 
C1q, and TGF-β (206). These discrepancies between studies are likely due to several 
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significant obstacles to the evaluation of cytokines in AD. Cytokine concentration can 
vary considerably over time, and can be influenced by an individual's genetic 
background, comorbid systemic inflammatory processes, usage of anti-inflammatory 
drugs, and exposure to environmental factors (206). Moreover, many studies use 
subjects with neurological diseases other than AD, such as Parkinson’s disease (PD) or 
amyotrophic lateral sclerosis, as “controls.” 
 
Proteomics 
A newer field of biomarker studies is moving away from the traditional approach 
of investigating levels of a single, or several, candidate biomarkers that have been 
implicated in the pathogenesis of AD, and is instead focusing on nonbiased profiling of 
human fluids in an attempt to discover novel biomarkers. As a result of improved mass 
spectrometry (MS) techniques, proteomics has emerged as a powerful tool for biomarker 
discovery. General methods in proteomic studies typically include protein separation by 
two-dimensional gel electrophoresis (2-DE), liquid chromatography (LC), or protein-chip 
arrays, followed by MS or tandem MS and database searches to determine protein 
identity. Recent efforts to characterize the human CSF proteome have identified 2,594 
proteins (239) and 563 peptide forms and 798 proteins (240) using a combination of 
approaches. By comparing the differences in protein expression levels between AD and 
control CSF samples, a number of studies have identified potential diagnostic markers 
(222, 241-246). Additional studies have carried out similar analyses in samples with 
postmortem neuropathological confirmation of AD (247, 248), with one study analyzing 
both antemortem and postmortem CSF from the same individuals (249).  
An important concern of proteomics-based discovery, however, is that often 
candidate markers identified by a study are not confirmed in independent studies or by 
other more quantitative methods, indicating the present need for large validation studies 
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and corroboration by alternative techniques. While some candidates have been 
identified in multiple studies, and furthermore have been implicated in AD pathogenesis, 
they unfortunately have not been consistently reported as increased or decreased in AD 
CSF. For example, β2-microglobulin, the constant component of the class I major 
histocompatibility complex, has been identified as increased (241, 243, 245, 250, 251) 
and decreased (242) in AD CSF. Although the function of this protein is still unclear, it 
has been shown to accumulate as amyloid fibrils in dialysis patients (252, 253). 
Similarly, transthyretin has been reported to be increased (241, 245) and decreased 
(242, 248) in AD CSF. Transthyretin is thought to play a role in AD pathogenesis, as it 
can form complexes with Aβ40 and Aβ42, thus preventing Aβ aggregation (254-256) and 
has been shown to negatively correlate with senile plaque abundance (257). Such 
inconsistencies in proteomics studies, and more broadly in biomarker studies in general, 
may be due in part to post-translational modifications, such as limited proteolysis in vivo, 
which are often overlooked.   
Many studies have formulated panels of proteins for the discrimination of AD 
from normal cohorts. For example, using 2-DE and tandem MS, Finehout et al., (2006) 
formulated a panel of 23 protein spots that differentiated AD from non-AD with a 
sensitivity and specificity of 94% and a predictive error rate of 5.9%; the application of 
this same panel to a validation cohort yielded only slightly lower values (258). Moreover, 
panels derived from proteomic studies have been shown to differentiate AD, PD, and 
DBL with high accuracy (246) and to distinguish MCI individuals who progress to AD 
from those who do not (250). Interestingly, the fragment signature of four CSF Aβ 
species (Aβ1-16, Aβ1-33, Aβ1-39, and Aβ1-42) as analyzed by Matrix-Assisted Laser 
Desorption/Ionization Time-of-Flight MS (MALDI-TOF-MS) has been shown to 
discriminate AD with a sensitivity of 89%, specificity of 83%, and accuracy of 86% (259). 
Finally, the few proteomic studies of serum (260, 261) and of plasma (262, 263) have 
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similarly yielded markers to distinguish AD from controls, as well as to predict 




Neuroimaging techniques have increasingly been used to detect brain changes 
associated with AD, and thus have potential as markers of disease progression, 
monitors of therapeutic effects, and predictors of future dementia prior to symptoms. 
Because the work in this thesis is focused on the search for novel fluid biomarkers of 
AD, only a cursory overview of imaging biomarkers will be provided. In brief, in MCI and 
AD subjects, computed tomography (CT) (264, 265) and magnetic resonance imaging 
(MRI) (266-274) have been used to examine atrophy and rates of atrophy of various 
brain regions, functional MRI (fMRI) has been used to examine abnormalities in brain 
activation (275-285), and single photon emission computed tomography (SPECT) (264, 
286-298) and arterial spin-labeling perfusion MR imaging (ASL-MRI) (299-301) have 
been used to study cerebral perfusion defects. Additionally, positron emission 
tomography (PET) has been employed in a number of AD studies to examine regional 
cerebral metabolism using 18F-2-deoxy-2-fluoro-D-glucose (CMRglc using FDG-PET) 
(302-310).  
While currently definitive diagnosis of AD relies on the presence of amyloid 
plaques and neurofibrillary tangles at autopsy, recent studies have aimed at developing 
compounds for the in vivo imaging of AD pathology. These imaging markers would allow 
for earlier diagnosis, as AD pathology precedes the onset of dementia symptoms by 
many years, and for the monitoring of disease progression and treatment efficacy. 
Promising results have been reported using PET and SPECT ligands for microglial 
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activation ([11C](R)-PK11195 (311, 312) and [18F] FE-DAA1106 (313, 314)). Over the last 
decade there has been intense interest in PET ligands for brain amyloid, with a 
proliferation of new tracers in development or clinical trials, such as 11C-SB-13 (315) and 
11C-BF-227 (316). The most widely studied amyloid imaging agent, and the one used in 
our studies, is 11C-labelled Pittsburgh compound B, or PIB, (2-[4’-(methylamino)phenyl]-
6-hydrobenzothiazole) (317). In AD, PIB retention is increased in the frontal, parietal, 
temporal, and occipital cortices and striatum, and studies have consistently shown that 
nearly all patients diagnosed with Alzheimer’s dementia test PIB-positive (318-321). 
Additionally, the difference in ligand binding in AD versus controls is significantly more 
robust with PIB than with another commonly used amyloid agent, FDDNP (318, 322-
324). PIB binding correlates well with rates of cerebral atrophy in AD (325) and with 
reductions in CSF Aβ42 (107, 127, 326). PIB retention is also inversely correlated with 
cerebral glucose metabolism as determined by FDG-PET (318), and is strongly related 
to the degree of memory impairment in MCI and AD (321, 326, 327). Interestingly, a 
longitudinal study of early AD patients taking cholinesterase inhibitors and/or the NMDA 
antagonist memantine, found that PIB retention did not change over a two-year follow-
up, although cortical rCMRGlc decreased (327). This suggests that amyloid burden 
reaches a maximum early in the course of the disease, and indeed, several studies have 
found that certain MCI individuals have PIB uptake in the AD range (320, 321, 328, 329). 
Importantly, studies have also shown PIB uptake in a proportion of non-demented 
elderly controls (127, 320, 321, 329-332), consistent with the known presence of AD 
pathology in a subset of cognitively normal elders as reported in clinicopathological 
studies (66, 150). These subjects presumably have preclinical AD, but longitudinal 
studies are needed to test this hypothesis before we can conclude that brain amyloid 
has adequate sensitivity and specificity to be considered a viable biomarker of AD. PIB 
retention is not observed in frontotemporal lobar degeneration (FTLD) (319), or more 
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specifically in its two syndromes FTD (320) and semantic dementia (333). PIB imaging 
has also been shown to detect cerebral amyloid angiopathy (334, 335).  
Although as of 2008 PIB had been used in over 40 centers and 3000 individuals 
world-wide (336), the 20 minute half-life of 11C has restricted its use to centers with an 
on-site or near-by cyclotron. For this reason, recent efforts have focused on the 
development of tracers labeled with 18F, which has a half-life of 110 minutes, facilitating 
wider use in research and clinical centers. The first 18F labeled tracer, [18F]FDDNP (324, 
337-339), has quickly been followed up by the development at least nine other agents, 
including 18F-BAY94-9172 (340), 18F-GE-067 (341), 18F-3’-F-PIB (342), and, the 
particularly promising 18F-AV-45. Currently in FDA phase III clinical trials, 18F-AV-45 has 
shown favorable brain uptake and amyloid imaging properties (343-345). As detailed 
above, the great wealth of information on imaging with 11C-PIB suggest that it may be 
suitable for confirming the diagnosis of AD in symptomatic cases as well as for 
identifying individuals in the pre-symptomatic (preclinical) stage of the disease. It is 
likely, however, that in the future, more than one amyloid imaging agent will be 
commonly used, and the goal of the many 18F studies currently underway is to find a 
tracer with diagnostic potential similar to that of PIB. No imaging agent selective for tau 
aggregates has yet been developed, and such a discovery would be a major contribution 
to the field.   
 
Conclusions 
The urgent need for biomarkers is reflected by the growing number of studies 
aimed at investigating biomarker candidates for AD. Additionally, the biomarker field has 
experienced a renewed level of enthusiasm due to better reagent availability and novel 
methods for the assessment of a variety of fluid and imaging measures. Apart from brain 
25 
 
Chapter 1. Introduction and Perspective 
biopsy or brain catheterization, the collection of CSF and blood is the most direct and 
convenient approach to studying the biochemical changes that occur in the brain. Thus, 
these fluids, and in particular CSF because of its direct contact with the extracellular 
space of the brain, have been considered attractive sources for potential AD biomarkers. 
Indeed, the biomarkers showing the greatest promise to date for use in AD diagnosis 
and prognosis are CSF Aβ42, tau, and p-tau. CSF Aβ42 and tau have proved 
particularly promising as potential predictors of cognitive decline in individuals with very 
mild cognitive impairment, as well as future dementia in non-demented cohorts. Further, 
low levels of CSF Aβ42 are an excellent marker for the presence of neocortical amyloid 
deposition, in the presence or absence of dementia. Whether brain amyloid invariably 
leads to subsequent dementia in AD is currently being studied. Even for these promising 
biomarkers, however, there is substantial overlap in levels between AD and control 
groups, and specificity against other dementing conditions is not perfect. Consequently, 
there remains a need for supplemental biomarkers to improve diagnostic accuracy. More 
rigorous investigation of fluid markers of inflammation, oxidative damage, and neuronal 
death is clearly warranted. Plasma and serum analytes have been notoriously difficult to 
interrogate, with most studies yielding inconsistent results. Improved techniques have 
lead to the emergence of the field of proteomics as a powerful tool for biomarker 
discovery; however, an important concern of proteomics-based discovery is that 
candidate markers are often not confirmed in independent cohorts or by other 
quantitative methods, indicating the present need for large validation studies and 
corroboration by alternative techniques. Additionally, most proteomics studies, and the 
majority of biomarker studies in general, have compared AD subjects to non-demented 
controls (or controls with other neurological conditions), thus identifying biomarkers with 
diagnostic potential, but not necessarily prognostic potential. Moreover, of the studies 
aimed at discovering prognostic biomarkers, most have focused on the search for 
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markers predictive of progression from MCI to AD. Increased efforts should be placed on 
identifying markers predictive of the progression from cognitive normalcy or preclinical 
stages to AD, as emerging therapies will best preserve cognitive function if at-risk 
individuals are identified in these earlier stages. These studies will require large, well-
characterized, longitudinally followed cohorts of study participants, which are not readily 
available for evaluation at most institutions. The development of imaging agents for the 
detection of AD pathologies (amyloid, tangles, activated microglia) has propelled the 
imaging field forward, with PIB-PET imaging emerging as a particularly promising 
modality. Given the multifactorial nature of the disease, it is unlikely that a single 
biomarker will meet the needs for clinical diagnosis, while a panel of biomarkers and 
multiple biomarker modalities, especially combinations of fluid and imaging measures, 
may offer improved sensitivity, specificity, and positive and negative predictive values. 
Biomarkers may be useful in the more immediate future in clinical trial design and 
enrollment, allowing for the enrichment of study populations for characteristics of 
interest, thereby helping to reduce sample size, trial duration, and ultimately cost. 
Finally, newly identified candidate biomarkers, regardless of whether they outperform 
existing biomarkers, may advance our understanding of the pathophysiology of the 
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Figure 1.1. Hypothesized relationship between the time course of changes in 
various biomarkers in relation to the neuropathology and clinical changes of 
Alzheimer's disease. The stages of AD (bar) are associated with the formation of 
amyloid plaques (red line), the accumulation of neurofibrillary tangles (blue line), and 
synaptic and neuronal loss (green line). The most promising biomarker candidates are 
listed (in chronological order from bottom to top) according to the earliest stage of the 
pathological process they appear to demonstrate utility. For example, genetic variations 
(SNPs) may be considered biomarkers that allow the earliest possible estimation of risk, 
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Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic 
resonance imaging; PET, positron-emission tomography; fMRI, functional magnetic 
resonance imaging; PIB, Pittsburgh compound B; SNPs, single nucleotide 
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Table 1.1. Select candidate fluid and imaging biomarkers of AD 
Fluid Biomarker Observations References 
CSF Aβ42 1. Decreased in AD 
2. Decreased in subjects with brain 
amyloid deposition 
3. Predictive of conversion from 
MCI to AD   
1. (88-112, 346) 
2. (107, 127) 
3. (109, 117, 118, 120-124) 
Plasma and/or serum Aβ42 1. Mostly no difference in AD 
2. Mixed results for prediction of 
conversion from normal or MCI to 
AD 
3. Increased in FAD 
1. (98, 107, 112, 134-137) 
2. (124, 139-141, 143) 
3. (137, 138) 
CSF Aβ40 No difference in AD (90, 98, 106, 107) 
Plasma and/or serum Aβ40 1. Mostly no difference in AD 
2. Mixed results for prediction of 
conversion from normal or MCI to 
AD 
3. Decreased in FAD 
1. (98, 107, 135-137) 
2. (124, 142, 143) 
3. (137)  
CSF Ratio of Aβ species 
(Aβ40 and Aβ42) 
1. Discriminates AD from normals 
2. Predictive of conversion from 
MCI to AD 
1. (92, 106, 107, 131) 
2. (122) 
CSF Tau Increased in AD (88, 91, 92, 96, 97, 100-102, 
107, 110, 114, 131, 155-181, 
346) 
CSF p-tau231, p-tau181, and 
p-tau199 
1. Increased in AD 
2. p-tau231 predicts conversion 
from MCI to AD 
1. (107, 179, 183, 184, 347) 
2. (185) 
CSF Ratio of tau species to 
Aβ42 
1. Increased in AD 
2. Predictive of conversion from 
normal to MCI or AD 
3. Predictive of conversion from 
MCI to AD 
1. (104, 107, 114, 133) 
2. (107, 132) 
3. (348) 
CSF Isoprostanes 1. Increased in postmortem and 
antemortem AD CSF 
2. Predictive of conversion from 
normal to MCI or AD 
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3. Increased in preclinical FAD 
mutation carriers 
Plasma Isoprostanes Results mixed, showing increase or 
no change in AD 
(193, 195, 201-203) 
Urine Isoprostanes Results mixed, showing increase or 
no change in AD 
(193, 195, 203-205) 
CSF α1-antichymotrypsin Results mixed, showing increase or 
no change in AD 
(211, 215-217, 218 , 222, 349) 
Plasma and/or serum α1-antichymotrypsin 1. Results mixed, showing increase 
or no change in AD 
2. Predictive of AD risk 
1. (211-214, 216-219, 349) 
2. (221) 
CSF Interleukin-6 Results mixed (218, 224-233) 
Plasma Interleukin-6 Results mixed, showing increase or 
no change in AD 
(218, 219, 233-236) 
CSF and plasma Various markers of 
inflammation 
Results mixed For reviews see (206, 238) 
    
Imaging Modality  Observations References 
CT and MRI  1. Regional atrophy in AD 
2. Whole brain atrophy in AD 
3. Predictive of conversion from 
MCI to AD 
4. Predictive of conversion from 
normal to MCI 
1. (264, 265, 350) 
2. (269, 270) 
3. (266-268) 
4. (351) 
fMRI  1. Altered activation in AD 
2. Altered activation in MCI 
1. (275-278, 283, 352)  
2. (276, 277, 279-284) 
FDG-PET  1. Regional hypometabolism in AD 
2. Predictive of conversion from 
MCI to AD 
1. (302-305) 
2. (306-310) 
H215O-PET  Altered activation in AD (353-356) 
SPECT  1. Altered regional cerebral 
perfusion in AD 
2. Predictive of conversion from 
MCI to AD 
1. (264, 286-291) 
2. (292-297)  
ASL-MRI and contrast-based MRI  Regional hypoperfusion in AD  (288, 299-301, 357, 358) 
FDDNP-PET  Increased retention in AD and MCI (324, 337, 339) 
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PIB-PET  1. Increased retention in AD brain 
2. Increased retention in a subset 
of cognitively normal controls 
3. Detects cerebral amyloid 
angiopathy 
1.(318-321) 
2. (127, 320, 321, 329-332) 
3. (334, 335) 
Other PET amyloid imaging agents: 11C-SB-13, 
11C-BF-227, 18F-BAY94-9172, 18F-GE-067, 18F-
3’-F-PIB, 18F-AV-45 
 Increased retention in AD brain (315, 316, 340-345) 
PET markers of microglial activation: [11C](R)-
PK11195 and [123I]iodo-PK11195 




AD, indicates clinical diagnosis of dementia believed to be Alzheimer’s disease, not necessarily autopsy confirmed AD cases.  
FAD, Familial Alzheimer’s disease 
MCI, mild cognitive impairment 
 
 
Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early 












Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging 

















Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early 
Alzheimer’s Disease Using Proteomics and ELISA 
 
Summary 
Background:  Ideally, disease modifying therapies for Alzheimer disease (AD) will be 
applied during the ‘preclinical’ stage (amyloid plaques and other pathology present with 
cognition intact) before severe neuronal damage occurs, or at the first signs of cognitive 
impairment. Developing and judiciously administering such therapies will require 
biomarker panels that can identify early AD pathology, classify disease stage, monitor 
pathological progression, and predict cognitive decline. To discover biomarkers that may 
be useful in this regard, we measured AD-associated changes in the cerebrospinal fluid 
(CSF) proteome. 
Methods and Findings:  Because low CSF Aβ42 has previously been shown to 
correlate with amyloid deposition, we selected N=24 CSF samples from cognitively 
normal controls (Clinical Dementia Rating [CDR] 0) with high Aβ42 concentrations and 
N=24 from mild "probable AD” (CDR 1) individuals with low Aβ42. Samples were 
subjected to two-dimensional difference-in-gel electrophoresis (2D-DIGE). Gel features 
(protein spots) with intensity differences between groups were excised, trypsinized, and 
subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS) for protein 
identification. Within 119 gel features that differed in intensity between groups, 47 
proteins were identified.  Eleven candidate biomarker proteins were re-evaluated by 
enzyme-linked immunosorbent assays (ELISA) in the original sample set.  Six of these 
candidates (NrCAM, YKL-40, chromogranin A, carnosinase I, transthyretin, cystatin C) 
showed  differences in mean concentration between the original AD (CDR 1) and control 
(CDR 0) groups, and were subsequently evaluated in a larger independent sample set 
(N=292) that included CDR 0, CDR 0.5 (very mild dementia), and CDR 1 groups. CSF 
Aβ42, tau and phospho-tau (p-tau181) concentrations were also measured. In this larger 
34 
 
Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early 
Alzheimer’s Disease Using Proteomics and ELISA 
independent sample set, CDR 0 and CDR>0 groups showed significant differences in 
mean concentrations of YKL-40, carnosinase I, tau, p-tau181 and Aβ42; CDR 1 and 
CDR <1 groups showed differences in carnosinase I, chromogranin A, NrCAM, tau, p-
tau181 and Aβ42.  Receiver-operating characteristic curve analyses using a stepwise 
logistic regression model yielded optimal biomarker panels to distinguish CDR 0 from 
CDR>0 (tau, YKL-40, NrCAM) and CDR 1 from CDR<1 (tau, chromogranin A, 
carnosinase I) with areas under the curve of 0.90 (0.85 - 0.94 95% confidence interval 
[CI]) and 0.88 (0.81 – 0.94 CI), respectively. 
Conclusions:  This study identifies 47 candidate CSF protein biomarkers for mild AD, 
and, in an independent cohort, demonstrates that four of these biomarkers (NrCAM, 
YKL-40, chromogranin A, carnosinase I), can improve upon the ability of CSF Aβ42 and 
tau to define three clinical categories: cognitive normalcy (CDR 0), very mild dementia 
(CDR 0.5), and mild dementia (CDR 1).  Building upon findings from previous studies of 
Aβ42 and tau (107, 121, 132), this panel of six CSF biomarkers might aid subject 
categorization into six early clinicopathological stages (cognitively normal without 
amyloid, cognitively normal with amyloid [‘preclinical AD’], cognitively normal at 
increased risk for dementia [‘at risk’], very mild symptomatic AD, very mild symptomatic 
AD at increased risk of short-term progression, and mild symptomatic AD).  Use of such 
a biomarker panel to guide subject enrollment might increase the efficiency of clinical 
trials.  Future study of these candidate CSF biomarkers will be required to evaluate their 
potential for monitoring disease progression and for distinguishing AD from other 






Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early 
Alzheimer’s Disease Using Proteomics and ELISA 
 
Introduction  
Clinicopathological studies suggest that Alzheimer’s disease (AD) pathology 
(amyloid plaque formation, followed by gliosis and neurofibrillary tangle formation) 
begins 10-15 years before the onset of very mild dementia (43, 44). This period of 
‘preclinical AD’ could provide an opportunity for disease modifying therapies to prevent 
or forestall the synaptic and neuronal losses associated with cognitive impairment (65, 
67, 359). However, before such interventions can be developed and judiciously 
administered, accurate tools must be in place to diagnose and monitor the 
pathophysiological condition of individuals with preclinical AD and very early stage AD 
dementia. Clinical examination cannot detect preclinical disease or measure cellular and 
molecular changes within the brain, and has limited accuracy when diagnosing the very 
earliest symptomatic stages of AD. Therefore, there is an urgent need to identify 
biomarkers that can do so.  Because its composition is rapidly and directly influenced by 
the brain, the cerebrospinal fluid (CSF) proteome represents an appealing source for 
such biomarkers. 
 Indeed, a few CSF proteins have already shown promise as diagnostic 
biomarkers for clinical AD (Dementia of the Alzheimer Type [DAT]) and even preclinical 
AD.  Lower mean levels of CSF Aβ42 and higher mean levels of tau and phosphorylated 
tau can distinguish groups with DAT from cognitively normal controls (88, 346).  
Unfortunately, value ranges for each biomarker show substantial overlap between 
groups.  
 Recently, using PET imaging with Pittsburgh Compound B (PIB) to measure 
brain amyloid in vivo, it has been demonstrated that low CSF Aβ42 can serve as an 
indicator of amyloid deposition (107, 127), and that CSF tau levels correlate positively 
with in vivo brain amyloid load (128, 360).  Importantly, both of these associations are 
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independent of clinical diagnosis (107, 128), though CSF tau does correlate with more 
sensitive measures of cognition (360). These findings suggest that the overlap of 
biomarker values between clinical groups may, in part, reflect “contamination” of control 
groups by cognitively normal individuals with amyloid plaques and early 
neurodegeneration (preclinical AD), low CSF Aβ42 and elevated CSF tau.  Supporting 
this notion, elevated ratios of tau/Aβ42 and p-tau181/Aβ42 (consistent with the presence 
of amyloid plaques and neurodegeneration) have been associated with increased risk of 
converting from cognitive normalcy to dementia (107, 132). Together, these findings 
suggest that CSF biomarkers can describe neuropathological state and trajectory. They 
also suggest that a pathological staging system based on biomarkers might be a 
favorable alternative or adjunct to clinical staging for guiding treatment decisions or 
designing clinical trials. 
 Beyond amyloid plaque formation, other features of AD pathophysiology might 
also be exploited as therapeutic targets, sources of diagnostic biomarkers, or measures 
of disease progression. In addition to Aβ42 and tau, many other candidate AD 
biomarkers have been identified by either targeted or unbiased proteomics screens 
(241-243, 245, 246, 250, 263, 361-365). Only a few of these studies have tested large, 
well-characterized cohorts, however.  Even fewer have evaluated biomarkers for their 
ability to distinguish the very early stages of AD pathophysiology. Thus, there remains a 
critical need for validated AD biomarkers that can properly categorize individuals by 
early pathological stage; such markers may have potential for monitoring 
neuropathological decline and, thereby, for evaluating response to disease-modifying 
therapies.   
The goal of this study, therefore, is to identify such CSF protein biomarkers for 
AD using the unbiased proteomic technique of two-dimensional difference-in-gel 
electrophoresis (2D-DIGE) coupled with liquid chromatography and tandem mass 
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spectrometry (LC-MS/MS), and to evaluate them further in a larger independent cohort 
using quantitative enzyme-linked immunosorbent assays (ELISA). Our findings suggest 
that a small ensemble of novel biomarkers may be able to distinguish several stages of 
cognitive decline in early AD, and improve the ability of current leading biomarkers tau 




Subject selection - Discovery cohort   
Subjects (N=48), community-dwelling volunteers from University of Washington 
(N=18), Oregon Health and Science University (N=11), University of Pennsylvania 
(N=11), and University of California San Diego (N=8), were 51-87 years of age and in 
good general health, having no other neurological, psychiatric, or major medical 
diagnoses that could contribute to dementia, nor use of exclusionary medications (e.g. 
anticoagulants) within 1-3 months of lumbar puncture (LP). Cognitive status was 
evaluated based on criteria from the National Institute of Neurological and 
Communicative Diseases and Stroke-Alzheimer’s Disease and Related Disorders 
Association (57). In the morning after overnight fasting, CSF was collected in 
polypropylene tubes by LP and immediately frozen at -80°C. Subjects who were 
cognitively normal (CDR 0, N=24) or had mild “probable AD” (CDR 1, N=24), were 
selected from a larger group of 120 samples on the basis of CSF Aβ42 (relatively high 
and low values, respectively), and, when possible, CSF tau (relatively low and high 
values, respectively) to increase the likelihood of CDR 1 subjects having and CDR 0 
subjects not having AD pathology. CSF Aβ42 and tau levels for the discovery cohort 
were all measured in a single laboratory using well-established ELISA assays (366). 
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Although quantitative thresholds were not defined prior to sample selection, the lowest 
CDR 0 value and the highest CDR 1 value  for CSF Aβ42 in this discovery cohort were 
609 and 361 pg/mL, respectively; ranges for CSF tau were 141-461 pg/mL for CDR 0 
and 215-1965 pg/mL for CDR 1. 
 
Subject selection - Validation cohort 
Subjects (N=292), community-dwelling volunteers enrolled at the Knight  
Alzheimer Disease Research Center at Washington University (WU-ADRC), were ≥60 
years of age and met the same exclusion criteria as the discovery cohort. Cognitive 
status was determined as with the discovery cohort. Subjects who were cognitively 
normal (CDR 0, N=198), very mildly demented (CDR 0.5, N=65) or mildly demented 
(CDR 1, N=29) at the time of LP were selected without regard to previously measured 
biomarkers. Some CDR 0.5 subjects met criteria for mild cognitive impairment (MCI) and 
some were more mildly impaired, or “pre-MCI” (70). All CDR 1 individuals had received a 
diagnosis of DAT (demographic characteristics in Table 2.1). Apolipoprotein E (APOE) 
genotypes were determined by the WU-ADRC Genetics Core.  Fasted CSF was 
collected, gently mixed, centrifuged, and frozen at -80°C in polypropylene tubes (107). 
 
Multi-affinity immunodepletion of CSF 
A pooled CSF sample, containing an equivalent volume from every ‘discovery’ 
cohort sample, was prepared as an internal standard for 2D-DIGE to facilitate the 
matching of gel features, and to allow for normalization of the intensity of each gel 
feature among different gels. To enrich for proteins of low-abundance prior to 2D-DIGE, 
each CSF sample was depleted of six highly-abundant proteins (albumin, IgG, IgA, 
haptoglobin, transferrin, and α-1-antitrypsin) by immunoaffinity chromatography (Agilent 
Technologies, Palo Alto, CA) according to the manufacturer’s instructions and as 
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described previously (251). Depleted samples were then concentrated using 10 kDa 
exclusion filters to retain larger molecules. As a ‘benchmark’ of immunodepletion column 
performance, an aliquot of reference CSF was depleted after every group of seven 
experimental chromatographic depletions. Non-depleted reference CSF, depleted CSF 
and the proteins that were retained by the column were analyzed by 2D-DIGE as 
previously described (222, 251); gel images obtained from all reference CSF depletion 
analyses were similar (data not shown).  
 
2D-DIGE 
2D-DIGE was performed as described previously (222, 251). Briefly, CDR 0 and 
CDR 1 samples were randomly paired. Fifty-micrograms of protein from each paired 
sample and from an aliquot of the pooled CSF sample were labeled with one of three N-
hydroxysuccinimide cyanine dyes (Cy2, Cy3, or Cy5).  The labeled proteins and 100 
micrograms of unlabeled protein from each sample were mixed and equilibrated with an 
immobilized pH gradient strip for isoelectric focusing (first dimension), after which the 
strip was treated with reducing and alkylating solutions prior to SDS-PAGE (second 
dimension). Cy2, Cy3 and Cy5-labeled images were acquired on a Typhoon 9400 
scanner (GE Healthcare) at excitation/emission wavelengths of 488/520, 532/580, and 
633/670 nm, respectively. 
 
Gel image and statistical analysis 
The comparative two-dimensional gel analysis was performed using an 
established experimental design (367) in which the high variation between gels is 
minimized by including a common, labeled pooled sample in all gels. Intra-gel feature 
detection and quantification, and inter-gel matching and quantification were performed 
using the Differential In-Gel Analysis (DIA) and Biological Variation Analysis (BVA) 
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modules of DeCyder software v 6.5 (GE Healthcare), respectively, as described 
previously (251).  This process (DIA analysis) resulted in approximately 5,000 gel 
features per gel image. In five gels, one sample contained significant amounts of 
hemoglobin indicating possible blood contamination. Therefore, all images from gels with 
these hemoglobin-containing samples were removed from further analysis. Remaining 
gel images were separated into three sets: standard (pool of all samples), CDR 0 and 
CDR 1. The pooled sample image with the largest number of well-resolved gel features 
was chosen as a master image. Gel features in each remaining pooled sample image 
were hand matched to gel features in the master image.  For each gel feature that was 
matched across >50% of the gels (N=764), a Student’s t-test (α=0.05) was performed to 
determine the statistical significance of CDR 0/CDR 1 ratios, using the DeCyder EDA 
(Extended Data Analysis) module.  To maximize discovery rate and minimize type II 
error, no multiple test correction was applied. The image intensity data for the 
statistically significant gel features (N=119) were then subjected to unsupervised 
hierarchical clustering (DeCyder EDA module). 
 
Protein/peptide identification by LC-MS/MS  
Gel features with significant intensity differences were targeted by a robotic gel 
sampling system (ProPic; Genomics Solutions, Ann Arbor, MI) and transferred into 96 
well plates for in-gel digestion with trypsin using a modification of a method (368) 
described previously (222). Aliquots of these digests were processed for and analyzed 
by LC-MS/MS using a capillary LC (Eksigent, Livermore CA) interfaced to a nano-LC-
linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometer 
(nano-LC-FTMS) (369), QStar (370), or LTQ (369). The tandem spectra were searched 
against the National Center for Biotechnology Information non-redundant protein 
database NR (downloaded on 02-18-2007) using MASCOT, version 2.2.04 (Matrix 
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Sciences, London). The database searches were constrained by allowing for trypsin 
cleavage (with up to two missed cleavage sites), fixed modifications 
(carbamidomethylation of Cys residues) and variable modifications (oxidation of Met 
residues and N-terminal pyroglutamate formation). Protein identifications were 
considered genuine if at least two peptides were matched with individual MASCOT ion 
scores ≥ 40. 
Using nano-LC-MS/MS, multiple proteins were identified in the majority of 
individual gel features. The frequent observation of multiple proteins in single gel 
features was attributed to the sensitivity and greater peptide coverage that can be 
achieved with nano-LC-MS methods as compared to, for example, MALDI-MS analysis 
of peptides from gel features. Assignment of the major protein(s) from each gel feature 
was achieved using quantitative proteomics from spectra counting (371). The detection 
of multiple proteins within single gel features could also be attributed to artifacts and 
technical issues associated with 2D gel electrophoresis: 1) incomplete resolution of 
proteins by gel electrophoresis (due to similar charge and size characteristics, excessive 
abundance of neighboring proteins, or artifactual streaking); 2) changes in molecular 
weight associated with cyanine dye labeling, particularly for lower molecular weight 
proteins; and 3) sample ‘carryover’ during robotic gel sampling or during nano-LC-
MS/MS.   
 
Enzyme Linked Immunosorbent Assays (ELISAs) and statistical analyses 
CSF samples were analyzed by ELISA in duplicate for Aβ42, total tau, and 
phospho-tau181 (Innotest, Innogenetics) after one freeze-thaw cycle, and in triplicate for 
all other ELISAs after two freeze-thaw cycles. Samples were evaluated using 
commercially available ELISAs for NrCAM (R&D Systems), YKL-40 (Quidel), 
apolipoprotein E (Medical and Biological Laboratories), clusterin/apolipoprotein J 
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(ALPCO Diagnostics), pigment epithelium-derived factor (PEDF)/serpin-F1 (Chemicon 
International), β-2 microglobulin (ALPCO Diagnostics), ceruloplasmin (Assaypro), 
chromogranin A (ALPCO Diagnostics, low binding capacity manufacturing protocol), 
transthyretin (Assaypro), and cystatin C (US Biological), according to manufacturer’s 
instructions, with adjustments for the analysis of CSF. A sandwich ELISA was developed 
for carnosinase I using goat anti-human carnosinase I antibody (2 μg/mL, R&D Systems) 
for capture, rabbit anti-human carnosinase I antibody (1 μg/mL, Sigma) for detection, 
goat anti-rabbit:horseradish peroxidase (1:5000, Upstate) for reporting, and TMB Super 
Slow (Sigma) for color development; recombinant carnosinase I (R&D Systems) was 
used as standard.   
 Statistical analyses were performed using commercially available software: SAS 
9.2 (SAS Institute Inc, Cary, NC) for ROC/AUC calculations and logistic regression 
analyses, and SPSS 18 (SPSS Inc, Chicago, IL) for all other analyses.  
 Comparisons between CDR 0 and CDR 1 groups of the discovery cohort (one 
sample was unavailable for re-evaluation, N=47) were performed using unpaired t-test. 
For the validation cohort (N=292), correlations with age and gender were evaluated 
using the Spearman rho correlation coefficient (α=0.05). Chi-square analyses were 
performed to evaluate need for adjustment for observed correlations. Comparisons 
between the three CDR groups were performed using one-way analysis of variance 
(ANOVA), with Bonferroni and LSD post-hoc tests for pair-wise group comparisons, with 
the following exceptions: one-way ANOVA with Welch’s correction was applied for 
markers (transthyretin) demonstrating unequal variances (Levene <.05); markers 
correlating with age (tau, p-tau181, Aβ42, YKL-40) were evaluated by analysis of 
covariance (ANCOVA) adjusting for age, followed by Bonferroni and LSD post-hoc tests.  
Multiple post-hoc tests were applied in recognition of their different levels of stringency 
(Bonferroni > LSD), and their non-uniform popularity among statisticians.  For CDR 0 vs 
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>0 comparisons and CDR 1 vs <1 comparisons, unpaired t-test was used; Welchs’ 
correction for unequal variances was applied for YKL-40, p-tau, tau, and Aβ42. For each 
biomarker measured in the larger ‘validation’ cohort, the receiver operating characteristic 
(ROC) curve and the area under the ROC curve (AUC) were calculated for predicting 
CDR 0 versus CDR>0. A stepwise logistic regression analysis was used to identify an 
optimal combination of these biomarkers for this data set. These analyses were 
repeated for CDR 1 vs CDR<1.  
 
Results 
Sample processing and 2D-DIGE analysis 
 To identify new candidate biomarkers for AD, we utilized an unbiased proteomics 
approach, 2D-DIGE LC-MS/MS (222, 251), to compare the relative concentrations of 
CSF proteins in individuals with mild “probable AD” (CDR 1, N=24) to those in individuals 
without dementia (CDR 0, N=24). The two clinical groups were selected on the basis of 
relative biomarker values for CSF Aβ42 and tau (see Methods), and differed somewhat 
with respect to age at LP and gender (CDR 0: 64.8 ± 8.8 yrs, 38% female; CDR 1: 72.8 
yrs ± 7.9 yrs, 54% female).  Five samples showed evidence of blood contamination by 
2D-DIGE; the five gels containing these samples were excluded from subsequent image 
analysis.  The remaining individual sample images (N=38, from 19 gels) were aligned 
using the BVA modules (see Methods).  
 Among the 764 gel features that were present in >50% of the gels, 119 were 
found to have significant intensity differences between CDR 0 and CDR 1 groups 
(Student’s t-test [α=0.05]) (Figure 2.1A). The image intensity data for these 119 gel 
features were subjected to unsupervised hierarchical clustering (EDA module, DeCyder 
software) and the gel features themselves were analyzed for protein composition. 
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Protein identification by LC-MS/MS 
LC-MS/MS identified single dominant proteins in 77 of the 119 gel features 
(Table 2.2). In 30 gel features, our analyses identified two or more co-dominant proteins. 
The 12 remaining gel features were not annotated from the nano-LC-MS/MS data. 
Among the characterized gel features, there was considerable redundancy in protein 
identifications, with some proteins appearing in multiple gel features. Such ‘redundant’ 
gel features, likely representing a modified form or variant of the same ‘parent’ protein, 
generally migrated with some proximity on 2D-gel electrophoresis (Figure 2.1). Forty-
seven unique proteins were identified (Table 2.2).  Thirteen of these unique proteins had 
been identified in our previous studies (222, 251) (including chromogranin B, cystatin C, 
prostaglandin H2 D-isomerase/beta trace, neuronal pentraxin receptor, gelsolin, β-2 
microglobulin, carnosinase I, angiotensinogen, apolipoprotein H, secretogranin III, α-1-
antichymotrypsin, chitinase 3-like 1 / YKL-40, and kininogen I) and others have been 
reported by other groups (243, 245, 246, 361, 363, 364). These previous reports provide 
supporting evidence that this list of proteins may contain viable candidate biomarkers for 
AD that are worthy of pursuit in validation experiments. 
 
Unsupervised clustering analysis 
 The intensity data from the 119 gel features of interest were subjected to an 
unsupervised clustering analysis to evaluate their ability to segregate the CDR 0 and 
CDR 1 subjects, and to assess their collective potential as a diagnostic biomarker panel 
(Figure 2.2).  The ‘heatmap’ generated from this analysis appeared to segregate CDR 0 
and CDR 1 individuals (indicated by green and red squares, respectively) almost 
completely, with only four subjects ‘misclassified.’  However, closer examination 
revealed an additional layer of segregation on the basis of APOE genotype (indicated by 
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‘ApoE 4+ Cluster’ and ‘ApoE 4 – Cluster’) which showed perfect subject segregation.  
Given that the APOE-ε4 allele is a dominant genetic risk factor for AD, some clustering 
of individuals by APOE genotype might be expected simply from successful segregation 
of CDR 0 and CDR 1 subjects. However, we hypothesize that the apoE protein exerts a 
dominant clustering influence through the markedly different electrophoretic profiles of its 
different isoforms derived from APOE-ε2, APOE-ε3 and APOE-ε4 alleles (illustrated in 
Figure 2.3).  ApoE was present in 24 of the 119 gel features found to differ in intensity 
between the CDR groups, and was found to be the primary protein in 12 of these gel 
features.  This heterogeneous electrophoretic mobility of apoE results from the inherent 
charge differences of the three major apoE isoforms (-E2, -E3, -E4) and the appearance 
of each isoform as an array of multiple distinct gel features caused by post-translational 
modifications.  These isoform-specific differences are reflected in the prominent red and 
green clusters, located within the lower third of Figure 2.2 (corresponding to gel features 
83-90 and 107-116), that correlate very closely with subject APOE genotypes.  
Recognizing this correlation, we hypothesized that APOE genotypes were in large part 
driving the clustering of subjects in Figure 2.2.  To test this hypothesis, we performed a 
second unsupervised clustering analysis, including only those gel features from the initial 
analysis that did not contain apoE protein (Figure 2.4).  Although this ‘apoE-free’ 
analysis segregated CDR 1 and CDR 0 groups less completely, it appropriately re-
clustered (by CDR status) several subjects (#12, 36, 37) who were aberrantly 
segregated in Figure 2.2, potentially due to their APOE genotypes.  Moreover, clustering 
of subjects into APOE genotype subgroups in Figure 2.4 appears negligible.  The 
underlying benefit of this ‘apoE-free’ analysis is that it reveals the subject-clustering 
potential of other gel features, which was previously obscured by the inclusion of apoE-
containing gel features.  As can now be better visualized in Figure 2.4, gel features 
appearing within the upper three-fourths of the heatmap appear to show greater intensity 
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in CDR 1 subjects; the converse is true of gel features within the lower fourth.  It is 
important to note that measurements of Aβ42 and tau (two proteins measured by ELISA 
and not detected by 2D-DIGE) were not included in these clustering analyses; because 
these subjects were selected on the basis of CSF Aβ42 and tau levels, such inclusion 
would presumably yield perfect or near-perfect segregation by CDR status in this 
‘discovery’ cohort.  Therefore, this analysis reflects the potential of these candidate 
biomarkers to segregate CDR 0 and CDR 1 subjects independent of any contribution 
from current leading CSF biomarkers Aβ42 and tau.  It does not address whether these 
biomarker candidates might improve upon the utility of Aβ42 and tau, however. 
 
Validation of candidate biomarkers by ELISA 
Before evaluating a subset of these candidate biomarkers in a larger 
independent sample set, we first assessed the capacity of protein-specific quantitative 
ELISAs to detect significant differences between the CDR 0 and CDR 1 subject groups 
of the original discovery cohort.  When possible, to facilitate future reproduction of our 
findings by other groups and potential translation to clinical use, we applied 
commercially available ELISA kits.  
Of the eleven ELISAs applied to the discovery cohort (N=47, one sample was 
unavailable for validation), six (NrCAM, YKL-40, chromogranin A, carnosinase I, 
transthyretin, cystatin C) showed statistically significant or near-significant differences 
between CDR 0 and CDR 1 groups (Figure 2.5); five others (PEDF, β-2 microglobulin, 
clusterin/apoJ, ceruloplasmin, apoE) did not.   
 The six ELISAs that measured differences between the CDR 0 and CDR 1 CSF 
samples of the discovery cohort were subsequently applied to a larger, independent set 
of CSF samples (N=292) collected from volunteer participants studied by the WU-ADRC. 
This ‘validation’ cohort included a CDR 0.5 group in addition to CDR 0 and CDR 1 
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groups, allowing for biomarker assessment in the very early clinical stage of AD. 
Demographic, clinical, and genetic characteristics of these subjects at time of sample 
collection are presented in Table 2.1.  Unlike the discovery cohort, this validation cohort 
was not preselected on the basis of prior biomarker values (CSF Aβ42 and tau), 
although assays for CSF Aβ42, tau, and p-tau181 were performed.  
 Because the age and gender compositions differed among the clinical groups of 
the validation cohort, we evaluated each of the 9 biomarkers (six novel candidates, 
Aβ42, tau, and p-tau181) for age and gender correlations in order to apply covariate 
analyses appropriately. Correlating with age were: tau (r=0.318, p<0.0001), p-tau181 
(r=0.2216, p<0.001), Aβ42 (r=-0.2334, p<0.0001) and YKL-40 (r=0.4001, p<0.001); no 
biomarkers correlated with gender (p>0.05).   
 As shown in Figure 2.6, statistically significant differences between clinically 
defined groups were measured for Aβ42, tau, p-tau181, NrCAM, YKL-40, chromogranin 
A, and carnosinase I; for transthyretin and cystatin C, non-significant trends were 
measured.  These differences appeared in three patterns: Aβ42 showed a pronounced 
decrease from CDR 0 to CDR 0.5 and a lesser reduction from CDR 0.5 to CDR 1; tau, p-
tau 181, and YKL-40 showed increases that were equivalent in CDR 0.5 and CDR 1 
relative to CDR 0; NrCAM, chromogranin A, and carnosinase I showed decreases 
relative to CDR 0 only in CDR 1, and not in CDR 0.5. 
 
Diagnostic utility of validated candidate biomarkers  
 To evaluate and compare the potential of the validated candidate biomarkers and  
Aβ42, tau, and p-tau181 for identifying either very mild to mild dementia (combined CDR 
0.5 and CDR 1) or mild dementia (CDR 1), ROC curves and AUCs were calculated for 
each biomarker using data from the validation cohort (Figure 2.7A, B, Table 2.3A, B). 
Stepwise logistic regression analyses indicated that, among the nine biomarkers under 
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consideration, YKL-40, NrCAM, and tau yielded an AUC of 0.896 in discriminating 
cognitive normalcy (CDR 0) from very mild to mild dementia (CDR>0) (Figure 2.7C,Table 
2.3A); for discriminating mild dementia (CDR 1) from CDR<1, carnosinase I, 
chromogranin A and tau yielded an AUC of 0.876 (Figure 2.7D, Table 2.3B).  
 
Discussion 
 The results from the 2D-DIGE LC-MS/MS portion of this study suggest that many 
of the recognized neuropathological changes of AD are represented by changes in the 
CSF proteome.  Most of the 47 candidate biomarker proteins identified in this study can 
be placed into structural and/or functional categories (e.g. synaptic adhesion, synaptic 
function, dense core synaptic vesicle proteins, inflammation/complement, protease 
activity/inhibition, apolipoproteins, etc.) associated with accepted 
neuropathophysiological changes in AD (Table 2.4). Unsupervised clustering analyses of 
this 2D-DIGE data, performed without the influence of CSF Aβ42, tau, p-tau and APOE 
genotype, additionally suggest that these biomarker candidates collectively show utility 
for discriminating groups with and without mild DAT (Figure 2.4). 
 In the second phase of this study, designed to measure a subset of candidate 
biomarker proteins in two independent sample sets by ELISA, four of the eleven 
candidate biomarkers tested showed capacity to distinguish clinical groups.  However, 
seven candidate biomarkers did not show statistically significant differences between 
clinical groups in either the smaller discovery cohort or the larger validation cohort. 
Superficially, this ‘failure rate’ might cast doubt on the list of candidate biomarkers 
identified through 2D-DIGE.  However, it is important to note that 2D-DIGE is sensitive to 
changes in concentrations of minor protein isoforms and post-translational modifications 
that may not significantly alter the global concentrations of a ‘parent’ protein, which 
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would be measured by ELISA. Therefore, it is not surprising that some of the candidate 
biomarker ELISAs did not replicate the findings from 2D-DIGE. Transthyretin provides a 
prime example: all of the significant gel-features ascribed to transthyretin (gel features # 
20, 52, 57, 58, 60, 77, 78, 79, 84, 87, 110, 115; Table 2.2) showed unusual 
electrophoretic patterns and were dwarfed by the canonical transthyretin gel features 
that did not individually show statistical differences (Figure 2.1B).   In fact, whereas most 
of the significant transthyretin 2D-DIGE gel features were decreased in AD, the global 
transthyretin levels measured by ELISA in the discovery and validation cohorts were 
actually mildly increased in groups with cognitive impairment (CDR>0) relative to those 
without (CDR 0) (Figures 2.5 and 2.6). To measure the sub-species of transthyretin that 
were identified by 2D-DIGE as decreasing in AD will require assays that specifically 
target relevant post-translational modifications and exclude other forms of transthyretin.  
Similarly, other 2D-DIGE biomarker candidates may also require specifically tailored 
assays for accurate, high-throughput measurement. 
 Nevertheless, four candidate biomarkers were successfully validated in both 
cohorts, and two others showed non-significant trends by ELISA in the larger validation 
cohort (Figure 2.6). This larger cohort represented three different cognitive stages: 
normalcy, very mild dementia, and mild dementia (CDR0, CDR 0.5, CDR 1, 
respectively), and revealed different patterns of CSF biomarker levels, vis-a-vis cognitive 
status.  The CSF concentration of YKL-40, an astrocytic marker of plaque-associated 
neuroinflammation (372-383), is increased by the very earliest stage of clinical disease 
(CDR 0.5).  Transthyretin (241, 248, 384-390) and cystatin C  (362, 390-394), two 
proteins with neuroprotective qualities that are implicated in preventing amyloidogenesis 
of Aβ peptide, show a similar pattern.  In contrast, the concentrations of NrCAM, a 
synaptic adhesion molecule (361, 395-398), chromogranin A,  a dense core synaptic 
vesicle protein (361, 362, 399-402), and carnosinase I, a neuronal dipeptidase 
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responsible for degradation of the anti-oxidant and metal-chelating dipeptide carnosine 
(403-405), do not decline until mild dementia ensues (CDR 1).  
 Like the current leading CSF biomarkers for AD (Aβ42, tau and p-tau181), all of 
these biomarker candidates show ranges with substantial overlap between clinically 
defined subject groups.  This issue of overlapping values, common among candidate AD 
CSF biomarkers reported to date, suggests that any one biomarker will be insufficient to 
accurately identify early AD, and that an ensemble of complementary biomarkers will be 
required to provide adequate sensitivity and specificity. Therefore, to identify an optimal 
combination of these biomarkers that can distinguish the early clinical stages of AD from 
cognitive normalcy, we applied stepwise logistic regression analyses to the ELISA data 
from our ‘validation’ cohort (Figure 2.7, Table 2.3). These analyses suggest that four 
candidate AD biomarkers (YKL-40, NrCAM, chromogranin A, carnosinase I) can improve 
the ability of tau to classify individuals into CDR0, CDR 0.5 and CDR 1 groups with 
appreciable accuracy.  
 It may appear counter-intuitive that Aβ42 and p-tau, which individually 
discriminate very mild AD and mild AD from cognitively normal groups quite well, were 
not incorporated into either ‘optimal’ biomarker panel by the stepwise linear regression 
analyses.  Likewise, NrCAM was included in the optimal CDR 0 vs CDR>0 biomarker 
panel (AUC 0.896) even though its mean levels did not independently show a statistical 
difference between CDR 0 and CDR>0 groups. In considering this outcome, it may be 
worth noting that if NrCAM, transthyretin, chromogranin and cystatin C are removed from 
consideration, the stepwise linear regression model for the CDR 0 vs CDR>0 
comparison yields an ‘optimal’ biomarker panel that includes only tau, Aβ42 and 
carnosinase I, with an AUC of 0.849. In this restricted analysis, the paired contribution of 
Aβ42 and carnosinase I to tau is apparently greater than that of YKL-40.  These 
analyses illustrate how ‘unpredictable’ and context-dependent optimal biomarker 
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combinations can be, and suggest that biomarker complementarity may be more 
important to consider than each biomarkers’ independent performance, when choosing a 
biomarker panel.  Of course, it will be important to replicate these findings in additional 
independent cohorts. It will also be important to evaluate a greater number of candidate 
biomarkers in similar fashion, in order to construct a biomarker panel with even greater 
accuracy.  
 Nevertheless, by providing proof of concept, this study outlines a scheme to 
categorize the early stages of AD using CSF protein biomarkers that reflect established 
features of the pathophysiological evolution of the disease (Figure 2.8). Building upon 
previous findings that low CSF Aβ42 can identify cognitively normal individuals with 
plaques (preclinical AD) (127), and that  tau/Aβ42 and YKL-40/Aβ42 ratios can predict 
risk of developing cognitive impairment (107, 132, 372), this minimal panel of six CSF 
biomarkers  (YKL-40, NrCAM, chromogranin A, carnosinase I, tau and Aβ42) begins to 
segregate subjects into six clinicopathological categories: normal cognition without 
amyloid plaques, normal cognition with amyloid plaques (preclinical AD), normal 
cognition at increased risk to develop dementia (converters), very mild dementia (CDR 
0.5), very mild dementia at increased risk for progression, and mild dementia (CDR 1) 
(Figure 2.8). 
 We acknowledge that this minimal panel of biomarkers currently has insufficient 
sensitivity and specificity for clinical application, particularly because it has not been fully 
evaluated for its ability to discriminate AD from non-AD causes of dementia (Aβ42, p-
tau181, tau, and specific fragments of chromogranin A and cystatin C have shown some 
ability to distinguish AD from FTLD (362, 406, 407).  The incorporation of additional 
biomarkers that are likely to discriminate early AD from cognitive normalcy, such as 
those identified in the first phase of this study, or other biomarkers that have already 
shown promise for distinguishing AD from other leading causes of dementia (e.g. agouti 
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related peptide, eotaxin-3, and hepatocyte growth factor (361), complement C3a des-arg 
and integral membrane protein 2B CT (362) for FTLDs; and alpha-synuclein (408), ApoH 
and vitamin D binding protein (246) for Lewy body disorders), would likely improve the 
panel’s diagnostic utility.  However, even in its current form, this initial panel might show 
value if applied in the context of clinical trial design, wherein simple enrichment of study 
populations for characteristics of interest would increase efficiency and power and 
reduce duration and cost.  A biomarker panel like this one might also allow clinical trials 
to evaluate stage-specific responses to treatment, which may differ.  Finally, because 
most of these biomarkers reflect underlying pathological changes in real time, it is 
appealing to speculate that these biomarkers may have additional utility for evaluating 
clinically imperceptible treatment responses (as in (409)) and for monitoring 
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Figure 2.1. Two-dimensional difference in gel electrophoresis (2D-DIGE) of 
cerebrospinal fluid immunodepleted of six high abundance proteins.   
A) Representative 2D-DIGE (grayscale) image with labeled locations of 119 gel features 
that differed in intensity between CDR 0 and CDR 1 groups.  Gel features are numbered 
1 through 119, and relevant information about each is listed in Table 2.2.  Approximate 
molecular weight (in kDa) is indicated along the right border; pI ranges from 3 (left) to 11 
(right) and is non-linear. B) Two-dimensional gel electrophoresis pattern of transthyretin. 
The large, intense, protein spots commonly attributed to transthyretin are boxed; those 
appearing in our study as differentially abundant between cognitively normal (CDR 0) 
and mildly demented participants (CDR 1) are circled in red, and are partially obscured 
by yellow dots (yellow dots indicate sites targeted by robotic sampling for mass 
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Table 2.2. Proteins that were identified by 2D-DIGE and LC-MS/MS to have differences in mild DAT versus non-demented control CSF   
Spot BVA GI number(s) Protein Change p value 
Protein 
# 
1 4709 31543193 hypothetical protein LOC146556 -1.36 7.02E-04 1 
2 5659 4502807 chromogranin B -1.31 1.18E-03 2 
3 4683 4502101 annexin I  -1.31 9.54E-04 3 
4 4608 62089004 chromogranin B -1.24 6.49E-03
  181387 cystatin C 4 
  134464 Secretogranin-2 5 
5 4297 4502807 chromogranin B -1.26 0.0157 
6 4545 -1.34 3.86E-03
7 4695 4502807 chromogranin B  -1.27 0.0115 
8 4044 4502807 chromogranin B  -1.32 2.15E-03
9 1314 1621283 neuronal cell adhesion molecule (NrCAM) -1.22 0.0119 6 
10 1320 1621283 neuronal cell adhesion molecule (NrCAM) -1.33 6.31E-04
11 1382 6651381 neuronal cell adhesion molecule (NrCAM) -1.28 9.53E-04
12 1383 6651381 neuronal cell adhesion molecule (NrCAM) -1.25 6.64E-03
13 4033 4502807 chromogranin B  -1.21 0.0419 
14 4191 4502807 chromogranin B  -1.23 0.0107 
15 4293 4502807 chromogranin B  -1.33 4.64E-03
  825635 calmodulin 7 
16 4266 62089004 chromogranin B  -1.22 0.0315 
17 4615 -1.22 0.0188 
18 4677 -1.3 9.63E-03
19 4906 5454032 S100 calcium binding protein A1  -1.3 1.36E-04 8 
  62898141 prosaposin  9 
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  627391 brain-associated small cell lung cancer antigen / NCAM-140 / CD56  10 
  17136078 VGF nerve growth factor inducible precursor 11 
20 5014 443295 transthyretin  -1.3 2.10E-03 12 
21 4884 224917 apolipoprotein CIII -1.34 9.78E-04 13 
  337760 prosaposin / cerebroside sulfate activator protein 
22 3423 39654998 Chain A, Hr1b Domain From Prk1 -1.27 0.0133 14 
  32171249 prostaglandin H2 D-isomerase / beta trace 15 
23 3470 17402888 neuronal pentraxin receptor  -1.25 7.23E-03 16 
24 4954 34616 beta-2 microglobulin -1.3 4.15E-03 17 
25 3436 32171249 prostaglandin H2 D-isomerase  -1.22 0.0266 
  178775 proapolipoprotein 18 
  39654998 Chain A, Hr1b Domain From Prk1 
26 3714 -1.27 0.03 
27 4922 39654998 Chain A, Hr1b Domain From Prk1 -1.27 0.0194 
28 3786 2072129 chromogranin A -1.38 8.96E-03 19 
29 4076 7341255 brain acetylcholinesterase putative membrane anchor -1.25 0.0375 20 
30 4111 62089004 chromogranin B  -1.28 0.0206 
31 4167 4502807 chromogranin B  -1.29 0.0207 
32 2652 28373309 gelsolin -1.23 0.0346 21 
33 1313 6651381 neuronal cell adhesion molecule (NrCAM) -1.19 8.08E-03
34 1372 1620909 ceruloplasmin  -1.19 9.00E-03 22 
  1483187 inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) 23 
  31874098 hypothetical protein (NrCAM)  
  6651381 neuronal cell adhesion molecule (NrCAM) 
35 1387 68534652 neuronal cell adhesion molecule (NrCAM) -1.29 8.16E-05
  1620909 ceruloplasmin  
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36 4808 337760 prosaposin / cerebroside sulfate activator protein -1.22 0.0114 
37 1319 68534652 neuronal cell adhesion molecule (NrCAM) -1.19 0.0198 
  1942284 ceruloplasmin 
38 1386 6651381 neuronal cell adhesion molecule (NrCAM) -1.29 1.24E-03
39 1353 21706696 calsyntenin 1  -1.22 0.0417 24 
40 1329 1621283 neuronal cell adhesion molecule (NrCAM) -1.22 4.61E-03
41 2456 5802984 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1  -1.13 0.0449 25 
42 2550 20178323 pigment epithelium-derived factor precursor (PEDF) / Serpin-F1 / EPC-1 -1.15 0.022 26 
43 2125 21071039 carnosinase 1  -1.21 0.0245 27 
44 2131 21071039 carnosinase 1  -1.19 0.049 
45 2152 21071039 carnosinase 1  -1.15 0.0366 
46 5614 21071039 carnosinase 1  -1.18 0.0109 
47 2166 21071039 carnosinase 1  -1.21 0.0122 
48 2328 416180 Man9-mannosidase / a1,2-mannosidase IA -1.16 0.0464 28 
49 3360 -1.15 0.045 
50 3447 32171249 prostaglandin H2 D-isomerase / beta trace -1.19 0.0334 
51 3546 1621283 neuronal cell adhesion molecule (NrCAM) -1.17 0.0368 
  32171249 prostaglandin H2 D-isomerase / beta trace 
52 4745 443295 transthyretin -1.26 0.0181 
53 3032 11056046 Nectin-like molecule-1 / SynCAM3 / TSLL1 -1.13 0.0472 29 
  4506147 protease, serine, 2 preproprotein  30 
54 3718 39654998 Chain A, Hr1b Domain From Prk1 -1.14 0.0455 
  32171249 prostaglandin H2 D-isomerase / beta trace 
55 4902 14277770 apolipoprotein C-Ii -1.19 0.0495 31 
  337760 prosaposin / cerebroside sulfate activator protein 
  2072129 chromogranin A 
58 
 
Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer’s Disease Using Proteomics and 
ELISA 
56 3290 409725 carbonic anhydrase IV -1.14 0.0141 32 
57 4379 17942890 transthyretin  -1.15 0.0219 
  39654998 Chain A, Hr1b Domain From Prk1 
34999 cadherin 2 precursor 33 
58 4388 32171249 prostaglandin H2 D-isomerase / beta trace -1.14 0.0218 
  39654998 Chain A, Hr1b Domain From Prk1 
  443295 transthyretin 
59 2192 21071039 carnosinase 1  -1.34 6.56E-03
  532198 angiotensinogen 34 
  5531817 secretogranin III  35 
  9665262 EGF-containing fibulin-like extracellular matrix protein 1 / Fibulin-3 36 
  177933 alpha-1-antichymotrypsin  37 
  4504893 kininogen 1  38 
  36573 vitronectin 39 
60 5336 443295 transthyretin -1.17 0.0301 
61 3009 178855 apolipoprotein J / clusterin -1.26 0.0288 40 
  4557325 apolipoprotein E 41 
  4506147 protease, serine, 2 preproprotein  
62 3042 4557325 / 178853 apolipoprotein E -1.21 0.047 
  338305 apolipoprotein J / clusterin 
63 3016 338305 apolipoprotein J / clusterin -1.32 6.69E-05
64 3050 4557325 / 178853 apolipoprotein E -1.24 5.19E-04
  178855 apolipoprotein J / clusterin 
65 3075 4557325 / 178853 apolipoprotein E -1.42 5.59E-06
  178855 apolipoprotein J / clusterin 
66 3038 4557325 / 178853 apolipoprotein E -1.41 2.84E-05
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  178855 apolipoprotein J / clusterin 
67 3301 178849 apolipoprotein E -1.4 1.29E-05
68 3182 4557325 / 178853 apolipoprotein E -1.41 3.43E-04
  178855 apolipoprotein J / clusterin 
69 2443 532198 angiotensinogen -1.2 6.85E-03
70 2493 4503009 carboxypeptidase E precursor -1.23 6.09E-03 42 
71 5621 532198 angiotensinogen -1.17 0.0434 
72 5624 532198 angiotensinogen -1.22 0.0147 
73 5622 553181 angiotensinogen -1.17 0.04 
74 5625 532198 angiotensinogen -1.16 0.0423 
75 5627 -1.22 0.0113 
76 2849 4557325 apolipoprotein E -1.28 6.26E-03
77 5009 443295 transthyretin  -1.24 0.0268 
78 5033 443295 transthyretin -1.27 4.59E-03
79 5078 443295 transthyretin  -1.2 0.0144 
80 2958 4504067 aspartate aminotransferase 1 -1.22 8.60E-03 43 
81 3657 32171249 prostaglandin H2 D-isomerase / beta trace -1.22 3.07E-03
82 3867 -1.28 0.0437 
83 3176 4557325 apolipoprotein E -1.63 3.03E-04
84 3228 4557325 apolipoprotein E -1.4 1.39E-03
  443295 transthyretin 
85 3074 4557325 / 178853 apolipoprotein E -2.36 4.41E-09
86 5647 4557325 apolipoprotein E  -2.35 2.92E-07
87 3224 4557325 / 178853 apolipoprotein E -2.13 6.36E-07
  443295 transthyretin  
88 3126 4557325 / 178853 apolipoprotein E -1.93 7.55E-06
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89 5297 -1.44 0.0473 
90 3083 4557325 apolipoprotein E -1.7 2.82E-05
91 2218 112911 alpha-2-macroglobulin 1.22 0.0282 44 
92 2226 6573461 apolipoprotein H  1.27 0.0305 45 
93 2252 112911 alpha-2-macroglobulin 1.26 0.0267 
  4557327 apolipoprotein H  
94 3255 1.24 0.0315 
95 3630 178775 proapolipoprotein 1.24 0.0287 
  32171249 prostaglandin H2 D-isomerase / beta trace 
  39654998 Chain A, Hr1b Domain From Prk1 
96 2229 177933 alpha-1-antichymotrypsin 1.42 3.09E-03
97 2235 177933 alpha-1-antichymotrypsin  1.35 0.0388 
98 2261 177933 alpha-1-antichymotrypsin  1.3 6.04E-03
99 2262 177933 alpha-1-antichymotrypsin  1.25 0.0294 
100 2220 1.29 0.0158 
101 3084 1.16 0.0211 
102 3508 32171249 prostaglandin H2 D-isomerase / beta trace 1.22 9.21E-03
103 2825 23512215 chitinase 3-like 1 / YKL-40 / HC-gp39 1.41 0.0167 46 
104 2863 4557018 chitinase 3-like 1 / YKL-40 / HC-gp39 1.5 0.0144 
105 2846 29726259 chitinase 3-like 1 / YKL-40 / HC-gp39 1.46 7.88E-03
106 2843 23512215 chitinase 3-like 1 / YKL-40 / HC-gp39 1.32 0.0241 
107 3030 4557325 apolipoprotein E 2.46 3.70E-05
108 3152 4557325 / 178853 apolipoprotein E 2.39 8.73E-07
109 3203 178853 apolipoprotein E 3.23 3.13E-07
110 3185 4557325 / 178853 apolipoprotein E 1.9 9.72E-04
  443295 transthyretin 
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111 3069 338305 apolipoprotein J / clusterin 1.5 6.40E-04
112 3079 1.64 4.47E-04
113 3133 178853 apolipoprotein E 1.49 8.66E-04
  338057 apolipoprotein J / clusterin 
114 3151 178853 apolipoprotein E 1.28 9.25E-03
338057 apolipoprotein J / clusterin 
115 3249 4557325 apolipoprotein E  1.37 2.46E-03
  178855 apolipoprotein J / clusterin 
  443295 transthyretin 
116 3118 4557325 / 178853 apolipoprotein E 1.64 9.96E-04
117 5698 178855 apolipoprotein J / clusterin 1.73 5.82E-04
118 2819 40737343 C4B3  2 0.038 47 
119 3137 4557325 apolipoprotein E -2.5 8.52E-07
 
Table 2.2.  Proteins that were identified by 2D-DIGE and LC-MS/MS to have differences in mild DAT versus non-demented 
control CSF.  Column 1, coded protein spot ID (as in Figure 2.1).  Column 2, biological variation analysis (BVA) number for that 
spot generated by the DeCyder software. Column 3, GI accession number(s) assigned to the proteins identified by MASCOT.  
Column 4, name of the protein identified by MASCOT.  Column 5, fold change in protein abundance comparing CDR 1 with CDR 0 
samples (negative values indicate decreases in abundance in CDR 1 samples compared to controls (CDR 0)).  Column 6, p value of 
the CDR 0 versus CDR 1 comparison (Student's t test).  Column 7, consecutive numbering identifying proteins as unique. 
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Figure 2.2. Unsupervised Clustering of CSF Samples by 2D-DIGE data from the 119 
statistically significant gel features (Student’s t-test, α=0.05, present in >50% of images). 
Five gels containing hemoglobin (N=10 samples) were excluded. Columns represent 
samples; rows, numbered 1 through 119 from top to bottom, represent gel features 
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depicted in Figure 2.1A. Gel feature intensity is encoded colorimetrically from red (high 
in AD) to green (low in AD). CDR status of individual subjects at time of CSF collection is 
encoded below by small green and orange squares; CDR 0 and CDR 1 clusters are 
indicated below by green and orange bars, respectively. APOE-ε4 allele status of 
individuals and groups, alike, is indicated by black (possessing one or two APOE-ε4 
alleles) or blue (possessing no APOE-ε4 alleles).  Rows representing gel features 
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Figure 2.3. ApoE protein isoforms appear in different gel features on 2D-DIGE.  
Overlays of fluorescent 2D-DIGE images from gels representing CSF from two 
individuals with homozygosity for APOE-ε2 (green) or APOE-ε3 (red) (center, upper 
image) and for APOE-ε3  (green) or APOE-ε4 (red) (center, lower image) illustrate the 
heterogeneity of signal distribution by isoelectric point and molecular weight among 
ApoE protein isoforms derived from different alleles.  Signal intensities of individual CSF 
samples, grouped by genotype (2/2, 3/3 and 4/4 represent homozygotes; 2/3, 3/4 
represent heterozygotes) is indicated for six ApoE gel features, illustrating that gel 
features 1 and 2 represent ApoE2; gel feature 3 represents multiple forms; gel feature 4 
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Figure 2.4. Unsupervised Clustering of CSF Samples by 2D-DIGE data, excluding 
gel features containing ApoE protein; all other statistically significant gel features 
(Student’s T-test α=0.05, present in >50% of images) are retained. As in Figure 2.2, five 
gels containing hemoglobin (N=10 samples) were excluded. Columns represent 
samples, numbered by position in Figure 2.2; rows represent gel features, numbered by 
position in Figure 2.2, with ApoE-containing features removed. Gel feature intensity is 
encoded colorimetrically from red (high in AD) to green (low in AD); white indicates 
absent data. CDR status of subjects at time of CSF collection is encoded below, by 
small green and orange squares. APOE-ε4 status is indicated in blue or black. 
Clustering pattern of samples relative to Figure 2.2 is indicated below. 
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Figure 2.5. Quantitative ELISAs for 11 biomarker candidates were applied to the 
discovery cohort of CSF samples (one sample was unavailable for analysis, N=47). 
Each assay was performed in triplicate, with one mean value reported for each sample.  
The six assays represented in the upper row (NrCAM, YKL-40, chromogranin A, 
carnosinase I, transthyretin, and cystatin C) measured promising differences between 
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Figure 2.6.  ELISAs for six biomarker candidates and established biomarkers tau, 
p-tau181 and Aβ42 applied to validation cohort CSF samples (N=292). Each 
candidate biomarker assay was performed in triplicate, with one mean value reported for 
each sample; assays for tau, p-tau181 and Aβ42 were performed in duplicate.  In 
addition to A. tau, B. p-tau181 and C. Aβ42 (top row), four assays (D. YKL-40, E. 
carnosinase I, F. chromogranin A, G. NrCAM) measured statistical differences between 
clinically defined groups, as indicated; H. transthyretin and I. cystatin C did not reach 
criterion (α=0.05) for any comparisons. * p<0.05;  * * p<0.01;  * * * p< 0.001;  
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* * * * p<0.0001; solid circle p<0.05 by LSD only; double solid circle p<0.05 by unpaired 
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Figure 2.7.  Receiver Operating Characteristic (ROC) curves of ELISA data from 
validation cohort.  Simple ROC analyses were performed for each biomarker to 
distinguish a) CDR>0 from CDR 0 (“earlier diagnosis”) and b) CDR 1 from CDR<1 
(“early diagnosis”).  Stepwise logistic regression models were used to identify 
combinations of these biomarkers that would distinguish c) CDR>0 from CDR 0 (“earlier 
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Table 2.3.  Statistical analyses associated with Receiver Operating Characteristic 
(ROC) curves of ELISA data from validation cohort.  ROC analyses were performed 
for each biomarker to distinguish A. CDR>0 from CDR 0 (“earlier diagnosis”) and B. 
CDR 1 from CDR<1 (“early diagnosis”).  Stepwise logistic regression models were 
applied to identify a complementary combination of these biomarkers for each analysis 
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that would optimize accuracy (maximize area under the curve [AUC]) without including 
additional non-contributory biomarkers. In A, the stepwise logistic regression model 
accepted tau, YKL-40 and NrCAM and yielded an AUC of 0.8955 (Logistic Regr.).  In B, 
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Table 2.4. CSF biomarkers grouped by functional/structural category 
Functional / Structural Category Protein 
Adhesion molecules N-Cadherin 
 NrCAM 
 Calsyntenin 
 Neuronal Pentraxin Receptor 
 Brain Associated Small Cell Lung Cancer Antigen (NCAM-140/CD56) 
 Nectin-like molecule-1 / TSLL1 / SynCam3 
Dense core vesicles Chromogranin A 
 Chromogranin B 
 Secretogranin II 
 Secretogranin III 
 VGF NGF Inducible precursor 
 Carboxypeptidase E 
Synaptic/Neuronal metabolism Aspartate aminotransferase I 
Synaptic Function S100A1 (binds synapsins) 
 Neuronal Pentraxin Receptor (presynaptic) 
 Brain Acetylcholinesterase Putative Membrane Anchor (CutA1) 
 Calsyntenin (postsynaptic) 
Neuroprotection PEDF (Serpin-F1) 
 Annexin I 
 Prosaposin 
 Secretogranin II 
 Carnosinase I 
Apoptosis / actin remodeling Gelsolin 
 Prk-1 (PKN) 
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Synaptic plasticity / learning and memory VGF NGF inducible precursor 
 NrCAM 
 B3GnT1 
 Carnosinase I 
 Carbonic Anhydrase IV 
 S100A1 
 Carboxypeptidase E 
 Calmodulin 
Inflammation / Complement YKL-40 / Chitinase 3-Like 1 
 PEDF (Serpin-F1) 
 Annexin I 
 IHRP / ITIH4 
 Vitronectin 
 Complement C4B3 
 Kininogen I 
 Chromogranin A 
 Secretogranin III 
 Apolipoprotein J 
 Beta 2-microglobulin 
Prostaglandin metabolism Prostaglandin H2 D Isomerase / Beta-trace 
Amyloid beta peptide binding / amyloidogenesis Apolipoprotein A1 (proapolipoprotein) 
 Apolipoprotein E 




 Cystatin C 
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 Prostaglandin H2 D Isomerase / Beta-trace    
 a-2-macroglobulin 
 a-1-antichymotrypsin 
Protease activity a-1-antichymotrypsin 
 a-2-macroglobulin 
 Cystatin C 
 Carboxypeptidase E 
Matrix proteins Fibulin 3 (EFEMP1) 
 Vitronectin 
Phospholipase activity Annexin I (Lipocortin) 
 Prosaposin 
Apolipoproteins Apolipoprotein A1 (proapolipoprotein) 
 Apolipoprotein CII 
 Apolipoprotein CIII 
 Apolipoprotein E 
 Apolipoprotein J 
 Apolipoprotein H 
Calcium binding / homeostasis Calmodulin 
 S100A1 
 Annexin I (Lipocortin) 
 Calsyntenin (post-synaptic cytoplasmic domain) 
 Gelsolin 
Metal (Copper and Iron) Binding Carnosinase I 
 Ceruloplasmin 
 Brain Acetylcholinesterase Putative Membrane Anchor (CutA1) 
Chaperone complex / activity S100A1 
 Transthyretin (prealbumin) 
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Endoplasmic Reticulum - Associated Degradation 
(ERAD) Man9-mannosidase 
Extracellular and Intraneuronal pH Carbonic Anhydrase IV 
 Carnosinase I 
Glycobiology (lactosamine synthesis) B3GnT1 (lactosamine synthesis) 
CNS renin-angiotensinogen system Angiotensinogen 
Thyroid hormone transport Transthyretin (prealbumin) 
Unknown Hypothetical protein 
Table 2.4. Candidate CSF biomarkers reflect AD-related pathophysiological 
changes. Candidate CSF biomarkers are grouped according to reported function(s) and, 









Chapter 2. Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early 
Alzheimer’s Disease Using Proteomics and ELISA 
 
 
Figure 2.8. Hypothetical model to define early stages of AD by temporal pattern of 
CSF protein biomarker levels. The horizontal bar (below) describes the early 
clinicopathological progression from non-AD to mild dementia (CDR 1) in six stages. As 
depicted by the curves above, ‘Non-AD’ CSF has high Aβ42 (red line), high 
chromogranin A (Chr A), carnosinase I (Carno I) and NrCAM (green line), and low YKL-
40 and tau (blue line). Reduced CSF Aβ42 correlates with amyloid plaque deposits, the 
first sign of neuropathologically identifiable AD (“preclinical AD”) (127). CSF Aβ42 
appears to decline further as cognition declines from CDR 0 to 0.5 to 1. When 
considered as ratios with Aβ42, CSF markers of neuroinflammation (e.g. YKL-40) and 
neurofibrillary tangle pathology (e.g. tau) appear to increase before and predict the onset 
of very mild cognitive impairment (CDR 0.5), defining a CDR 0 group ‘At Risk’ for 
cognitive decline (107, 121, 132, 372); YKL-40 and tau also appear to be higher among 
those who progress rapidly from very mild to mild dementia, defining a CDR 0.5 group 
‘At Risk’ for cognitive decline.  Reductions in synapse-associated (NrCAM, 
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chromogranin A) and neuronal (carnosinase I) proteins, and increases in tau mirror the 
progression and anatomical spread of synaptic and neuronal losses and tau pathology 


























YKL-40: A Novel Diagnostic and Prognostic Fluid Biomarker for Preclinical and 



















Background:  Disease-modifying therapies for Alzheimer’s disease (AD) would be most 
beneficial if applied during the ‘preclinical’ stage (pathology present with cognition intact) 
before significant neuronal loss occurs. Therefore, biomarkers that can detect AD 
pathology in its early stages and predict dementia onset and progression will be 
invaluable for patient care and efficient clinical trial design.  
Methods:  Previously, 2D-difference gel electrophoresis and liquid chromatography 
tandem mass spectrometry were used to measure AD-associated changes in 
cerebrospinal fluid (CSF). Concentrations of one of the most promising candidates 
identified by this method, CSF YKL-40, were further evaluated by enzyme-linked 
immunosorbent assay in the discovery cohort (N=47), an independent sample set 
(N=292) with paired plasma samples (N=237), frontotemporal lobar degeneration (N=9), 
and progressive supranuclear palsy (PSP, N=6). Human AD brain was studied 
immunohistochemically to identify potential source(s) of YKL-40.  
Results:  In the discovery and validation cohorts, mean CSF YKL-40 was higher in very 
mild and mild AD-type dementia (Clinical Dementia Rating [CDR] 0.5 and 1) vs. controls 
(CDR 0) and PSP. Importantly, CSF YKL-40/Aβ42 ratio predicted risk of developing 
cognitive impairment (CDR 0 to CDR>0 conversion) as well as the best CSF biomarkers 
identified to date, tau/Aβ42 and p-tau181/Aβ42. Mean plasma YKL-40 was higher in 
CDR 0.5 and 1 vs. CDR 0 groups, and correlated with CSF levels. YKL-40 
immunoreactivity was observed within astrocytes near a subset of amyloid plaques, 
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Conclusions:  These data demonstrate that YKL-40, a putative indicator of 
neuroinflammation, is elevated in AD, and that, together with Aβ42, has potential 























Clinicopathological studies suggest that the pathological hallmarks of AD, 
amyloid plaques and neurofibrillary tangles, begin to appear ~10-20 years before the 
synaptic and neuronal loss that accompany dementia onset (44, 66, 72). Identifying and 
treating individuals during this preclinical stage will maximize benefit from disease-
modifying therapies. By definition, this preclinical phase of AD will elude detection by 
conventional clinical examination, and will therefore require the use of biomarkers for 
diagnosis. Beyond diagnosis, biomarkers may also provide prognostic information and 
facilitate the monitoring of disease progression and response to treatment. In addition, 
novel biomarkers may advance our understanding of AD pathophysiology, and thereby 
inform future treatment strategies.  
Because many proteins expressed in the brain are present in the cerebrospinal 
fluid (CSF), the CSF proteome is a logical source for potential AD biomarkers. Indeed, 
CSF amyloid-β42 (Aβ42), tau, and phosphorylated forms of tau (p-tau) have already 
shown great promise for use in AD diagnosis and prognosis (410-413). Nevertheless, 
there remains a need for supplemental biomarkers that represent different aspects of AD 
pathophysiology and can improve diagnosis and prognosis at early disease stages. 
To discover additional CSF biomarkers for early AD, we used two-dimensional 
difference gel electrophoresis in conjunction with tandem mass spectrometry (2-D DIGE 
LC-MS/MS) to identify proteins that increase or decrease in the setting of early AD 
relative to age-matched cognitively normal controls (see Chapter 2 for details). One 
protein found in that study to be significantly more abundant in AD CSF, YKL-40  
(chitinase-3 like-1 [CHI3L1], human cartilage glycoprotein-39 [HC-gp39], and chondrex), 
is a secreted 40-kDa glycoprotein with sequence homology to bacterial and fungal 
chitinases and chitin binding ability, but no chitinase activity (379). Reports suggest a 
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role in inflammation and tissue remodeling, and an upregulation in AD brain (373), but its 
physiological function remains unclear (414, 415). Nevertheless, plasma/serum and/or 
CSF levels of YKL-40 have been proposed as a candidate biomarker for arthritis, 
asthma, multiple sclerosis, and myriad cancers (414-416). 
In this study, we evaluate the potential of CSF and plasma YKL-40 to serve as 
diagnostic and prognostic biomarkers for AD; additionally, using immunohistochemistry, 
we investigate the source(s) of YKL-40 in the brain in the setting of AD. Our data 
suggest that CSF YKL-40 is produced by astrocytes, is significantly elevated in very mild 





Discovery cohort:  Subjects (N=48), community-dwelling volunteers from 
University of Washington (N=18), Oregon Health and Science University (N=11), 
University of Pennsylvania (N=11), and University of California San Diego (N=8), were 
51-87 years of age and in good general health, having no other neurological, psychiatric, 
or major medical diagnoses that could contribute importantly to dementia, nor use of 
exclusionary medications within 1-3 months of lumbar puncture (LP) (e.g. neuroleptics, 
anticonvulsants, anticoagulants). Study protocols at each institution were approved by 
their respective Institutional Review Boards and written informed consent was obtained 
from each participant. Cognitive status was evaluated based on criteria from the National 
Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease 
and Related Disorders Association (57). CSF was collected in the morning by LP after 
overnight fasting and immediately frozen at -80°C. Subjects with a clinical dementia 
rating (CDR) of 0 (N=24), indicating no dementia, and CDR 1 (N=24), indicating mild 
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dementia, were selected from a larger group of 120 samples on the basis of CSF Aβ42 
(relatively high and low values, respectively), and, when possible, CSF tau (relatively low 
and high values, respectively) to increase the likelihood of CDR 1 subjects having and 
CDR 0 subjects not having AD pathology. CSF Aβ42 and tau levels were measured in a 
single laboratory using well-established ELISAs ((366) and Innotest, Innogenetics, 
respectively). Quantitative thresholds were not defined prior to sample selection; the 
lowest CDR 0 and highest CDR 1 CSF Aβ42 value were 572 and 399 pg/mL, 
respectively; CSF tau ranges were CDR 0: 141-448 pg/mL, CDR 1: 216-1965 pg/mL.    
 
Validation cohort: Subjects (N=292), community-dwelling volunteers enrolled in 
longitudinal studies of healthy aging and dementia at the Washington University 
Alzheimer Disease Research Center (WU-ADRC), were ≥60 years of age and met the 
same exclusion criteria as the discovery cohort. The study protocol was approved by the 
Human Studies Committee at WU, and we obtained written and verbal informed consent 
from participants at enrollment. CDR status was determined as with the discovery 
cohort, with an additional category of CDR 0.5, indicating very mild dementia; some of 
these met criteria for MCI and some were more mildly impaired, or “pre-MCI” (70). A 
subset of subjects (N=159) underwent positron emission tomography (PET) imaging with 
Pittsburgh Compound-B (PIB) for assessment of in vivo amyloid burden (127, 318, 330). 
Apolipoprotein E (APOE) genotypes were determined by the WU-ADRC Genetics Core. 
Fasted CSF was collected, mixed, centrifuged, and frozen at -80°C in polypropylene 
tubes; blood was collected at the time of LP, and plasma prepared by centrifugation and 
stored at -80°C (107). 
 
FTLD/PSP Cohort: Volunteer subjects were diagnosed with frontotemporal lobar 
degeneration (FTLD) (N=9) or progressive supranuclear palsy (PSP) (N=6) at the 
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University of California San Francisco (UCSF) Memory and Aging Center using 
published criteria (417, 418). Subjects in the FTLD group met criteria for one of the three 
clinical syndromes that comprise FTLD: frontotemporal dementia (FTD) (N=6), semantic 
dementia (SD) (N=1), and progressive non-fluent aphasia (PNFA) (N=2) (417). The 
study protocol was approved by the UCSF Committee on Human Research, and 
informed consent was obtained from all participants. CSF was collected by LP and 
immediately frozen at -80°C. 
 
2-D DIGE LC-MS/MS Proteomic Analysis 
Details for sample processing and analysis can be found in Chapter 2. In brief, discovery 
cohort CSF samples and a pooled reference sample were immunodepleted of six highly 
abundant proteins (albumin, IgG, α1-antitrypsin, IgA, haptoglobin, transferrin). Samples 
were randomly paired (CDR 0 and CDR 1), labeled with one of three cyanine dyes, and 
loaded with the labeled reference sample onto the same 2-D gel. Protein spot 
quantification and between-gel spot matching were performed on digitized images. To 
focus efforts on candidate biomarkers more likely to be measurable in the CSF of a 
majority of individuals, only gel features with significant intensity differences between 
CDR 0 and CDR 1 groups (Student’s t-test, α=0.05) that were present in >50% of gels 
were excised, trypsinized, and subjected to LC-MS/MS. Proteins were identified from 
peptide fragmentation spectra using MASCOT (v2.8, Matrix Sciences) and the NCBI 
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Enzyme Linked Immunosorbent Assays (ELISAs) 
CSF and plasma samples were analyzed by ELISA for Aβ42, total tau, and 
phospho-tau181 (Innotest, Innogenetics) after one freeze-thaw, and for YKL-40 (Quidel) 
after two freeze-thaw cycles. Intra- and inter-assay coefficient of variation for CSF YKL-
40 were 5.27% and 6.03%, respectively; for plasma, 5.73% and 11.26%.   
 
Statistical Analyses 
Correlations were evaluated using the Pearson rho correlation coefficient 
(α=0.05). Survival analyses assessed the ability of baseline biomarkers and biomarker 
ratios to predict time to conversion from cognitive normalcy (CDR 0) to very mild or mild 
dementia (CDR 0.5, 1) and time to progression from very mild dementia (CDR 0.5) to 
more severe dementia (CDR>0.5). Data from subjects who did not convert/progress 
were statistically censored at the date of last assessment. Biomarker measurements 
were converted to standard Z-scores to allow comparison of hazard ratios between 
different biomarkers. Cox proportional hazard models adjusted for age and gender were 
conducted treating the CSF biomarkers as continuous and categorical variables. 
Categorical analyses compared subjects within the highest tertile of baseline values to 
those within the lowest two tertiles; this tertile-based assessment was applied because 
Kaplan-Meier curves illustrating the unadjusted time to CDR>0 for each tertile of each 
biomarker suggested similar outcomes for the lower two tertiles. The difference between 
the survival curves reflecting the upper tertile versus the lower tertiles of each biomarker 
was tested using the log-rank test. Survival analyses were conducted using baseline 
CDR scores determined at clinical assessment prior to LP; analyses using scores 
determined at clinical assessment closest to LP yielded almost identical results. Similar 
survival analyses were carried out for plasma YKL-40. 
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Six-µm-thick sections of formalin-fixed, paraffin-embedded human postmortem 
brain tissue (middle frontal gyrus, post mortem interval <6 hrs) from the WU-ADRC 
Neuropathology Core were double-labeled using rabbit anti-human YKL-40 antibody 
(Quidel) in series with either goat anti-human GFAP (Santa Cruz), mouse anti-human 
HLA Class II antigen, LN-3 (Novocastra), RCA-1 (Vector), or mouse anti-human PHF-1 
(gift of Dr. Peter Davies), followed by staining with the ImmPress kit (Vector). In control 
experiments, the primary antibody was omitted and replaced with 1% bovine serum 
albumin-PBS. Thioflavin S stain (1% aqueous) was applied for 20 minutes and destained 




Proteomic Analysis Identifies YKL-40 as Increased in AD CSF 
To identify new candidate biomarkers for AD, we utilized an unbiased proteomics 
approach, 2-D DIGE LC-MS/MS (222, 251), to compare the concentrations of CSF 
proteins in individuals with mild dementia (CDR 1, N=24) of the Alzheimer’s type to those 
in individuals without dementia (CDR 0, N=24) (see Chapter 2 for details of this portion). 
The two groups differed with respect to age at LP and gender (CDR 0: 64.8 yrs, 38% 
female; CDR 1: 72.8 yrs, 54% female). From this proteomic analysis, we identified 47 
proteins that differed in abundance between the CDR 0 and CDR 1 groups (Chapter 2); 
one of the most promising, in terms of fold-change and novelty, was YKL-40. 
Interestingly, in a smaller, previous study, we identified YKL-40 as being significantly 
more abundant in CSF from CDR 0.5 relative to CDR 0 subjects (251). YKL-40 
appeared in four gel features that were more abundant in the CDR 1 group (Figure 
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3.1A). Tryptic peptides from these spots collectively provide amino acid sequence 
coverage of 52% and span virtually the full length of the protein (Figure 3.1B), 
suggesting that these spots represent full-length secreted YKL-40. We hypothesize that 
this pattern of four spots may be due to allelic differences, post-translational 
modifications, or both.  
 
ELISA Confirms Increased CSF YKL-40 in AD in Original and Independent Cohorts 
To validate our 2-D DIGE findings, we applied a YKL-40 ELISA to the original 
‘discovery’ cohort samples (one sample was unavailable for re-evaluation, N=47). Mean 
CSF YKL-40 was increased 43% in the CDR 1 vs CDR 0 group (p=.0016) (Figure 3.2A), 
consistent with the fold-changes measured by 2-D DIGE. We next assayed a larger, 
independent set of CDR 0, 0.5, and 1 CSF samples collected at the WU-ADRC (N=292) 
that was not preselected on the basis of CSF Aβ42 and tau values (characteristics at 
baseline assessment in Table 3.1). In this validation cohort, mean CSF YKL-40 was 
significantly (27%) higher in the CDR 0.5 and CDR 1 groups vs. CDR 0 (p<.0001 and 
p=.004, respectively) (Figure 3.2B). An analysis of covariance (ANCOVA) revealed that 
this increase remained significant after adjusting for age, F(2, 288) = 9.075, p<.0001. 
 
CSF YKL-40 is Increased in FTLD and Decreased in PSP 
In an effort to determine whether CSF YKL-40 might have potential to distinguish 
AD from other dementing illnesses, we evaluated levels in two other neurodegenerative 
diseases: frontotemporal lobar degeneration (FTLD, N=9) and progressive supranuclear 
palsy (PSP, N=6). Mean CSF YKL-40 was increased in FTLD relative to AD, although a 
wide range of values was observed, possibly reflecting the pathological heterogeneity of 
FTLD; in contrast, PSP cases showed relatively low levels and range of CSF YKL-40 
(Figure 3.3A). Although this study does not evaluate the complete differential diagnosis 
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for mild cognitive impairment or mild dementia, these data suggest that CSF YKL-40 
may be useful to distinguish AD from some other forms of neurodegenerative disease.   
 
Correlation of CSF YKL-40 With Demographic Features and Other Biomarker 
Values 
Because the CDR 0, 0.5, and 1 groups show somewhat different distributions 
with regard to age at LP, gender, and APOE genotype, levels of CSF YKL-40 were 
evaluated for potential correlation with these variables. CSF YKL-40 levels did not vary 
based on gender (p=.8355) or APOE genotype (not shown) but did correlate with 
increasing age (r=.3943, p<.0001) (Figure 3.4). Next, seeking insight into the role of 
YKL-40 in AD pathology, we evaluated its associations with CSF Aβ42, CSF tau, and 
cortical amyloid burden measured by PIB-PET imaging. In this validation cohort, CSF 
YKL-40 did not correlate with CSF Aβ42 (r=-.02463, p=.6745), but did correlate with CSF 
tau (r=.6331, p<.0001), and p-tau181 (r=.5947, p<.0001), and modestly with cortical 
amyloid burden (r=.2093, p=.0081) (Figure 3.4). Interestingly, a similar correlation of 
CSF YKL-40 with tau was observed in FTLD (r=.9109, p=.0006), but not in PSP 
(r=.2434, p=.6422) (Figure 3.3B,C), suggesting that these two biomarkers are not 
inextricably linked, and that they may reflect separate but interrelated pathophysiological 
processes. 
 
Ability of CSF YKL-40 To Predict Onset and Progression of Dementia  
Recognizing the need for preclinical diagnosis and prognosis, we applied survival 
analyses to evaluate whether CSF YKL-40 can predict risk of developing cognitive 
impairment (conversion from CDR 0 to CDR>0) and of dementia progression (CDR 0.5 
to CDR>0.5). Of the 174 CDR 0 subjects with at least one follow-up clinical assessment, 
26 received a CDR>0 at follow-up, and thus were classified as “converters.” Since CSF 
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tau/Aβ42 and p-tau181/Aβ42 ratios have been shown to predict cognitive decline in 
cognitively normal (107, 132) and MCI (348, 419) cohorts, survival analyses were also 
conducted for these biomarkers. Treated as categorical variables, subjects with high 
ratios (upper tertile) of CSF YKL-40/Aβ42, tau/Aβ42, and p-tau181/Aβ42 were faster to 
convert to CDR>0 than were subjects with lower ratios (lower tertiles) (Figure 3.5A), 
even after adjusting for age and gender (Figure 3.6). Likewise, when treated as 
continuous variables, CSF YKL-40/Aβ42, tau/Aβ42, and p-tau181/Aβ42 ratios again 
predicted conversion from CDR 0 to CDR>0 (p=0.0003, p=0.0001, p<.0001, 
respectively) after adjustment for age and gender (Figure 3.6). Importantly, when 
evaluated individually, CSF YKL-40, Aβ42, tau, and p-tau181 did not perform as well as 
the YKL-40/Aβ42, tau/Aβ42, and p-tau181/Aβ42 ratios at predicting conversion from 
CDR 0 to CDR>0 (Figure 3.7). Thus, the CSF YKL-40/Aβ42 ratio, as a prognostic 
biomarker of future cognitive impairment in normal individuals, is comparable to the best 
CSF biomarkers of this type to date, tau/Aβ42 and p-tau181/Aβ42. 
Of the 59 CDR 0.5 subjects with at least one follow-up clinical assessment, 24 
received a CDR>0.5 at follow-up, and thus were classified as “progressors.” Kaplan-
Meier estimates of the rate of progression suggest that those with high CSF YKL-
40/Aβ42 ratios (upper tertile) were faster to progress to CDR>0.5 than those with lower 
CSF YKL-40/Aβ42 ratios (lower two tertiles) (p=.0648) (Figure 3.5B). The tau/Aβ42 and 
p-tau181/Aβ42 ratios showed similar patterns (Figure 3.5B). After adjustment for age 
and gender, similar results were found for all three categorical biomarker variables 
(Figure 3.6). Treated as a continuous variable and adjusted for age and gender, p-
tau181/Aβ42 and YKL-40/Aβ42 ratios showed trends associated with time to 
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 Plasma YKL-40 Demonstrates Limited Utility as AD Biomarker  
To evaluate plasma YKL-40 as a potential AD biomarker, we applied the ELISA 
to 237 plasma samples from the validation cohort. Mean plasma YKL-40 was 
significantly higher in the CDR 0.5 and CDR 1 vs CDR 0 group (p=.046, p=.031, 
respectively, One-way ANOVA, Tukey post-hoc), with percent increases similar to those 
observed in CSF (Figure 3.8A). Plasma and CSF YKL-40 levels correlated modestly 
(r=.2376, p=.0002) (Figure 3.8B), with levels roughly 5-fold higher in CSF. Plasma YKL-
40 also correlated with increasing age (r=.2284, p=.0004), but not with gender 
(p=.6558), CSF Aβ42 (r= -.07902, p=.2255), CSF tau (r=.03769, p=.5637), CSF p-
tau181 (r=-.02738, p=.6749), or cortical amyloid load (r=.01789, p=.8576) (Figure 3.9).  
Plasma YKL-40 did not demonstrate utility for predicting cognitive decline (not shown). 
 
In AD Brain, YKL-40 is Expressed in Astrocytes in Vicinity of Plaques and in Rare 
White Matter Neurons 
To investigate potential source(s) of YKL-40 in AD, we performed single and 
double-label immunohistochemistry on human frontal cortex. YKL-40 immunoreactivity 
was observed in the vicinity of a subset of thioflavin S-positive amyloid plaques (Figure 
3.10A,B,C) within GFAP-positive astrocytes (Figure 3.10D), and not within microglia 
stained with LN-3 (Figure 3.10E,F) or lectin RCA-1 (not shown). YKL-40 
immunoreactivity was also present in plaque-associated cell processes (Figure 3.10G) 
that lacked reactivity for dystrophic neurite marker PHF-1 (Figure 3.10H) and microglial 
marker LN-3 (Figure 3.10J,K,L representing adjacent focal planes), and that may 
represent astrocytic processes (suggested in Figure 3.10I by the plaque-associated 
YKL-40-positive astrocyte in lower left quadrant). YKL-40 immunoreactivity was also 
observed within the superficial cortical white matter in rare neurons (Figure 3.10M,N,O) 
with occasional PHF-1-positive neurofibrillary tangles (Figure 3.10N,O). These neurons 
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This study suggests that CSF YKL-40, a novel inflammatory biomarker for AD, is 
increased in AD, and, together with Aβ42, will assist in prognosis of patients and clinical 
trial participants who are under examination for the preclinical and early clinical stages of 
AD.  
Having identified CSF YKL-40 as a potential AD biomarker through non-biased 
proteomics, we verified this finding using a commercially available ELISA, and more 
importantly, validated the results in a much larger, independent cohort. By including very 
mildly impaired (CDR 0.5) individuals who may be classified at some other institutions as 
having MCI, or even “pre-MCI,” as some were insufficiently impaired to meet MCI 
criteria, this validation cohort revealed the promise of CSF YKL-40 as a biomarker for 
very early stage AD. By including individuals with FTLD and PSP, albeit in small 
numbers, we also demonstrated that CSF YKL-40 shows promise for distinguishing AD 
from PSP. 
By including individuals who were cognitively normal at the time of CSF 
collection, but subsequently developed cognitive impairment, this validation cohort also 
revealed the potential utility of YKL-40, coupled with Aβ42, to predict cognitive decline. It 
has previously been shown that ratios of CSF tau/Aβ42 and p-tau181/Aβ42 can predict 
conversion from cognitively normal to cognitively impaired over a 2-4 year period (107, 
132). Here we confirm those findings in a cohort of twice the size, and show that CSF 
YKL-40/Aβ42 has predictive value comparable to that of these best current CSF 
measures. This finding is particularly notable because, whereas CSF tau is derived 
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principally from neurons, YKL-40 appears to be secreted predominantly from astrocytes. 
To our knowledge, YKL-40 is the first astrocyte-derived marker shown to be useful in 
such a way. CSF YKL-40/Aβ42 also showed promise in predicting progression of 
dementia from CDR 0.5 to CDR>0.5. However, tau/Aβ42 and p-tau181/Aβ42 appear to 
show greater utility for predicting progression.  
We also evaluated plasma YKL-40 as a potential AD biomarker. While plasma 
YKL-40 levels displayed a pattern of elevation in the CDR 0.5 and 1 groups similar to 
that observed for CSF, and plasma and CSF levels were modestly correlated, plasma 
YKL-40 did not show similar prognostic utility. Whether this increase in plasma YKL-40 
reflects passive or active export of central nervous system (CNS)-derived YKL-40 or 
coincident peripheral production in response to a systemic inflammatory signal is 
unclear. Similar coincident elevations of CSF and serum YKL-40 levels have been 
reported with aneurysmal subarachnoid hemorrhage (421) and multiple sclerosis (416). 
However, in the setting of CNS infection, CSF levels of YKL-40 appear to rise without a 
concomitant increase in serum levels (375, 376), suggesting that YKL-40 produced in 
the brain does not influence serum/plasma levels. Data to address the converse- 
whether YKL-40 produced in the periphery can influence CSF levels- have not yet been 
reported. This issue is important to assess in future studies because peripheral 
inflammatory and neoplastic conditions are not uncommon within populations most likely 
to be screened for AD.  
To examine its role in AD and to identify potential sources of CSF YKL-40, we 
immunohistochemically double-labeled human AD brain tissue for YKL-40 and other cell-
specific markers, and observed YKL-40 in a subset of plaque-associated astrocytes and 
in rare white matter neurons. These results should help to clarify the origins of CSF YKL-
40, which have been controversial among the small number of relevant studies (375, 
383, 422). Additionally, the pattern of expression within a subset of plaque-associated 
93 
 
Chapter 3. YKL-40: A Novel Diagnostic and Prognostic Fluid Biomarker for Preclinical and Early 
Alzheimer’s Disease 
 
astrocytes may account for the positive correlation we observe between CSF YKL-40 
and cortical amyloid load (Figure 3.4); as amyloid plaque burden increases, so does the 
amount of plaque associated-astrocyte activation, and likely, the amount of CSF YKL-40. 
It may also account for the lack of correlation we observe between CSF YKL-40 and 
CSF Aβ42, and for the relatively equal levels of CSF YKL-40 between CDR 0.5 and 
CDR 1 groups; once plaque formation commences, which is estimated to occur ~15 
years prior to cognitive decline (410, 411, 413), CSF Aβ42 remains at a low steady state 
(94, 127, 128, 423), so no correlation with YKL-40 would be expected. Likewise, amyloid 
burden appears close to its maximal extent once cognitive decline begins (107, 127, 
128), so plaque burden and CSF YKL-40 levels might be expected to be similar in CDR 
0.5 and CDR 1 groups. More importantly, these results implicate YKL-40 in the astrocytic 
neuroinflammatory response to fibrillar Aβ deposition that appears to play a role in AD 
pathogenesis (207, 424, 425). 
What induces YKL-40 expression in the presence of AD pathology, and how 
increased YKL-40 expression may influence the disease process are unknown. In 
models of peripheral inflammation such as asthma and arthritis, tumor necrosis factor-α 
(TNF-α) and interleukin-1β (IL-1β) appear to stimulate YKL-40 synthesis in macrophages 
and chondrocytes (382, 426). Since TNF-α and IL-1β are implicated in AD 
neuroinflammation, it is reasonable to hypothesize that astrocytic expression of YKL-40 
may be similarly induced. Given that TNF-α and IL-1β can cross the blood brain barrier, 
it is also reasonable to hypothesize that YKL-40 levels in plasma and CSF might be 
modulated by systemic or central inflammation. Defining the factors required to induce 
YKL-40 expression in astrocytes will be an important first step in understanding the role 
of YKL-40 in AD and, more generally, in the CNS.  
Defining the targets of YKL-40 in the brain is also critically important for 
understanding its role in AD. In the periphery, YKL-40 can reportedly stimulate 
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connective tissue cell growth (427, 428); modulate the effects of inflammatory cytokines 
in fibroblasts (381); bind collagen and influence its fibrillogenesis (429); stimulate 
endothelial cell migration (430); modulate vascular smooth muscle cell adhesion and 
migration (431); support antigen-induced Th2 inflammatory responses (432); and 
stimulate alveolar macrophages to release metalloproteinases and pro-inflammatory and 
fibrogenic chemokines (382). In the brain, YKL-40 is reported to release extracellular 
matrix-bound bFGF (375). Clearly, further study of YKL-40 in AD and, more generally, 
within the CNS and periphery, is warranted to define its pathophysiological role(s).  
This study identifies YKL-40 as a novel astrocyte-derived CSF biomarker that 
can distinguish groups of AD and control subjects and predict risk of developing 
dementia among cognitively normal subjects. Nevertheless, like all AD biomarker 
candidates to date, YKL-40 is likely to have less value when applied in isolation, and, 
alone, will be insufficient to provide definitive information for an individual patient. While 
significant differences in mean CSF and plasma YKL-40 levels exist between CDR 0 and 
CDR 0.5, and CDR 0 and CDR 1 groups, the ranges of YKL-40 values among the 
groups show considerable overlap. This overlap may stem from several sources. The 
greatest contribution is likely due to the inclusion of individuals with asymptomatic 
(preclinical) AD pathology in the CDR 0 group; AD neuropathology is present in ~25% of 
non-demented individuals age ≥75 years (150, 433). It is also possible that different 
alleles of the CHI3L1 gene may influence baseline or reactive levels of YKL-40 protein 
expression, or that members of this cohort may be afflicted by other diseases that affect 
CSF YKL-40 levels. For example, elevated CSF YKL-40 has been reported in the setting 
of other CNS pathologies (375, 376, 416, 421); however, most of these conditions would 
be easily distinguishable from early AD on the basis of clinical assessment. It is 
important to note that the overlap observed for CSF YKL-40 is comparable to that seen 
for the best biomarkers identified to date, CSF Aβ42 and CSF tau (Figure 3.2 D&E) 
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(346). The best use of YKL-40 may be in a panel of biomarkers that provide 
complementary information to guide diagnosis, prognosis, clinical trial design, and 
treatment decisions. Indeed, in other work stemming from this 2-D DIGE study, stepwise 
logistic regression analyses indicate that YKL-40, as part of a panel with other CSF 
biomarkers, contributes additional sensitivity and specificity for discriminating mildly 
demented individuals from cognitively normal individuals (see Chapter 2). Additionally, 
YKL-40 may confer specificity to a panel by distinguishing PSP or other illnesses from 
AD, as our early results suggest. It will be of interest in future studies to confirm these 
results and to evaluate CSF YKL-40 levels in the setting of additional dementing 
conditions. Perhaps more importantly, YKL-40, for its own part, might contribute 
diagnostic sensitivity for early cognitive impairment, prognostic information for risk of 
cognitive decline in normal and very mildly impaired individuals, and, more 
























Figure 3.1.  (A) A representative 2-D DIGE image of CSF from the discovery cohort. 
Samples were depleted of six highly abundant proteins, fluorescently labeled, and 
subjected to isoelectric focusing followed by SDS-PAGE. YKL-40 is more abundant in 
four spots in the CDR 1 group (labeled 1-4 in the inset, with mean fold changes of 1.41, 
1.50, 1.46, 1.32, respectively). The near invisibility of spot 4 in this printed representation 
illustrates the great sensitivity of 2-D DIGE to detect proteins of low abundance. (B) 
Sequence coverage of human YKL-40 by mass spectrometry. Indicated in red is the 
compilation of peptides identified in the four spots. The signal sequence is shown in 








Table 3.1. Demographic, Clinical, and Genotypic Characteristics of Validation 
Cohort. 
Abbreviations: CDR, Clinical Dementia Rating; APOE, apolipoprotein E; MMSE, Mini-
Mental State Examination; LP, lumbar puncture; SD, standard deviation; CSF, 
cerebrospinal fluid; Aβ-42, amyloid-beta peptide 1-42; ptau181, tau phosphorylated at 











Figure 3.2. Mean YKL-40 is increased in the CSF of CDR 0.5 and CDR 1 subjects. (A) 
CSF from the discovery cohort (CDR 0, N= 24; CDR 1, N=23) was analyzed for YKL-40 
by ELISA (CDR 0= 293.6 +/- 23.9; CDR 1= 422.2 +/- 30.0, ng/mL, mean +/- SEM). CSF 
YKL-40 was significantly higher in the CDR 1 group as compared to the CDR 0 group 
(p=.0016, unpaired student’s t-test). (B) CSF from a larger, independent sample set 
(N=292) was analyzed for YKL-40 by ELISA. Mean CSF YKL-40 was significantly higher 
in the CDR 0.5 and CDR 1 groups as compared to the CDR 0 group (** p=.004, *** 
p<.0001; One-way ANOVA with Welch’s correction for unequal variances, Tukey post-
hoc Test) (CDR 0= 282.1 +/- 6.7; CDR 0.5= 358.9 +/- 16.9; CDR 1= 351.7 +/- 22.6, 
ng/mL, mean +/- SEM). (C) Mean CSF YKL-40/Aβ42 was significantly higher in the CDR 
99 
 
Chapter 3. YKL-40: A Novel Diagnostic and Prognostic Fluid Biomarker for Preclinical and Early 
Alzheimer’s Disease 
 
0.5 and CDR 1 groups as compared to the CDR 0 group (*** p<.0001; One-way ANOVA 
with Welch’s correction for unequal variances, Tukey post-hoc Test). (D & E) Mean CSF 
Aβ42 was significantly higher while mean CSF tau was significantly lower in the CDR 0.5 
and CDR 1 groups as compared to the CDR 0 group (*** p<.0001; One-way ANOVA 
with Welch’s correction for unequal variances, Tukey post-hoc Test). The degree of 
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Figure 3.3. (A) CSF samples from subjects with FTLD (N=9) and PSP (N=6) were 
analyzed for YKL-40 by ELISA, and levels were compared to those of the validation 
cohort (CDR 0 and CDR>0 [CDR 0.5&1 combined], N=292). Because the groups 
differed with respect to mean age at LP (FTLD: 59 yrs, PSP: 66 yrs, CDR 0: 71 yrs, CDR 
0.5&1: 75 yrs), analyses were adjusted for age. CSF YKL-40 was significantly higher in 
the FTLD group as compared to the PSP, CDR 0, and CDR>0 groups (*** p<.0001; 
ANCOVA, LSD post-hoc Test). While not reaching statistical significance (defined here 
as α=0.05), CSF YKL-40 levels trended lower in the PSP group as compared to the 
CDR>0 group. (B-C) CSF YKL-40 and CSF tau values correlated strongly in the FTLD 
group, but did not correlate in the PSP group.  
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Figure 3.4. In the validation cohort, CSF YKL-40 levels do not vary based on gender 
and are not correlated with CSF Aβ42. However, CSF YKL-40 levels are correlated with 
age, CSF tau, CSF p-tau181, and mean cortical PIB binding potential. 
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Figure 3.5. CSF YKL-40/Aβ42, tau/Aβ42, and p-tau/Aβ42 as predictors of (A) 
conversion from CDR 0 to CDR>0 and (B) progression from CDR 0.5 to CDR>0.5. 
Kaplan-Meier estimates of rates of conversion and progression are shown with red 
curves representing the upper tertile and black curves representing the lower two 
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tertiles. The bottom panel shows for the CSF YKL-40/Aβ42 analyses the number of 
























Figure 3.6.  Cox proportional hazards models were used to assess the ability of CSF 
YKL-40/Aβ42, tau/Aβ42, and ptau/Aβ42 to predict (top) conversion from cognitive 
normalcy (CDR 0) to cognitive impairment (CDR>0) and (bottom) progression from very 
mild dementia (CDR 0.5) to mild or moderate dementia (CDR>0.5). Biomarker measures 
were analyzed as both continuous and categorical variables, and were converted to 
standard Z-scores to allow comparison of hazard ratios between different biomarkers. In 
evaluating risk, analyses were adjusted for age and gender. Abbreviations: HR, hazard 
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Figure 3.7. (A) CSF YKL-40, tau, p-tau181, and Aβ42 as predictors of conversion from 
CDR 0 to CDR>0. Kaplan-Meier estimates of rates of conversion are shown with red 
curves representing the upper tertile and black curves representing the lower two 
tertiles. (B) Cox proportional hazards models were used to assess the ability of CSF 
YKL-40, tau, p-tau181, and Aβ42 to predict conversion from cognitive normalcy (CDR 0) 
to cognitive impairment (CDR>0). Biomarker measures were analyzed as both 
continuous and categorical variables. In evaluating risk, “Biomarker” analyses (YKL-40, 
tau, p-tau181, Aβ42) were adjusted for age and gender. Likewise, analyses for “Age” 
were adjusted for biomarker and gender, and analyses for “Women” were adjusted for 














Figure 3.8. Plasma samples of the validation cohort (N=237) were evaluated for YKL-40 
by ELISA. (A) Mean plasma YKL-40 was significantly higher in the CDR 0.5 and CDR 1 
groups as compared to the CDR 0 group (+ p=.046, * p=.031; One-way ANOVA, Tukey 
post-hoc Test) (CDR 0= 62.5 +/- 3.4; CDR 0.5= 81.1 +/- 8.0; CDR 1= 91.9 +/- 15.0, 










Figure 3.9. Plasma YKL-40 levels do not vary based on gender, but are correlated with 
age. Plasma YKL-40 levels are not correlated with other CSF biomarkers such as Aβ42, 








Figure 3.10. In AD neocortex, YKL-40 immunoreactivity is observed in the vicinity of 
thioflavin S-positive fibrillar amyloid plaques (A,B,C). YKL-40 immunoreactivity is present 
within a subset of GFAP-positive astrocytes (D) and not in LN-3-positive microglia (E,F). 
YKL-40 is also observed in cell processes associated with plaques (G); these processes 
lack reactivity for dystrophic neurite marker PHF-1 (H,I) and microglial marker LN-3 
(J,K,L representing adjacent focal planes), and may represent astrocytic processes. 
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YKL-40 immunoreactivity is also observed in occasional neurons in the superficial white 
matter (M,N,O), some of which contain neurofibrillary tangles (evidenced by PHF-1 
staining, N,O). These neurons may represent cells of multiform layer VI or ‘interstitial 
neurons’ of the white matter. Scale bars = 50 μm; scale bar in A applies to A-C; scale 
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Chapter 4. Follow-up study: Quantitation by ELISA of four candidate biomarkers identified by 2D-
DIGE LC-MS/MS 
 
Prior to the experiments described in Chapters 2 and 3, a similar series of 
proteomics experiments utilizing 2-D DIGE, but on a smaller scale, were performed by 
the Holtzman lab in conjunction with the Proteomics Core. As in Chapter 2, a number of 
candidate biomarkers were identified in these preliminary studies, and were 
subsequently evaluated by ELISA in an independent cohort.  To follow up on these 
studies, I sought to evaluate several of these biomarkers on a larger scale; these 




The efficacy of emerging Alzheimer’s disease (AD) modifying treatments will 
likely rely on the ability to accurately and reliably diagnose individuals early in the 
disease process. Currently, diagnosis of AD is based upon clinical assessment, with 
definitive diagnosis requiring pathological evaluation at autopsy. The identification of 
biomarkers for AD may allow for a less invasive and more accurate diagnosis in the 
antemortem period. Additionally, biomarkers may facilitate early diagnosis, which is 
particularly difficult given that there are no signs or symptoms unique to AD. Indeed, a 
few cerebrospinal fluid (CSF) proteins (most notably Aβ42, tau, and phosphorylated tau) 
have already shown great promise as diagnostic biomarkers for AD (346).  
To identify new candidate biomarkers for AD, our lab used an unbiased 
proteomic approach of two-dimensional difference in gel electrophoresis (2D-DIGE) 
coupled with liquid chromatography and tandem mass spectrometry (LC-MS/MS) to 
compare the relative concentrations of CSF proteins of individuals with mild dementia 
(Clinical Dementia Rating [CDR] 1, N=6) to those of cognitively normal individuals (CDR 
0, N=6) (222) [a larger validation/expansion 2D-DIGE study can be found in Chapter 2]. 
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From this analysis, 11 candidate biomarkers were identified, 6 of which were 
subsequently evaluated by enzyme-linked immunosorbent assay (ELISA) in the same 
discovery cohort (N=12) and in a larger, independent cohort (N=81). In the independent 
cohort, which also included very mildly demented (CDR 0.5) individuals, CSF levels of 
α1-antichymotrypsin (ACT), antithrombin III (ATIII), and zinc-α2-glycoprotein (ZAG) were 
significantly higher in the very mild/mild AD (CDR 0.5 and 1) group, confirming the 2D-
DIGE findings. Levels of carnosinase 1 (CNDP1) were lower in the very mild/mild AD 
group, but did not reach statistical significance (p=0.076). In contrast to the 2D-DIGE 
findings, levels of gelsolin (GSN) and angiotensinogen (AGT) were not found by ELISA 
to be significantly different between the clinical groups. Importantly, the combination of 
these promising novel biomarkers (ACT, ATIII, ZAG, CNDP1) with more ‘established’ 
biomarkers CSF Aβ42 and tau, resulted in a higher AUC and sensitivity than for any 
biomarker individually. This increase in AUC did not reach statistical significance, but it is 
worth noting that this study may have been underpowered to detect the biological 
differences between groups. It will be of interest whether the changes observed in this 
panel of markers will reach statistical significance in a larger, independent data set or if 
alternative combinations of biomarkers (including fluid or imaging markers) will result in 
improved performance. The current study was undertaken to address these issues. 
However, evaluation of the levels of ACT, ATIII, ZAG, and AGT by ELISA in 138 CSF 
samples from cognitively normal, very mildly, and mildly demented individuals did not 













Participants (N=138) were community-dwelling volunteers at the Knight 
Alzheimer’s Disease Research Center at Washington University (ADRC-WU). Informed 
consent was obtained from all study participants, and protocols were approved by the 
WU institutional review board for human studies. At sample collection, subjects were 37 
to 90 years of age and in good general health, having no other neurological, psychiatric, 
or major medical diagnoses that could contribute importantly to dementia. Cognitive 
status was evaluated and rated by the ADRC Clinical Core based on criteria from the 
National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer’s 
Disease and Related Disorders Association (57). A clinical dementia rating (CDR) of 0 
(N=81) indicated no dementia, CDR 0.5 (N=41) indicated very mild dementia, CDR 1 
(N=14) indicated mild dementia, and CDR 2 (N=2) indicated moderate dementia. Some 
of the CDR 0.5 participants met the criteria for mild cognitive impairment (MCI) and 
some were more mildly impaired and could be considered “pre-MCI” (70). Twenty-five to 
30 mL of CSF was collected by lumbar puncture (LP) at 8 AM following overnight fasting. 
Samples were inverted to avoid gradient effects, centrifuged (2,000g, 5 minutes, 4°C) to 
remove any cellular elements, and aliquoted into polypropylene tubes for freezing and 
storage at -80°C.  
 
Enzyme Linked Immunosorbent Assays (ELISAs) 
CSF samples were analyzed for Aβ42, total tau, and phospho-tau181 in duplicate 
by quantitative ELISA after a single freeze-thaw cycle according to the manufacturer’s 
instructions (Innotest, Innogenetics, Ghent, Belgium). CSF samples were analyzed for 
ACT, ATIII, ZAG, and AGT in triplicate after two freeze-thaw cycles using ELISAs 
115 
 
Chapter 4. Follow-up study: Quantitation by ELISA of four candidate biomarkers identified by 2D-
DIGE LC-MS/MS 
 
developed ‘in-house.’ A sandwich ELISA was developed for α1-antichymotrypsin (ACT) 
using rabbit anti-human ACT antibody (1:1000; DAKO, Carpinteria, CA) for capture, 
sheep anti-human ACT antibody (1:1000; The Binding Site, San Diego, CA) for 
detection, biotinylated rabbit anti-sheep antibody (1:5000; Vector, Burlingame, CA) for 
reporting, poly-HRP streptavidin (Vector, Burlingame, CA), and Elite ABC (Vector, 
Burlingame, CA) for color development; ACT purified from human plasma was used as 
standard (Sigma, St. Louis, MO). A sandwich ELISA was developed for antithrombin III 
(ATIII) using rabbit anti-human ATIII antibody (1:1000; DAKO, Carpinteria, CA) for 
capture, mouse anti-human ATIII antibody (1:2000; Antibody Shop, Denmark) for 
detection, biotinylated rabbit anti-mouse antibody (1:5000; Jackson, West Grove, PA) for 
reporting, poly-HRP20 streptavidin (1:2000; Fitzgerald, Concord, MA), and Super Slow 
TMB (Sigma, St. Louis, MO) for color development; ATIII purified from human plasma 
was used as standard (Sigma, St. Louis, MO). A sandwich ELISA was developed for 
zinc-α2-glycoprotein (ZAG) using rabbit anti-human ZAG antibody (1:1000; gift from Dr. 
Iwao Ohkubo, Shiga University of Medical Science, Japan) for capture, mouse anti-
human ZAG antibody (clone 1D4, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA) for 
detection, biotinylated rabbit anti-mouse antibody (1:5000; Jackson, West Grove, PA) for 
reporting, poly-HRP20 streptavidin (1:2000; Fitzgerald, Concord, MA),and Super 
Sensitive TMB (Sigma, St. Louis, MO) for color development; ZAG purified from human 
seminal plasma was used as standard (gift from Dr. Iwao Ohkubo). A sandwich ELISA 
was developed for angiotensinogen (AGT) using mouse anti-AGT antibody (clone F8A2, 
1:288; gift from Dr. Claus Oxvig, University of Aarhus, Denmark) for capture, chicken 
anti-AGT antibody (1:1200; gift from Dr. Claus Oxvig) for detection, rabbit anti-chicken: 
horseradish peroxidase antibody (1:15,000; Sigma, St. Louis, MO) for reporting, and 
Super Sensitive TMB (Sigma, St. Louis, MO) for color development; AGT purified from 
human plasma was used as standard (Calbiochem, San Diego, CA).  
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Statistical analyses were performed in PASW 18 (SPSS Inc, Chicago, IL). The 
distributions of analytes were tested for normalcy by Shapiro-Wilk test, and, when 
appropriate, log10 transformed to approximate a normal distribution. Analysis of 
covariance (ANCOVA) using the General Linear Model (GLM) procedure in PASW was 
used to determine analytes that differed in concentration between AD (CDR>0) and 
control (CDR 0) groups while adjusting for the effects of age and gender. Because 
nearly identical results were obtained for analyses using log transformed data as for 
analyses using data in the original scale (non-transformed), results are reported using 
the original scale data.  
 
Results 
To follow-up on the candidate biomarkers identified in the initial discovery study 
(222), we used ELISAs to measure the levels of ACT, ATIII, ZAG, and AGT in CSF from 
63 cognitively normal (CDR 0), 36 very mildly demented (CDR 0.5), and 11 mild-
moderately demented (CDR 1&2) individuals. In the initial discovery study, for the very 
mild/mild AD group, ACT, ATIII, and ZAG levels were significantly higher, CNDP1 levels 
trended lower, and GSN and AGT levels were unchanged. Because GSN did not 
demonstrate promise in the initial study and because of CNDP1 reagent limitations, 
these two markers were not chosen for further analysis in the current study.  
Although the CDR 0 and CDR>0 groups were well matched with regard to age 
(CDR 0= 71.9 +/- 7.1, CDR>0= 72.4 +/- 9.7, mean +/- SD), they differed with respect to 
gender (CDR 0= 63% female, CDR>0= 43% female). Additionally, because our initial 
study found some of the analytes to correlate with these variables, we evaluated the 
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levels of each analyte for potential correlation with age and gender. CSF ACT and AGT 
levels correlated modestly with increasing age (r=0.265, p=0.005, and r=0.242, p=0.024, 
respectively), while levels of ACT, ATIII, and ZAG were significantly higher in males than 
in females (p=.047, p=.019, p<.001, respectively, Student’s t-test). Additionally, 
participants with very mild to moderate dementia exhibited the typical AD CSF biomarker 
profile characterized by significantly lower mean levels of CSF Aβ42 (CDR>0= 406.8 +/- 
200.9, CDR 0=573.8 +/- 269.7 pg/mL, mean +/- SD) and higher mean levels of CSF tau 
(CDR>0= 538.5 +/- 280.9, CDR 0=313.3 +/- 188.5 pg/mL, mean +/- SD) and CSF p-
tau181 (CDR>0= 76.8 +/- 38.0, CDR 0=52.8 +/- 24.7 pg/mL, mean +/- SD).  
No difference in ACT, ATIII, ZAG, or AGT levels was found between the AD 
(CDR>0) and control (CDR 0) group by analysis of covariance adjusting for the effects of 
age and gender (p=0.535, p=0.332, p=0.403, p=0.651, respectively). These 
observations were not qualitatively different from those using the log-transformed or 
unadjusted data.  
The ELISA protocols used here varied slightly from those of the initial study due 
to changes in personnel, reagent availability, and optimizations for assay performance. 
To assess whether these changes may have contributed to the inability to validate our 
initial findings, 28 samples (CDR 0, N=18; CDR>0, N=10) of the initial study were re-
assayed (‘overlap’ samples). Although concentrations measured for these overlap 
samples correlated strongly between the two experiments (ACT r=0.849, ATIII r=0.837, 
ZAG r=0.798, AGT r=0.823), absolute values were approximately 50% higher for the 
new ATIII, ZAG, and AGT measurements. For these 28 overlap samples, levels of ZAG 
were significantly higher in the CDR>0 group compared to the CDR 0 group (p=0.014), 
while levels of ACT, ATIII, and AGT were not different between the clinical groups 
(p=0.184, p=0.131, p=0.480, respectively). Combining the 110 new CSF samples of this 
study with the 28 overlap samples still did not reveal any differences in ACT, ATIII, ZAG, 
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or AGT levels between the clinical groups (p=0.939, p=0.772, p=0.982, p=0.417, 




Figure 4.1.  Mean levels of CSF ACT, ATIII, ZAG, and AGT are not significantly different 
between AD (CDR>0) and control (CDR 0) groups (analysis of covariance, adjusting for 
age and gender). CSF from a total of 81 CDR 0 and 57 CDR>0 participants (110 
samples from this study + 28 samples overlapping from initial discovery study) was 
analyzed by ELISA (original-scale data shown; outlier indicated by the unfilled circle for 











In a 138-subject cohort we were unable to validate the findings of an initial report 
of increased ACT, ATIII, and ZAG levels in AD (CDR>0) CSF. However, interestingly, an 
increase in ZAG levels in the AD group was observed for the 28 samples that 
overlapped between the initial report and this study, suggesting that the results of the 
initial study may have been cohort-dependent. The inconsistency in ACT results 
between our two studies may not be particularly surprising, given that a number of other 
studies have found either increased (211, 215, 220) or unchanged ACT levels in AD 
CSF (216-218). The other markers (i.e. ATIII, ZAG, and AGT) have not been well 
studied in AD, and to our knowledge, changes in their levels in AD CSF have not been 
evaluated by other groups. These findings would appear not to support a role for ACT, 
ATIII, ZAG, or AGT as biomarkers for AD. However, it is important to note that these four 
proteins were first identified as differing significantly in abundance between the AD and 
control group by 2D-DIGE, a technique sensitive to concentration changes of minor 
protein isoforms and post-translational modifications which may not substantially alter 
global concentrations of a ‘parent’ protein. For ELISAs that measure the parent protein, 
or total protein level, it is perhaps to be expected that some candidate biomarkers 
identified by 2D-DIGE would not be validated by ELISAs not tailored to detect only 
specific isoforms or protein ‘sub-species.’ Indeed, ATIII, ZAG, and AGT are known to 
have different isoforms (434-437), and ACT, ATIII, and AGT were identified in multiple 
protein spots on the 2-D gels of the discovery study, suggesting different protein 
isoforms. Therefore, a thorough evaluation of the potential of these analytes as 
biomarkers for AD would appear to require either high-throughput 2D-DIGE of every 
sample to be analyzed or the design of ELISAs targeting specific post-translational 
modifications or specific ‘sub-species’ of interest. 
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Chapters 2-4 of this work have focused on relatively intact, large molecular weight 
proteins, just as the bulk of published biomarker research.  A relatively unexplored 
avenue for research is the CSF peptidome. The following chapter describes the 
development of methods for such an analysis, as well as some preliminary results from 




Improved proteomics technologies, in particular advances in mass spectrometry 
(MS) techniques, have solidified proteomics as a valuable tool for biomarker discovery. 
Indeed, during the last two years, over one thousand articles have been published on 
the subject, including recent efforts to characterize the human cerebrospinal fluid (CSF) 
proteome (239, 240). General methods in proteomic studies typically include protein 
separation by two-dimensional gel electrophoresis (2-DE), liquid chromatography (LC), 
or protein-chip arrays, followed by MS or tandem MS and database searches to 
determine protein identity. Powerful proteomic approaches, allowing for the 
simultaneous screening of large numbers of proteins in a given sample, expand the 
possibilities for biomarker discovery beyond standard targeted techniques, such as 
enzyme linked immunosorbent assay, that assess single or small numbers of proteins. 
Applied to Alzheimer’s disease (AD), proteomic studies comparing the differences in 
protein expression levels between AD and control CSF samples have identified a 
number of potential diagnostic markers (222, 241-246). Few studies, however, have 
investigated the low molecular weight (MW) components of CSF for potential AD 
biomarkers. This is primarily due to a lack of techniques for isolating and detecting low 
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MW, low abundance species for mass spectrometry. In our prior proteomic studies 
(Chapter 2 and 4), for example, CSF samples were initially processed with 10 kDa MW 
exclusion filters to remove salts and to retain and analyze the larger molecules (222, 
251). Additionally, many proteomics studies utilize 2-DE, a technique which is usually 
unable to resolve peptides and proteins smaller than 15 kDa (438). Because the low MW 
components of CSF remain a relatively untapped source for potential novel biomarkers, 
we have developed a protocol for the extraction and identification of peptides from CSF. 
With this protocol, the ≤10 kDa fraction can be probed for peptides that differ in 
abundance between AD and control groups. More generally, this protocol can be applied 
to the search for novel biomarkers or altered proteolytic pathways of a number of central 
nervous system (CNS) diseases. 
 
Methods   
CSF sampling: 
CSF samples were obtained by lumbar puncture (LP) from volunteer participants 
enrolled in longitudinal studies of healthy aging and dementia at the Knight Alzheimer’s 
Disease Research Center at Washington University (ADRC-WU). Study protocols were 
approved by the WU Institutional Review Board, and written informed consent was 
obtained from each participant. Cognitive status was evaluated and rated based on 
criteria from the National Institute of Neurological and Communicative Diseases and 
Stroke-Alzheimer’s Disease and Related Disorders Association (57). A clinical dementia 
rating (CDR) of 0 indicated no dementia, whereas CDR 1 indicated mild dementia. For a 
‘mixed clinical sample,’ de-identified, discarded CSF from diagnostic LPs was pooled 
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from 20+ patients with a variety of medical conditions to provide a large source of CSF 
for protocol development and testing.  
 
Sample preparation, solid phase extraction, and mass spectrometry: 
To isolate low MW species, CSF samples were passed through a 10-kDa MW 
cut-off centrifugal filter unit (Amicon Ultra-4 centrifugal filter units). Sample filtrates were 
then acidified with trifluoroacetic acid (TFA) and spiked with a mixture of tryptic peptides 
from bovine serum albumin (BSA) as an internal standard (1% TFA final, 2 pmol 
BSA/200 uL CSF). For desalting and concentrating low MW proteins and peptides, solid 
phase extraction procedures were developed using Hypercarb (porous graphitic carbon) 
material in both a column (Hypersep, Thermo Scientific) and tip (NuTip, Glygen) format. 
For the tips, the Hypercarb chromatography material was first washed with 60% 
acetonitrile (ACN)/ 1% formic acid (FA) and then equilibrated with 1% ACN/1% FA.  A 
more stringent initial wash sequence was used for the columns, involving washes with 
95% ACN/1% TFA, 60% ACN/1% TFA, and 90% ACN/1% TFA, to remove polymer 
contamination likely leaching from the column. Samples were loaded onto washed 
columns or tips; peptides that did not bind the first column or tip were sequentially 
extracted from the same sample with additional columns or NuTips. Columns and tips 
were rinsed with 1% ACN/1% FA, and peptides were eluted with sequential applications 
of 60% ACN/1% FA and 90% ACN/1% FA. MALDI-TOF/TOF (Proteomics 4700, Applied 
Biosystems) was used to evaluate the recovery of the internal standard BSA peptides 
and to assess intra- and inter-sample preparation reproducibility. Samples were then 
evaporated to dryness in a Speed-Vac centrifuge, and dissolved in 1% ACN/1% FA for 
LC-MS/MS (nano-LC-linear quadrupole Fourier transform ion cyclotron) for peptide 
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identification and quantification. Tandem spectra were searched against the National 
Center for Biotechnology Information non-redundant database NR using MASCOT, 
version 1.9 (Matrix Science, London) and neurloProSight (University of Illinois). Relative 
peptide quantification was determined using X-calibur (Thermo Fisher Scientific) and 
Rosetta Elucidator (Rosetta Biosoftware).  
 
Results and Discussion 
In developing a solid phase extraction protocol for CSF peptides, we evaluated 
the performance of Hypercarb chromatography material in both column and tip formats 
(Figure 5.1). In the tip format, the chromatography material is embedded in the inner 
surface of a pipette tip. Hypercarb material is composed of flat sheets of hexagonally 
arranged carbon atoms, and is capable of separating very closely related compounds, 
including geometric isomers and diastereoisomers. Analyte binding is multimodal, with 
interactions through both hydrophobic and electrostatic mechanisms. The efficiency of 
CSF processing with the two formats differed; initially, all NuTips were processed 
manually one-at-a-time, while the columns could be connected to a vacuum manifold, 
allowing for the processing of 16 samples simultaneously (Figure 5.1). Subsequently, we 
integrated a robot with the NuTip protocol, allowing up to 96 samples to be processed 
simultaneously with excellent tip-to-tip reproducibility.  
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Figure 5.1.  Solid phase extraction procedures were developed using Hypercarb 
(porous graphitic carbon) material in both A) column (Hypersep, Thermo 
Scientific) and B) tip (NuTip, Glygen) format. The columns can be connected to a 
vacuum manifold (A), while the tips can be processed using a pipettor (B) or can 
be interfaced with a robot (not pictured).  
 
The general steps of a typical solid phase extraction involve 0) (may not be 
necessary) washing the cartridge (i.e. column or tip), 1) equilibrating or conditioning of 
cartridge with a non-polar or slightly polar solvent that prepares/’wets’ the surface, 2) 
loading the sample, 3) rinsing the cartridge to remove residual unbound species, and 4) 
eluting with solvents of varying strengths. For our analyses, initial sample preparation 
involved filtering the samples (10-kDa MWCO) to obtain peptides and low molecular 
weight proteins, acidifying the filtrate, and spiking it with a mixture of tryptic peptides 
from BSA as an internal standard. This BSA standard allowed us to compare the 
reproducibility between columns/tips and between runs, and to assess recovery 
performance.  
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Using the columns, many of our initial spectra contained a series of peaks with a 
major mass difference between them of 44 Da, suggesting polyethylene glycol 
contamination that was likely a by-product of column manufacturing. Therefore, we 
tested a series of different column washes to remove the polymer contamination, and 
found that sequential 95% ACN/1% TFA, 60% ACN/1% TFA, and 90% ACN/1% TFA 
washes were successful. We did not observe polymer contamination with the tips. 
Indeed, one advantage reported by the NuTip manufacturer is the lack of polymers or 
glue, thus avoiding potential contamination or permeability problems (Glygen).  
Initial recovery of BSA peptides was low; however, the flow-through lacked BSA 
peptides, indicating that the issue was not with binding to the column, but with elution 
from the column. Thus, to increase percent recovery, we tested various elution solvents 
and electronic modifiers, including  60% ACN, 90% ACN, 60% ACN/1% TFA, 90% 
ACN/1% TFA, 60% ACN/1% FA, 90% ACN/1% FA, 20% IPA/50% ACN, 40% IPA/50% 
ACN, 20% IPA/50% ACN/1% TFA, and 40% IPA/50% ACN/1% TFA (TFA= 
trifluoroacetic acid; ACN= acetonitrile; FA= formic acid; IPA= isopropanol). We found that 
60% ACN/1% FA gave the greatest peptide recovery, and that following it with 90% 
ACN/1% FA eluted additional (albeit fewer) peptides of a different general profile.   
In developing a protocol for the extraction and identification of peptides from 
CSF, we discovered that Hypercarb material yielded better results in the NuTip format 
(higher signal intensity, more recovered peptides) than in the column format. Although 
we tested a number of elution solvents of varying strengths, used 25 mg and 50 mg 
capacity columns and loaded varying CSF volumes, incorporated additional wash steps 
after sample loading to remove residual salt that can cause signal attenuation, and 
employed other ‘troubleshooting’ techniques, the performance of the columns appeared 
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inferior to that of the tips. To test whether multiple tips would be needed for each sample 
to ensure maximal peptide recovery, unbound peptides were sequentially extracted from 
the same sample using three NuTips. The majority of the BSA peptides were extracted 
with the first tip, with the number of peptides and the signal intensity decreasing 
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We then applied our NuTip protocol to CSF from a cognitively normal individual 
(CDR 0), an individual with mild dementia of the Alzheimer’s type (CDR 1), and a mixed 
clinical sample (20+ subjects with a variety of medical conditions). In this preliminary 
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study, MALDI-TOF/TOF and LC-MS/MS analysis of internal standard BSA peptide 
recovery demonstrated good method reproducibility, thus providing confidence of the 
validity of endogenous peptides detected and identified. Specifically, MASCOT search of 
the LC-MS/MS data identified 100+ BSA peptides, ten of which were randomly selected 
for quantitation using X-calibur (Table 5.1). No differences were detected for BSA across 
the three samples (p=.1204, general linear model procedure in SAS). 
 
















CDR 1, CDR 




Fifty-six unique peptides (with MASCOT scores ≥30), representing nineteen 
unique proteins, were identified by tandem MS in the CDR 0, CDR 1, and mixed clinical 
CSF (Table 5.2). Five proteins were selected for further study based on their well shown 
association with AD (amyloid-beta precursor protein, tau, apolipoprotein E) or because 
our previous studies have identified them as being differentially expressed in AD versus 
control CSF (chromogranin B, VGF nerve growth factor (222)). For these five selected 
proteins, quantification of peptides from the ion currents that comprised the selected ion 
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chromatogram (illustrated in Figure 5.3, 5.4) revealed differences in abundance in these 
peptides between CDR 0, CDR 1, and mixed clinical CSF samples (Table 5.3).  
Using the protocol presented here, we have extracted and identified endogenous 
peptides from CSF. Quantification of a subset of these peptides revealed differences in 
abundance among pooled, CDR 1, and CDR 0 CSF samples, albeit with a limited 
sample number. Additionally, recovery of internal standard BSA peptides (~2 pmol from 
200 uL) was not statistically significantly different between sample runs, demonstrating 
the reproducibility of the extraction and LC-MS method. Sample preparation and 
obtaining high quality MS data are perhaps the largest challenges of proteomic analysis, 
and during our protocol development, many different experimental variations were 
tested, not all of which are represented here. Subsequent efforts to purify and 
concentrate the fractions eluted from the NuTips increased the number of peptides 
detected and the number of unique proteins (now, 36) represented. It will be of interest 
in future studies to find whether further protocol optimization, in particular sample 
digestion, can improve the detection and identification of peptides in CSF. For complex 
biological samples it is often necessary to digest prior to mass spectrometry; sample 
digestion generates peptides with molecular masses in the optimal range of the mass 
spectrometer that can also be fragmented more efficiently. Indeed, initial experiments 
have shown that our ability to identify peptides was increased upon trypsin digestion. 
The future application of this protocol to larger numbers of AD and control CSF samples 
may identify many novel candidate biomarkers for AD; additionally, this protocol for the 
low molecular weight species in CSF may be used for discovery studies of other 
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Figure 5.3. High-resolution two-dimensional LC-MS peptide map. 
Shown is a representative example of a two-dimensional LC-MS peptide map from one 
of the samples. Visualization of the LC-MS data in this way allows for assessment of the 
overall sample complexity and of the quality of the LC separation. Along the x-axis is 
shown retention time in minutes, while along the y-axis is shown the mass (m) to charge 
(z) ratio. Signal intensity is represented colormetrically, with yellow-red indicating 
features of greater intensity. The inset (a feature shown at greater magnification) shows 
the isotopic cluster for the doubly-charged chromogranin B peptide with m/z of 1013.41. 
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Figure 5.4. A) Representative LC-MS/MS data from low MW CSF eluate.  
(A) Selected ion chromatogram showing a single peak at the accurate mass of 1013.41, 
representing a chromogranin B peptide; (B) corresponding mass spectrum 
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Table 5.2. Peptides detected and identified by tandem MS in pooled, CDR 0, and 
CDR 1 CSF 
 Protein Peptide Sequence m/z Score
1 chromogranin B precursor RPQSEESWDEED 753.8056 55
  RSQEESEEGEEDATSEVD 1013.4159 97
  SKGQPRSQEESEEGEEDATSEVD 842.0328 90
  SSQGGSLPSEEKGHPQEESEESNVS 873.0621 60
  SSQGGSLPSEEKGHPQEESEESNVSMASLGE 1069.1471 67
  SSQGGSLPSEEKGHPQEESEESNVSMASLGE 1069.4847 57
2 VGF nerve growth factor 
inducible precursor 
LGGSEAGERL 494.7592 73
  LFAEEEDGEAGAED 741.3054 106
  QQETAAAETETRTHT 828.8937 55
  GLQEAAEERESAREEEEAEQE 807.361 55
  GLQEAAEERESAREEEEAEQE 807.365 63
  GGEERVGEEDEEAAEAEAEAEEAERA 922.0626 91
3 testican AVTEDDEDEDDDK 748.2952 51
  AVTEDDEDEDDDKE 812.8209 110
  AVTEDDEDEDDDKEDE 935.859 90
  AVTEDDEDEDDDKEDEVG 1013.3917 65
  AVTEDDEDEDDDKEDEVGY 1095.424 110
4 neuron-specific protein VLSEEKLSEQETEAAEKSA 693.684 87
5 extracellular matrix protein 
FRAS1 precursor 
QMMKHGNLEQ 625.3168 73
  LSEVSNFTMEDIN 757.4318 40
6 amyloid beta A4 precursor 
protein 
DHSKLVDVPFQVEFPAPKNELVQKF 729.6345 62
  DHSKLVDVPFQVEFPAPKNELVQKF 729.6364 52
  DHSKLVDVPFQVEFPAPKNELVQKF 729.8872 75
7 fibrinopeptide A DSGEGDFLAEGGGV 655.2823 92
  ADSGEGDFLAEGGGVR 768.8611 116
8 fibrinogen alphaA DSGEGDFLAEGGGV 655.2823 92
  ADSGEGDFLAEGGGVR 768.8611 116
  SMGSWNSGSSGTGSTGNQNP 643.2718 38
9 TPA: microtubule-
associated protein tau 
TGSSGAKEMKLKGAD 741.3054 69
10 hemicentin 1 FNAIGSF 756.3593 35
  EQVTNVSVLLNQL 732.3136 40
  QCTVSNAAGKQAKD 741.3054 79
  SGISTPARIDLLEL 495.2418 33
11 SLC43A2 protein VSCLLIAYGASK 642.3611 67
  DANQCVGRAGAPAPSPQP 897.863 33
12 poly(A) binding protein, 
cytoplasmic 3 
HQAKEATQKAVNSA 741.8063 72
  QKAVDEMNGKELNGKQIYVG 747.7208 56




14 leptin receptor isoform 2 SLYPIFMEGVGK 671.3491 44
  EQDRNCSLCADNIEGK 637.5971 37
  EQDRNCSLCADNIEGK 955.898 69
  EQDRNCSLCADNIEGK 956.4018 53
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  EQDRNCSLCADNIEGK 956.8949 64
  EQDRNCSLCADNIEGK 957.3944 52
15 apolipoprotein E KVKQAVETEPEPEL 799.9102 71
  KVKQAVETEPEPEL 800.41 71
  KVEQAVETEPEPEL 799.9102 84
  KVEQAVETEPEPEL 800.9118 58
16 unnamed protein product 
(GI # 34534986) 
HQAKETAQKAVNSA 741.8063 88
17 unnamed protein product 
(GI # 6551993) 
EQVTNVSVLLNQL 732.3136 40
  QCTVSNAAGKQAKD 741.3054 79
18 hypothetical protein (GI # 
47027976) 
TCAEKEEENQEN 741.3054 70
19 unnamed protein product 
(GI # 70905151) 
MQNIGEQGHMA 417.2122 54
  MQNIGEQGHMA 417.2133 65
  MQNIGEQGHMA 625.818 69
  MQNIGEQGHMA 625.8196 63
 
Table 5.2. Nineteen unique proteins (56 unique peptides with MASCOT scores ≥30) 
were identified by tandem MS in the CDR 0, CDR 1, and mixed clinical CSF.   
Abbreviations: m/z = mass to charge ratio. “Score” is the MASCOT ion score, which is a 
measure of the reliability of each identification; scores above 30 are generally 
considered significant.  
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Table 5.3.  Quantification of selected peptides 
Peptide Sequence m/z Peptide Score 
Area-      
Pooled 
Area-    
CDR 1 
Area- 
CDR 0  
chromogranin B precursor RPQSEESWDEED 753.806 55 107119 3256 3962 
RSQEESEEGEEDATSEVD 1013.416 97 266789 50777 148372 
SKGQPRSQEESEEGEEDATSEVD 842.033 90 245278 2048 4162 
SSQGGSLPSEEKGHPQEESEESNVS 873.062 60 2218 37165 88850 
SSQGGSLPSEEKGHPQEESEESNVSMASLGE 1069.147 67 0 46270 133 
SSQGGSLPSEEKGHPQEESEESNVSMASLGE 1069.485 57 0 27048 0 
VGF nerve growth factor 
inducible precursor LGGSEAGERL 494.759 73 98051 6903 992 
LFAEEEDGEAGAED 741.305 106 307906 0 592 
QQETAAAETETRTHT 828.894 55 5473 47895 3E+06 
GLQEAAEERESAREEEEAEQE 807.361 55 14947 72131 405950 
GLQEAAEERESAREEEEAEQE 807.365 63 14947 72131 405950 
GGEERVGEEDEEAAEAEAEAEEAERA 922.063 91 73079 0 9045 
amyloid beta A4 precursor 
protein  DHSKLVDVPFQVEFPAPKNELVQKF 729.635 62 431472 145650 87484 
DHSKLVDVPFQVEFPAPKNELVQKF 729.636 52 431472 145650 87484 
DHSKLVDVPFQVEFPAPKNELVQKF 729.887 75 345224 114203 79671 
TPA: microtubule-
associated protein tau TGSSGAKEMKLKGAD 741.305 69 307906 0 592 
apolipoprotein E KVKQAVETEPEPEL 799.910 71 4359929 4357 7075 
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KVKQAVETEPEPEL 800.410 71 1943888 1157 2180 
KVEQAVETEPEPEL 799.910 84 4359929 4357 7075 
KVEQAVETEPEPEL 800.912 58 565296 0 0 
 
Table 5.3. Quantification of peptides from the ion currents that comprised the selected ion chromatogram for each peptide are listed. 
Differences in peptide abundance can be seen between the samples; for example, the first chromogranin B peptide listed appears 
much higher in the pooled, or mixed clinical, sample as compared to the CDR 0 and CDR 1 samples.   
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Chapters 2-5 of this work reflect efforts to identify novel biomarkers for AD through 
unbiased approaches. Alternatively, targeted approaches focusing on molecules or 
processes already implicated in disease can also be used for biomarker discovery. A 
convenient compromise between these two approaches is offered by established 
targeted multiplexed immunoassay platforms, which allow for the simultaneous 
quantitation of large numbers of molecules. We utilized one such resource, Rules Based 
Medicine, which has assembled a platform for the analysis of 190 markers of varied 
functional classes, many of which have not been investigated in AD, in an attempt to 
identify novel biomarkers of AD.  
 
Introduction 
With the growing prevalence of Alzheimer’s disease (AD), the ability to accurately 
and reliably diagnose AD in its earliest stages has become a public health priority. The 
concept of ‘earliest stages,’ however, warrants revision as it is increasingly clear there 
exists a ‘preclinical’ or ‘presymptomatic’ stage during which the pathological changes 
associated with AD, amyloid plaques and neurofibrillary tangles, begin to appear without 
concomitant clinical features. This period has been estimated to be ~10-15 years in 
duration. Means to identify this preclinical phase of AD may facilitate medical 
intervention to prevent or slow neurodegeneration and the resulting cognitive 
impairment. Because clinical examination cannot detect preclinical disease and has 
limited accuracy with very mild stages of AD, there is a pressing need for biomarkers for 
AD. Furthermore, biomarkers may have significant utility in clinical trial design, providing 
greater diagnostic certainty for enrollment than is possible by clinical diagnosis alone, 
and allowing for the selective enrollment of individuals at greater risk of developing 
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future cognitive impairment, ultimately resulting in trials of shorter duration, smaller size, 
and reduced cost. 
The cerebrospinal fluid (CSF) is a logical source of potential AD biomarkers, as it 
reflects biochemical changes in the brain. Indeed, the fluid biomarkers thus far showing 
the greatest promise for use in AD diagnosis and prognosis are CSF amyloid-β42 
(Aβ42), tau, and phosphorylated forms of tau (p-tau) (119, 410-413). Concentrations of 
CSF Aβ42 decrease in association with the deposition of Aβ42 into plaques within the 
brain (107, 127, 128, 360). This process occurs years prior to the clinical onset of AD 
and may mark the earliest phase of AD pathology. CSF Aβ42 levels remain low 
throughout the disease course (94, 127, 423). In contrast, CSF tau and p-tau levels 
progressively increase with the advancing stages of AD, and in some individuals, begin 
to rise several years prior to diagnosis (107, 439, 440). The ratios of tau or p-tau to Aβ42 
have also proven useful for predicting clinical progression in individuals who have very 
mild dementia or mild cognitive impairment (MCI), and for predicting future AD dementia 
among those who are cognitively normal (107, 132, 348). Nevertheless, even for these 
analytes, there is substantial overlap between control and AD groups (346). 
Consequently, there remains a need for supplemental biomarkers to improve diagnosis 
and prognosis at different disease stages. Given the multifactorial nature of AD 
pathophysiology, it is likely that there will be other CSF biomarkers that will be useful in 
this regard. While proteomic screens have identified a number of other candidate AD 
biomarkers (222, 241-243, 245, 246, 250, 361, 362, 364), few studies have utilized 
large, well-characterized cohorts or have looked for biomarkers of preclinical or very 
early stage disease.  
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In this study, a large number of CSF samples (N=333) selected from well-
characterized MCI/very early stage-AD and cognitively normal control cohorts were 
chosen for protein profiling using a commercially available panel that measures a variety 
of cytokines, chemokines, metabolic markers, growth factors, and other markers. 
Multiplex immunoassay platforms such as the one used here, Rules Based Medicine 
Discovery MAP 1.0 panel, allow for the simultaneous quantitation of many analytes, and 
by adhering to clinical laboratory improvement amendments (CLIA) standards, are 
amenable for clinical trial work. Using multiple statistical approaches, our findings 
suggest novel biomarkers that may improve the ability of traditional AD biomarkers, 
Aβ42 and tau, to distinguish MCI/early-stage AD from cognitive normalcy and to predict 




Participants (N=333) were community-dwelling volunteers enrolled in longitudinal 
studies of healthy aging and dementia at the Knight Alzheimer’s Disease Research 
Center at Washington University (WU-ADRC). The study protocol was approved by the 
Human Studies Committee at Washington University, and written and verbal informed 
consent was obtained from participants at enrollment. At sample collection, participants 
were ≥60 years of age and in good general health, having no other neurological, 
psychiatric, or major medical diagnoses that could contribute importantly to dementia. 
Cognitive status was evaluated based on criteria from the National Institute of 
Neurological and Communicative Diseases and Stroke-Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) (57). A clinical dementia rating (CDR) of 0 
140 
 
Chapter 6. Use of a Multiplexed Immunoassay Panel for the Identification of Novel CSF 




(N=242) indicated no dementia, CDR 0.5 (N=63) indicated very mild dementia, and CDR 
1 (N=28) indicated mild dementia (68). Some of these CDR 0.5 participants met the 
criteria for mild cognitive impairment (MCI) and some were more mildly impaired and 
were considered “pre-MCI” (70, 441). A subset of participants (N=179) in this cohort had 
also undergone positron emission tomography (PET) imaging with Pittsburgh 
Compound-B (PIB) for assessment of in vivo amyloid burden (127, 318, 330). 
Apolipoprotein E (APOE) genotypes were determined by the WU-ADRC Genetics Core. 
Twenty-five to 30 mL of CSF was collected by lumbar puncture (LP) at 8 AM following 
overnight fasting. Samples were inverted to avoid gradient effects, centrifuged briefly 
(2,000g, 5 minutes, 4°C) to remove any cellular elements, and aliquoted into 
polypropylene tubes for freezing and storage at -80°C (107). 
 
Analyte Measurements 
CSF Aβ42, total tau, and phospho-tau181 levels (from here on referred to as 
‘traditional’ biomarkers) were analyzed in duplicate by the WU-ADRC Biomarker Core by 
quantitative ELISA after a single freeze-thaw cycle according to the manufacturer’s 
specifications (Innotest, Innogenetics, Ghent, Belgium). 
CSF samples were evaluated by Rules Based Medicine, Inc. (RBM) (Austin, TX) 
for levels of 190 analytes using the Human Discovery Multi-Analyte Profile (MAP) 1.0 
panel and a Luminex 100 platform. This 190 analyte panel (from here on referred to as 
‘RBM analytes’) was assembled by RBM to measure a range of cytokines, chemokines, 
growth factors, hormones, metabolic markers, and other proteins thought to be important 
in disease; a complete list of analytes is available at www.rulesbasedmedicine.com.  
141 
 
Chapter 6. Use of a Multiplexed Immunoassay Panel for the Identification of Novel CSF 




At RBM, the samples were thawed at room temperature (RT), vortexed, spun at 
13,000g for 5 minutes for clarification, and 1.0 mL was removed into a master microtiter 
plate for MAP analysis. Using automated pipetting, an aliquot of each sample was 
introduced into one of the capture microsphere multiplexes of the Human 
DiscoveryMAP. The mixtures of sample and capture microspheres were thoroughly 
mixed and incubated at RT for 1 hour. Multiplexed cocktails of biotinylated reporter 
antibodies for each multiplex were then added robotically, and after thorough mixing, 
were incubated for an additional hour at RT. Multiplexes were developed using an 
excess of streptavidin-phycoerythrin solution which was thoroughly mixed into each 
multiplex and incubated for 1 hour at RT. The volume of each multiplexed reaction was 
reduced by vacuum filtration and then increased by dilution into matrix buffer for 
analysis. Analysis was performed in a Luminex 100 instrument and the resulting data 
stream was interpreted using proprietary data analysis software developed at RBM. For 
each multiplex, both calibrators and controls were included on each microtiter plate. 
Eight-point calibrators were run in the first and last column of each plate and 3-level 
controls were included in duplicate. Testing results were determined first for the high, 
medium and low controls for each multiplex to ensure proper assay performance. 
Unknown values for each of the analytes localized in a specific multiplex were 
determined using 4 and 5 parameter, weighted and non-weighted curve fitting algorithms 
included in the data analysis package.  
 
Statistical Analysis 
Statistical analyses were performed in SAS 9.2 (SAS Institute Inc, Cary, NC) for  
univariate analyses, ROC/AUC calculations, and Cox proportional hazards models, and 
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in R version 2.10.1 for predictive modeling (442). For the RBM analytes, data below the 
lower detection limit (LDL) were imputed to LDL/2, and data more than five standard 
deviations beyond the mean were imputed using a nearest neighbor algorithm. Analytes 
with more than 10% of data missing or below the LDL were excluded from analysis. The 
distributions of analytes were tested for normalcy by Box-Cox analysis and, when 
appropriate, log10 transformed to approximate a normal distribution. Correlations 
between RBM analytes, traditional AD biomarkers, and demographic variables were 
evaluated using the Spearman rho correlation coefficient (α=0.05). Analysis of 
covariance (ANCOVA) using the General Linear Model (GLM) procedure in SAS was 
used to determine analytes that differed in concentration between AD and control groups 
while adjusting for the effects of age and gender. For each analyte showing promise by 
univariate analysis, the area under the receiver operating characteristic curve (AUC, 
ROC) was calculated for predicting CDR 0 versus CDR>0. The method of Xiong et al., 
2004 was implemented to determine the optimum linear combination of analytes and to 
calculate the confidence interval on the AUC and the sensitivity (443).To obtain relatively 
unbiased estimates of expected future performance of the three marker panels in 
predicting CDR 0 versus CDR>0, a bootstrapping resampling technique was used to 
randomly divide the dataset into many subsets. Averages of performance measures 
were taken over 100 repetitions.  
Cox proportional hazard models assessed the ability of baseline biomarkers to 
predict time to conversion from cognitive normalcy (CDR 0) to very mild or mild dementia 
(CDR 0.5 and 1). Data from subjects who did not convert were statistically censored at 
the date of last assessment. Biomarker measurements were treated as continuous 
variables and were converted to standard Z-scores to allow for comparison of hazard 
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ratios between different biomarkers. Baseline variables were considered for inclusion in 
multivariate models if they were associated with time to conversion in a univariate 
analysis (p<.15). Variables were retained in multivariate proportional hazard models if 
p<.05. AIC (Akaike Information Criterion), a measure of goodness of fit of an estimated 
statistical model, was used to compare different models, with a lower AIC indicating 
better model fit.  
Several statistical machine learning techniques were utilized to predict subject 
outcomes as a function of baseline characteristics (e.g. age) and the candidate 
biomarkers. Rather than focusing on a specific model, a panel of predictive modeling 
techniques was applied to the data. Most of these models contain “tuning parameters” 
that cannot be directly estimated from the data; these values were chosen using 
resampling techniques. The models used were:  
• Partial Least Squares (PLS) is a latent variable model that produces linear class 
boundaries and works well with correlated predictors (444). Candidate values of 
the tuning parameter, the number of PLS components, ranged from 1 to 20.  
• Sparse Partial Least Squares (SPLS) is a variant of PLS that incorporates 
feature selection in the model fitting (445). The number of PLS components was 
varied in the same manner as the basic PLS model and the additional tuning 
parameter for regularization was varied from 0.1 to 0.9. 
• Random Forests (RF) is a tree-based ensemble method (446). The number of 
randomly selected variables at each split was varied over five values (generally 2 
to the number of predictors in the model).  
• Boosted Trees are another tree-based ensemble model (447). The three tuning 
parameters are the depth of the tree (even values from 2 to 10 were evaluated), 
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the number of boosting iterations (20 iterations to 2000 in 100 iteration 
increments) and the learning rate (fixed at 0.1). 
• Support Vector Machine (SVM) are a kernel based method (448). The radial 
basis function kernel was used. The kernel parameter was estimated analytically 
(449) and the five candidate values of the cost parameter ranged from 0.1 to 
1,000 on the log10 scale. 
• Nearest Shrunken Centroids (NCS) is a prototype model that incorporates 
feature selection (450). The tuning parameter, the shrinkage threshold, was 
varied over 30 values. 
• Naïve Bayes (NB) is a simple classifier where each predictor variable contributes 
to the final class prediction independently (451). The conditional distributions 
were computed using a simple Gaussian distribution or using a nonparametric 
density estimator.  
• K-Nearest Neighbors (KNN) is a simple prototype based model (451). Candidate 
values for the number of neighbors ranged from 5 to 15. 
• Flexible Discriminant Analysis (FDA) is a partitioning based model that also 
incorporates feature selection (452). The multivariate adaptive spline basis 
function was used. Ten candidate values for the number of retained terms were 
evaluated.  
 
To determine the values for the tuning parameters and to estimate performance, 
resampling methods were used. The entire data set was repeatedly split into training 
(80%) and test sets (20%). This process was repeated 200 times. Models were fit on the 
training sets and the associated held-out values were used to estimate performance 
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(sensitivity, specificity, and the area under the ROC curve). The final estimates of 




Levels of 37 markers are altered in MCI/very mild and mild AD CSF 
To identify new candidate biomarkers for AD, multiplexed Luminex-based 
immunoassays were used to evaluate the levels of 190 analytes in the CSF of 242 
cognitively normal participants (CDR 0), 63 participants with very mild dementia (CDR 
0.5), and 28 participants with mild dementia (CDR 1) (participant characteristics at 
baseline assessment in Table 6.1). Of the 190 analytes, 65 had >10% of data missing or 
below the LDL, and were therefore excluded from analysis, yielding 125 ‘measurable’ 
analytes. The mean concentrations of 37 CSF analytes were found to differ between 
cognitively normal (CDR 0) and very mildly/mildly demented (CDR 0.5 and 1) 
participants by age and gender-adjusted analysis of covariance (ANCOVA) (p<.05) 
(Table 6.2). Additionally, participants with very mild/mild dementia exhibited the typical 
AD CSF biomarker profile characterized by significantly lower mean levels of CSF Aβ42 
and higher mean levels of CSF tau and CSF p-tau181 (Tables 6.1 and 6.2).  
 
Correlation of RBM analytes with demographic features and other biomarker 
values 
Because the CDR 0, 0.5, and 1 groups showed somewhat different distributions 
with regard to age at LP and gender, levels of the 37 RBM analytes were evaluated for 
correlation with these variables. Many analytes were significantly associated with age or 
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gender (Table 6.3). Additionally, seeking insight into the potential roles of the analytes in 
AD pathology, we evaluated their association with CSF Aβ42, tau, and p-tau181, and 
cortical amyloid burden measured by PIB-PET imaging. Many of the analytes correlated 
with CSF tau and CSF p-tau181 (31 and 30, respectively), while fewer correlated with 
CSF Aβ42 or cortical amyloid burden (8 and 5, respectively) (Table 6.3).  
 
Diagnostic utility of candidate biomarkers 
To assess the potential of the analytes for identifying very mild/mild dementia 
(combined CDR 0.5 and CDR 1), ROC curves and AUCs were calculated for each of the 
37 RBM analytes and for traditional AD biomarkers Aβ42, tau, p-tau181 and the ratios 
tau/Aβ42 and p-tau181/Aβ42 (Table 6.4). Although none of the RBM analytes alone out-
performed the traditional biomarkers, combining traditional biomarkers with RBM 
analytes improved upon the AUC of the traditional biomarkers in many cases; e.g., 
Aβ42: AUC= .7552, combinations ranging from .7553-.8201; tau/Aβ42: AUC= .8443, 
combinations ranging from .8444-.8819; p-tau181/Aβ42: AUC= .8065, combinations 
ranging from .8065-.8468 (Table 6.4). For these ‘2-marker panels’ of traditional 
biomarker plus RBM analyte, combinations with tau/Aβ42 consistently yielded the 
highest AUCs. To investigate whether combinations of three markers could yield a small 
panel with improved diagnostic accuracy, we utilized a targeted approach in which the 
four 2-marker panels with the highest AUCs (tau/Aβ42 + cystatin C, tau/Aβ42 + VEGF, 
tau/Aβ42 + KIM-1, tau/Aβ42 + PP) were combined with the 10 RBM analytes with the 
highest individual AUCs (indicated in Table 6.4). Because an independent validation 
cohort was not available for analysis, bootstrapping resampling with 100 iterations was 
performed to obtain relatively unbiased estimates of expected future performance of the 
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‘3-marker panels’ in predicting CDR 0 versus CDR>0 (Table 6.5). A number of the 3-
marker panels demonstrated significantly improved AUCs compared to the 
corresponding 2-marker panels, with the best achieving AUCs of ~.90 and sensitivities of 
~84% at 80% specificity (Table 6.5). 
Because AD is a complex, multifactorial disease and likely involves alterations in 
multiple biological pathways, it is possible that a larger panel of biomarkers 
encompassing various features of AD pathophysiology may be optimal for disease 
diagnosis. Thus, we utilized statistical machine learning algorithms, which are more 
amenable to potentially large numbers of analyte combinations and can identify highly 
complex nonlinear relationships, to discover whether groups of markers are capable of 
distinguishing very mildly/mildly demented (CDR 0.5 and 1 combined) from cognitively 
normal participants (CDR 0). A multi-pronged analytical approach including RF, PLS, 
SPLS, Boosted Tree, FDA, NB, NSC, LR, KNN, and SVM was used, as each approach 
has its own strengths and weaknesses. Models were fit with two sets of predictors: 1) 
traditional biomarkers, and 2) traditional biomarkers plus RBM analytes; additionally, 
age, gender, and ApoE4 allele status were included in all models. Model performance 
measures were based on cross-validation, in which the test set results were averaged 
from 200 splits of the data between training (80%) and test (20%) (Table 6.6). Using 
either traditional biomarkers or traditional biomarkers with RBM analytes, no model 
clearly out-performed the others; however, the RBM analytes appeared to contribute 
additional specificity to the biomarker panels (traditional: sensitivity 80.6-91.4%, 
specificity 42.4-56.6%; traditional+ RBM: sensitivity 79.1-93.2%, specificity 59.6-77.6%). 
This improvement is further reflected in the Youden Index, a single statistic that captures 
the performance of a diagnostic test and is a function of sensitivity and specificity, which 
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was higher on average for the models fitted with traditional plus RBM analytes 
(traditional: 0.230-0.438; traditional+RBM: 0.401-0.621). Additionally, models fitted with 
traditional plus RBM analytes yielded mostly higher AUCs (traditional: 0.680-0.827; 
traditional+RBM: 0.754-0.868). For the four models with a built-in importance statistic 
(i.e., Boosted Tree, NSC, RF, and PLS) there was considerable overlap in the top 15 
predictors for each model (Table 6.7). Importantly, nearly all of the markers found to best 
discriminate CDR 0 from CDR>0 participants in the more targeted ROC analyses (Table 
6.5) were also identified as the top predictors in the machine learning models (Table 
6.7), reconfirming the potential of these analytes as biomarkers for AD.  
 
Prognostic utility of candidate biomarkers 
Identifying individuals with AD neuropathology while they are still in the 
preclinical phase will be critically important, as disease-modifying therapies currently in 
development are likely to be most effective early in the disease process before 
significant synaptic and neuronal loss has occurred. Thus, we used univariate and 
multivariate Cox proportional hazards models to evaluate the ability of the analytes to 
predict risk of developing cognitive impairment (conversion from CDR 0 to CDR>0). Of 
the 215 CDR 0 subjects with at least one follow-up annual clinical assessment, 29 
received a CDR>0 at follow-up, and thus were classified as “converters.” Analyte 
measurements were converted to standard Z-scores to allow for comparison of hazard 
ratios between the different analytes. Variables with p<.15 in the univariate Cox 
analyses were considered for inclusion in the multivariate model; variables were retained 
in the final model if p<.05. The final multivariate model consisted of calbindin (HR=1.750, 
p=0.0063), 1/Aβ42 (HR=2.454, p<0.0001), and age at LP (HR=1.096, p=0.0002), with an 
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overall model HR of 4.704 (Table 6.8). Although calbindin and tau both had p<.05 in the 
univariate analysis, the significant correlation between the two (r=0.476, p<0.0001) 
prohibited inclusion of both variables in the multivariate model. Therefore, a second 
multivariate model consisted of tau (HR=1.467, p=0.0262), 1/Aβ42 (HR=2.247, 
p<0.0001), and age at LP (HR=1.098, p=0.0003), with an overall model HR of 3.619 
(Table 6.8). However, the higher HR of calbindin than of tau, and the higher overall 
model HR and lower AIC of the first model support it as the better model. 
 
Discussion 
Biomarkers that can detect AD in its early stages and, importantly, predict future 
dementia will be invaluable for efficient clinical trial design and eventually patient care. 
This study identifies novel biomarkers that improve upon the ability of the best identified 
biomarkers to date to discriminate very mildly demented from cognitively normal 
participants, and identifies a novel biomarker with significant prognostic potential.  
Using Luminex technology and a targeted multiplex panel, we identified 37 
analytes that are increased or decreased in the CSF of participants with early AD 
relative to cognitively normal controls. ROC analysis revealed that small combinations of 
a subset of these markers (cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-
10, MIF, GRO-α, fibrinogen, FAS, and eotaxin-3) can enhance the ability of the best-
performing of the traditional biomarkers, the tau/Aβ42 ratio, to discriminate CDR 0.5 and 
1 from CDR 0 participants. Using alternative statistical strategies that are more 
amenable to the analysis of larger combinations of markers, multiple machine learning 
algorithms likewise showed that the novel biomarkers improved upon the diagnostic 
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performance of the traditional biomarkers (Aβ42, tau, p-tau181). Importantly, nearly all of 
the markers found to best discriminate CDR 0 from CDR 0.5 and 1 participants in the 
more targeted ROC analyses were also identified as the top predictors in the machine 
learning models that contain a built-in importance statistic (10 of 12 markers). Thus, the 
potential of these analytes as biomarkers for AD is supported by alternative statistical 
approaches that resulted in a similar output. Further supporting these results is a recent 
report of the application of a smaller RBM Discovery MAP panel to a smaller cohort of 
AD, MCI, and control subjects (361); this study identified a number of same analytes as 
being differentially expressed in AD CSF as compared to control CSF and, although 
using different analytical approaches, included VEGF, TRAIL-R3, and eotaxin-3, in 
‘combined’ models of novel and traditional biomarkers.  
It is important to note that while the models used in our study suggest diagnostic 
value of the novel biomarkers, other combinations of these markers may be optimal; it 
will be of interest in future studies to validate the results of this discovery study in 
additional cohorts and to determine whether alternative combinations of these markers 
may demonstrate improved performance. The levels of at least 7 of the novel biomarkers 
have been evaluated in AD subjects in other studies: no change was observed in plasma 
PAI-1 levels (453); in agreement with our findings, two studies have reported increased 
CSF MIF in AD and MCI subjects (454, 455); also consistent with our findings, increased 
fibrinogen levels have been observed in AD and MCI CSF (456) and in AD plasma 
(457), and increased plasma levels have been associated with an increased risk of 
future dementia (458); results have been mixed regarding CSF FAS levels in AD (227, 
459); AD plasma/serum VEGF levels have been reported to be unchanged (460, 461), 
decreased (462), and increased (463), while CSF levels have been reported to be 
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unchanged (464) or increased (465); no change in CSF or serum levels of TNF R2 in AD 
has been reported (218); cystatin C findings have been inconsistent, with reports of 
serum/plasma levels unchanged (466), increased in AD (467) or in those who later 
develop AD (143), and decreased (468) or decreased levels associated with increased 
risk of future AD (469), while CSF levels have been reported to be unchanged (466, 
470), decreased  (390) (Chaper 2 and 3), or increased (243). These inconsistent results 
may be due in part to the existence of a truncated form of cystatin C, which was found to 
be increased in AD CSF, while the full length protein was decreased (243, 362). 
 Furthermore, the potential involvement of each marker in AD pathophysiology 
necessitates investigation. The candidate biomarkers identified in the ROC and machine 
learning portions of this study belong to a wide variety of functional classes and 
pathways, including tissue remodeling and angiogenesis (MMP-10, VEGF), regulation of 
apoptosis (TRAIL-R3, FAS, MIF), neutrophil, eosinophil, and/or basophil chemotaxis 
(GRO-α, eotaxin-3), blood coagulation (Fibrinogen, PAI-1), intravascular volume 
homeostasis (NT-proBNP), and gastrointestinal and pancreatic secretions (PP). In 
addition, a number of molecules involved in inflammatory pathways were identified in the 
machine learning models (IL-7, IL-17E, TNF RII, MCP-2, FASL). The association of 
several of the candidate biomarkers with AD pathophysiology has already been probed, 
most notably for cystatin C, which appears to play a role in preventing Aβ 
oligomerization and amyloidogenesis (391, 393, 394, 471, 472), and to a lesser extent 
for PAI-1 (473-475), MIF (454, 476), fibrinogen (477, 478), FAS and FASL (479-482), 
VEGF (483-485), and TNF RII (486-488). 
It will be important in future studies to assess each candidate biomarker’s value 
in diagnosis in independent sample sets when combined with other existing biomarkers 
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or imaging tools. Additionally, to follow up on these biomarker candidates, their ability to 
discriminate AD from other causes of dementia needs to be examined; indeed, several 
of these markers have already shown promise for distinguishing AD from frontotemporal 
lobar degeneration (cystatin C (362), eotaxin-3 (361), and HGF (361)). Incorporation of 
such markers into a biomarker panel may improve diagnostic specificity. Beyond their 
clinical use, these markers may have great value in the design of and enrollment in trials 
of disease-modifying therapies. By enrolling only subjects with lower or higher values of 
a particular marker (or panels of markers) indicative of AD, and excluding potential 
subjects with intermediate or ‘overlap’ values, one might provide greater diagnostic 
certainty than is possible through clinical evaluation alone. This is especially relevant for 
the design and evaluation of primary prevention trials in cognitively normal cohorts. 
Enriching study populations for subjects displaying certain biomarker levels may result in 
studies of greater efficacy, translating to reduced cost.  
This study also suggests a novel biomarker, CSF calbindin, that can predict risk 
of future dementia in individuals who are still cognitively normal. Previous studies have 
shown that Aβ42, tau, YKL-40 (an astrocyte marker), and the ratios tau/Aβ42 and YKL-
40/Aβ42 can predict subsequent cognitive decline in non-demented cohorts (107, 132) 
(and Chapter 3). Using multivariate Cox proportional hazards models to determine the 
best combination of biomarkers for prognosis, we show here that a panel of markers 
consisting of calbindin, Aβ42, and age has predictive value comparable to, if not better 
than, a second panel consisting of tau, Aβ42, and age. Tissue culture studies have 
shown that increased expression of calbindin, a calcium binding protein present in 
central and peripheral nervous system neurons, correlates with increased resistance to 
cell death triggered by a variety of causes, including exposure to excitatory amino acids, 
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ischemic injury, and Aβ (489-492). Decreases in calbindin protein and mRNA levels 
(493) and number of calbindin-immunopositive neurons (400, 494, 495) have been 
observed in AD brains compared to controls. Further suggesting there may be a role for 
calbindin in AD pathophysiology is the large body of literature demonstrating that 
increased oxidative stress and altered calcium homeostasis appear to be interrelated 
mechanisms in AD pathogenesis. Interestingly, although not quite reaching statistical 
significance, we found that CSF calbindin levels trended higher in the very mildly/mildly 
demented group (p=.0660), suggesting that perhaps degenerating neurons release 
calbindin into the CSF. The immunohistochemical findings of a small study of 6 AD 
brains suggesting that calbindin-immunopositive neurons are relatively preserved in 
cases with moderate amyloid plaque and neurofibrillary content but are lost in more 
severe cases (494) prompts the question of whether CSF calbindin levels would be more 
significantly elevated in more severely demented individuals. Further studies are needed 
to confirm the prognostic potential of CSF calbindin, to determine if other complementary 
fluid or imaging biomarkers may improve upon its performance, and to more definitively 
elucidate its role in AD pathophysiology. As with the candidate diagnostic biomarkers, 
CSF calbindin may have value for clinical trial design by allowing for the selective 
enrollment of individuals who are at greater risk of developing cognitive impairment, 










Chapter 6. Use of a Multiplexed Immunoassay Panel for the Identification of Novel CSF 




Table 6.1. Demographic, clinical, and genotypic characteristics of the 333 study 
participants 
Characteristic CDR 0 CDR 0.5 CDR 1 
N 242 63 28 
Gender (% Female) 65% 52% 50% 
APOE genotype, % ε4+ 32% 54% 57% 
Mean MMSE score (SD) 28.9 (1.3) 26.3 (2.8) 22.5 (4.0) 
Mean age at LP (SD), yrs 71.6 (7.4) 74.6 (7.3) 76.8 (6.2) 
Mean CSF Aβ42 (SD), pg/mL 607 (234) 436 (233) 355 (119) 
Mean CSF tau (SD), pg/mL 315 (169) 547 (278) 557 (266) 
Mean CSF p-tau181 (SD), pg/mL 56 (25) 85 (45) 78 (38) 
 
Abbreviations: CDR, Clinical Dementia Rating; APOE, apolipoprotein E; MMSE, Mini-
Mental State Examination; LP, lumbar puncture; SD, standard deviation; CSF, 
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Table 6.2. Analytes that differ in levels between cognitively normal (CDR 0) and 














Aβ42 (pg/mL) 607.45 418.85 <.0001 606.90 411.18
Tau (pg/mL) 315.59 533.60 <.0001 314.80 549.96
p-tau181 (pg/mL) 56.30 81.01 <.0001 56.32 82.98
Growth-Regulated alpha protein (GRO-
α) (pg/mL) 18.27 22.09 <.0001 18.30 22.44
Log Matrix Metalloproteinase-10 
(MMP-10) (pg/mL) 24.84 31.41 <.0001 24.11 32.61
Log N-terminal pro-brain natriuretic 
peptide (NT-proBNP) (pg/mL) 87.00 107.75 <.0001 87.70 111.12
Log Plasminogen Activator Inhibitor 1 
(PAI-1) (ng/mL) 1.05 1.28 <.0001 1.01 1.34
TNF-Related Apoptosis-Inducing 
Ligand Receptor 3 (TRAIL-R3)  
(ng/mL) 0.55 0.63 <.0001 0.55 0.65
Vascular Endothelial Growth Factor 
(VEGF) (pg/mL) 441.57 378.30 <.0001 437.83 386.01
Log Pancreatic Polypeptide (PP) 
(pg/mL) 0.94 1.30 0.0001 0.88 1.41
Log FAS (ng/mL) 0.57 0.65 0.0002 0.56 0.67
Log Macrophage Migration Inhibitory 
Factor (MIF) (ng/mL) 0.15 0.17 0.0004 0.15 0.18
Interleukin-7 (IL-7) (pg/mL) 12.63 9.47 0.0006 12.23 9.68
Log Cystatin C (ng/mL) 5613.84 4750.89 0.0011 5551.50 4835.30
Thrombopoietin (ng/mL) 0.43 0.37 0.0016 0.42 0.37
Sortilin (ng/mL) 6.32 6.92 0.0019 6.33 6.96
Monocyte Chemotactic Protein 2 
(MCP-2) (pg/mL) 4.03 4.61 0.0020 3.97 4.67
Log Fibrinogen (ug/mL) 0.63 0.78 0.0024 0.59 0.81
Log Creatine Kinase-MB (CKMB) 
(pg/mL) 26.55 20.97 0.0030 26.62 20.87
Cortisol (ng/mL) 11.21 12.65 0.0034 11.17 12.89
Thymus-Expressed Chemokine 
(TECK) (ng/mL) 6.38 6.85 0.0039 6.30 6.96
Eotaxin-3 (pg/mL) 56.78 62.09 0.0057 55.33 63.68
Interleukin-17E (IL-17E) (pg/mL) 8.63 7.75 0.0058 8.60 7.79
Kidney Injury Molecule-1 (KIM-1) 
(pg/mL) 78.97 83.46 0.0074 79.05 83.08
Log Heparin-binding epidermal growth 
factor-like growth factor (HB-EGF) 24.98 28.77 0.0077 25.05 28.70
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Log Osteopontin (ng/mL) 173.23 197.68 0.0078 174.15 202.31
Log α-1-Antitrypsin (ug/mL) 4.87 5.37 0.0102 4.73 5.49
Fatty Acid Synthase Ligand (FASL) 
(pg/mL) 4.85 5.40 0.0109 4.78 5.49
Log Insulin-like Growth Factor-Binding 
Protein 2 (IGFBP-2) (ng/mL) 199.58 212.16 0.0111 195.93 217.47
Log Interleukin-10 (IL-10) (pg/mL) 1.14 1.29 0.0131 1.12 1.29
Log Tumor necrosis factor-a receptor 2 
(TNF RII) (ng/mL) 0.53 0.59 0.0141 0.52 0.62
Log Resistin (pg/mL) 26.28 30.76 0.0146 25.20 32.14
Log Fatty Acid Binding Protein (FABP) 
(ng/mL) 3.03 3.62 0.0209 2.93 3.81
Log Apolipoprotein D (ApoD) (ug/mL) 4.18 4.57 0.0318 4.02 4.65
Log Hepatocyte Growth Factor (HGF) 
(ng/mL) 1.18 1.28 0.0349 1.18 1.30
Log Insulin (uIU/mL) 0.22 0.19 0.0359 0.21 0.19
Log Hemofiltrate cysteine-cysteine 
chemokine (HCC-4) (pg/mL) 30.25 33.13 0.0418 28.98 33.87
Log Interferon gamma Induced Protein 
10 (IP-10) (pg/mL) 299.63 341.86 0.0432 295.14 354.74
Log Gamma-Interferon-Induced 
Monokine (MIG) (pg/mL) 423.80 493.91 0.0452 400.16 572.75
Thrombomodulin (ng/mL) 0.17 0.18 0.0475 0.17 0.19
 
Table 6.2. Analysis of covariance (ANCOVA) using the General Linear Model (GLM) 
procedure in SAS was used to determine analytes that differed in concentration (p<.05) 
between CDR 0 and CDR>0 groups while adjusting for the effects of age and gender 
("adjusted means"). For markers that were log transformed to approximate a normal 
distribution, the resulting Least Squares mean (or estimated marginal mean) was back-
transformed to obtain the adjusted mean shown. Also provided are the raw mean 
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Table 6.3.  Correlations of RBM analytes with age, gender, and other biomarker 
values 
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Table 6.3. Correlations were evaluated using the Spearman rho correlation coefficient 
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Table 6.4. ROC analyses 
AUC of Traditional Biomarkers 
log Aβ42 0.7552     
log tau  0.7830     
log p-tau181  0.7149 
log tau/Aβ42 0.8443     
log p-tau181/Aβ42 0.8065     
AUC of RBM Biomarkers: alone and in combination with traditional biomarkers 
  Marker Marker+log tau/Aβ42 Marker+log p-tau181/Aβ42 
log α1A 0.6296 0.8578 0.8234 
log ApoD 0.6136 0.8489 0.8138 
log CKMB 0.6106 0.8475 0.8118 
Cortisol 0.6183 0.8510 0.8155 
log Cystatin C 0.5965 0.8819 § 0.8468 
Eotaxin-3 0.6448 § 0.8516 0.8202 
log FABP 0.6163 0.8499 0.8080 
log FAS 0.6689 § 0.8518 0.8209 
FASL 0.6134 0.8479 0.8116 
log Fibrinogen 0.6503 § 0.8564 0.8232 
GRO-α 0.7024 § 0.8609 0.8305 
log HB-EGF 0.5929 0.8445 0.8081 
log HCC-4 0.6172 0.8596 0.8281 
log HGF 0.5972 0.8458 0.8069 
log IGF-BP2 0.6378 0.8462 0.8116 
IL-7 0.6029 0.8508 0.8162 
log IL-10 0.6075 0.8575 0.8215 
IL-17E 0.5969 0.8487 0.8145 
log Insulin 0.5406 0.8453 0.8077 
log IP-10 0.5970 0.8460 0.8093 
KIM-1 0.5894 0.8668 § 0.8343 
MCP-2 0.6264 0.8554 0.8200 
log MIF 0.6651 § 0.8455 0.8117 
log MIG 0.6376 0.8544 0.8207 
log MMP-10 0.6929 § 0.8518 0.8232 
log NT-proBNP 0.6753 § 0.8562 0.8248 
log Osteopontin 0.6050 0.8508 0.8100 
log PP 0.6789 § 0.8644 § 0.8356 
log PAI-1 0.6814 § 0.8587 0.8273 
log Resistin 0.6218 0.8522 0.8211 
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Sortilin 0.6177 0.8444 0.8076 
log TNF RII 0.6319 0.8447 0.8065 
TRAIL-R3 0.6851 § 0.8523 0.8212 
Thrombomodulin 0.6004 0.8503 0.8150 
Thrombopoietin 0.5898 0.8465 0.8111 
TECK 0.6371 0.8525 0.8190 
VEGF 0.6146 0.8766 § 0.8441 
 
Table 6.4. To assess the ability of the markers to distinguish CDR>0 from CDR 0, ROC 
analyses were performed for each of the traditional biomarkers (Aβ42, tau, p-tau181 and 
the ratios tau/Aβ42 and p-tau181/Aβ42) and for the 37 RBM analytes with p<.05 in the 
univariate analyses. Each traditional biomarker was then combined with each RBM 
analyte to identify ‘2-marker panels’ with improved AUCs. Among the traditional 
biomarkers, the ratios tau/Aβ42 and p-tau181/Aβ42 demonstrated the highest AUCs; 
additionally, combining these ratios with the RBM analytes consistently yielded 2-marker 
panels with AUCs higher than combinations of the individual traditional biomarkers 
(Aβ42, tau, p-tau181) with the RBM analytes. Thus, only the most promising 2-marker 
panels (those with tau/Aβ42 and p-tau181/Aβ42) are shown here. To determine whether 
combinations of three markers could yield a small panel with improved diagnostic 
accuracy, the four 2-marker panels with the highest AUCs were combined with the 10 














Table 6.5. ROC analyses of 3-marker panels 
Marker Panels AUC  Stdev 95% CI 
Sensitivity 
(at 80% 
specificity) Stdev 95% CI 
P 
value Stdev 95% CI 
log tau/Aβ + log Cystatin C + TRAIL-R3 0.9014 0.0232 0.8969-0.9060 0.8367 0.0445 0.8280-0.8455 0.0299 0.0222 0.0255-0.0342 
log tau/Aβ + log Cystatin C + log PAI-1 0.9063 0.0221 0.9020-0.9106 0.8470 0.0438 0.8384-0.8556 0.0283 0.0344 0.0215-0.0351 
log tau/Aβ + log Cystatin C + log PP 0.9066 0.0203 0.9026-0.9106 0.8471 0.0400 0.8393-0.8550 0.0245 0.0319 0.0183-0.0307 
log tau/Aβ + log Cystatin C + NT-proBNP 0.9041 0.0228 0.8996-0.9086 0.8422 0.0445 0.8335-0.8509 0.0287 0.0330 0.0223-0.0352 
log tau/Aβ + log Cystatin C + log MMP-10 0.8987 0.0230 0.8942-0.9032 0.8317 0.0447 0.8230-0.8405 0.0647 0.0582 0.0533-0.0761 
log tau/Aβ + log Cystatin C + log MIF 0.8964 0.0249 0.8915-0.9013 0.8272 0.0487 0.8177-0.8368 0.0699 0.0569 0.0588-0.0811 
log tau/Aβ + log Cystatin C + GRO-α 0.9071 0.0218 0.9028-0.9113 0.8475 0.0412 0.8395-0.8556 0.0347 0.0410 0.0266-0.0427 
log tau/Aβ + log Cystatin C + log 
Fibrinogen 0.9033 0.0219 0.8990-0.9075 0.8403 0.0429 0.8319-0.8487 0.0357 0.0502 0.0259-0.0455 
log tau/Aβ + log Cystatin C + log FAS 0.9052 0.0220 0.9009-0.9095 0.8440 0.0425 0.8356-0.8523 0.0248 0.0248 0.0200-0.0297 
log tau/Aβ + log Cystatin C + Eotaxin-3 0.9051 0.0219 0.9008-0.9094 0.8441 0.0427 0.8357-0.8524 0.0273 0.0350 0.0205-0.0342 
                    
log tau/Aβ + VEGF + TRAIL-R3 0.9004 0.0226 0.8960-0.9049 0.8347 0.0437 0.8262-0.8433 0.0208 0.0158 0.0177-0.0239 
log tau/Aβ + VEGF + log PAI-1 0.9005 0.0225 0.8961-0.9049 0.8355 0.0445 0.8267-0.8442 0.0272 0.0320 0.0210-0.0335 
log tau/Aβ + VEGF + log PP 0.9039 0.0215 0.8997-0.9081 0.8423 0.0422 0.8340-0.8506 0.0167 0.0250 0.0118-0.0216 
log tau/Aβ + VEGF + NT-proBNP 0.9028 0.0224 0.8984-0.9072 0.8396 0.0439 0.8310-0.8482 0.0165 0.0207 0.0124-0.0205 
log tau/Aβ + VEGF + log MMP-10 0.8947 0.0242 0.8900-0.8995 0.8241 0.0471 0.8149-0.8333 0.0534 0.0519 0.0432-0.0636 
log tau/Aβ + VEGF + log MIF 0.8908 0.0261 0.8857-0.8959 0.8164 0.0506 0.8065-0.8264 0.0703 0.0570 0.0591-0.0815 
log tau/Aβ + VEGF + GRO-α 0.9003 0.0238 0.8956-0.9049 0.8348 0.0452 0.8259-0.8436 0.0365 0.0371 0.0292-0.0437 
log tau/Aβ + VEGF + log Fibrinogen 0.8988 0.0231 0.8943-0.9033 0.8317 0.0449 0.8229-0.8405 0.0327 0.0457 0.0237-0.0416 
log tau/Aβ + VEGF + log FAS 0.9012 0.0232 0.8967-0.9058 0.8363 0.0445 0.8276-0.8451 0.0232 0.0248 0.0183-0.0281 
log tau/Aβ + VEGF + Eotaxin-3 0.8991 0.0227 0.8947-0.9036 0.8325 0.0441 0.8239-0.8411 0.0293 0.0354 0.0224-0.0363 
                    
log tau/Aβ + KIM-1 + TRAIL-R3 0.8810 0.0256 0.8760-0.8860 0.7979 0.0486 0.7884-0.8075 0.1082 0.0747 0.0936-0.1229 
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log tau/Aβ + KIM-1 + log PAI-1 0.8866 0.0246 0.8818-0.8915 0.8087 0.0476 0.7993-0.8180 0.0614 0.0607 0.0495-0.0733 
log tau/Aβ + KIM-1 + log PP 0.8905 0.0239 0.8858-0.8952 0.8162 0.0467 0.8070-0.8253 0.0357 0.0452 0.0269-0.0445 
log tau/Aβ + KIM-1 + NT-proBNP 0.8821 0.0260 0.8770-0.8872 0.8001 0.0500 0.7903-0.8099 0.0926 0.0788 0.0772-0.1081 
log tau/Aβ + KIM-1 + log MMP-10 0.8787 0.0270 0.8734-0.8840 0.7940 0.0511 0.7840-0.8040 0.1497 0.1015 0.1298-0.1696 
log tau/Aβ + KIM-1 + log MIF 0.8775 0.0276 0.8721-0.8829 0.7918 0.0518 0.7816-0.8019 0.1478 0.0941 0.1294-0.1663 
log tau/Aβ + KIM-1 + GRO-α 0.8897 0.0242 0.8850-0.8945 0.8153 0.0448 0.8065-0.8241 0.0513 0.0498 0.0416-0.0611 
log tau/Aβ + KIM-1 + log Fibrinogen 0.8821 0.0267 0.8769-0.8874 0.8003 0.0507 0.7903-0.8102 0.0927 0.0809 0.0768-0.1085 
log tau/Aβ + KIM-1 + log FAS 0.8806 0.0248 0.8757-0.8855 0.7973 0.0472 0.7881-0.8066 0.1157 0.0852 0.0990-0.1324 
log tau/Aβ + KIM-1 + Eotaxin-3 0.8805 0.0264 0.8753-0.8857 0.7973 0.0498 0.7875-0.8071 0.1152 0.0943 0.0967-0.1337 
                    
log tau/Aβ + log PP + TRAIL-R3 0.8717 0.0249 0.8668-0.8766 0.7790 0.0488 0.7695-0.7886 0.2225 0.1023 0.2024-0.2425 
log tau/Aβ + log PP + log PAI-1 0.8715 0.0250 0.8666-0.8764 0.7782 0.0498 0.7685-0.7880 0.2034 0.1052 0.1828-0.2240 
log tau/Aβ + log PP + NT-proBNP 0.8723 0.0254 0.8674-0.8773 0.7806 0.0491 0.7710-0.7902 0.1705 0.1051 0.1499-0.1912 
log tau/Aβ + log PP + log MMP-10 0.8702 0.0256 0.8652-0.8753 0.7761 0.0507 0.7662-0.7860 0.2394 0.1204 0.2158-0.2630 
log tau/Aβ + log PP + log MIF 0.8685 0.0251 0.8635-0.8734 0.7723 0.0496 0.7625-0.7820 0.2909 0.1014 0.2711-0.3108 
log tau/Aβ + log PP + GRO-α 0.8755 0.0250 0.8706-0.8804 0.7875 0.0472 0.7783-0.7968 0.1329 0.0908 0.1151-0.1507 
log tau/Aβ + log PP + log Fibrinogen 0.8720 0.0255 0.8670-0.8769 0.7795 0.0498 0.7698-0.7893 0.1878 0.1160 0.1651-0.2106 
log tau/Aβ + log PP + log FAS 0.8701 0.0244 0.8653-0.8749 0.7752 0.0487 0.7657-0.7847 0.2335 0.1091 0.2121-0.2548 
log tau/Aβ + log PP + Eotaxin-3 0.8722 0.0245 0.8674-0.8770 0.7795 0.0487 0.7699-0.7890 0.1813 0.1087 0.1599-0.2026 
 
Table 6.5.  AUC= area under the curve; Stdev= standard deviation; CI= confidence interval.  Receiver operating characteristic (ROC) 
analyses assessed the ability of three marker panels to discriminate CDR 0 from CDR>0 participants. Averages of performance 
measures were taken over 100 iterations of the bootstrap. “p-value” assesses the difference between the three marker panel and the 
corresponding two marker panel (e.g. log tau/Aβ + log Cystatin C + TRAIL-R3 vs. log tau/Aβ + log Cystatin C). 
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Table 6.6. Performance measures of machine learning algorithms in 
discriminating cognitively normal (CDR 0) from very mildly/mildly demented (CDR 
0.5 and 1) participants 
 Traditional Biomarkers Traditional + RBM Biomarkers 
Model Sensitivity Specificity Youden 
Index 









0.882 0.546 0.428 0.827 0.827 0.672 0.499 0.808
K-Nearest 
Neighbors 
0.866 0.552 0.418 0.813 0.886 0.627 0.513 0.814
Logistic 
Regression 
0.902 0.490 0.392 0.819 0.791 0.667 0.458 0.757
Naïve Bayes 0.898 0.492 0.390 0.799 0.802 0.599 0.401 0.754
Partial Least 
Squares 




0.914 0.457 0.371 0.822 0.858 0.694 0.552 0.851
Random 
Forests 








0.806 0.424 0.230 0.680 0.929 0.645 0.574 0.868
 
Table 6.6. Ten statistical machine learning algorithms were used to determine groups of 
markers capable of distinguishing very mildly/mildly demented (CDR 0.5 and 1 
combined) from cognitively normal participants (CDR 0). Models were fit with two sets of 
predictors: 1) traditional biomarkers, or 2) traditional biomarkers plus RBM analytes; 
additionally, age, gender, and ApoE4 allele status were included in all models. Model 
performance measures shown are based on cross-validation, in which the test set 
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1 tau tau Aβ42 tau 
2 Aβ42 Aβ42 tau Aβ42 
3 VEGF p-tau181 MMP-10 VEGF 
4 MMP-10 GRO-α KIM-1 p-tau181 
5 PP VEGF VEGF GRO-α 
6 KIM-1 Eotaxin-3 IL-7 PP 
7 Cystatin C Age IL-17E Cystatin C 
8 Calbindin PP PP NT-proBNP 
9 NT-proBNP Cortisol NT-proBNP MMP-10 
10 MIF MCP-2 TRAIL-R3 KIM-1 
11 IGFBP-2 TECK p-tau181 Apo A1 
12 TRAIL-R3 MMP-10 Cystatin C ε3ε4 
13 FSH IL-17E MIF IL-7 
14 FAS IL-7 GRO-α Insulin 
15 TNF RII FASL CKMB Age 
 
 Table 6.7.  For the four models with a built-in importance statistic (i.e., Boosted Tree, 
NSC, RF, and PLS), there is considerable overlap in the top 15 predictors for each 
model. Additionally, nearly all of the markers found to best discriminate CDR 0 from 
CDR>0 participants in the more targeted ROC analyses (Table 6.5), as shown here, 
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Table 6.8. Cox proportional hazards models for predicting risk of developing 
cognitive impairment (conversion from CDR 0 to CDR>0) 
A. Marker HR 95% CI p  
 Log Calbindin 1.736 1.161-2.596 0.0072  
 Log 1/Aβ42 2.361 1.564-3.564 <0.0001  
 Age 1.094 1.043-1.147 0.0002  
 Gender 0.722 0.326-1.599 0.4216  
      
B. Marker HR 95% CI p Overall 
model HR 
 Log Calbindin 1.750 1.172-2.613 0.0063 
4.704  Log 1/Aβ42 2.454 1.637-3.679 <0.0001 
 Age 1.096 1.045-1.149 0.0002 
      
C. Marker HR 95% CI p  
 Log Tau 1.462 1.039-2.057 0.0294  
 Log 1/Aβ42 2.221 1.477-3.339 0.0001  
 Age 1.096 1.041-1.154 0.0005  
 Gender 0.724 0.334-1.566 0.4113  
      
D. Marker HR 95% CI p Overall 
model HR 
 Log Tau 1.467 1.046-2.056 0.0262 
3.610  Log 1/Aβ42 2.247 1.496-3.375 <0.0001 
 Age 1.098 1.043-1.156 0.0003 
 
Table 6.8.  Cox proportional hazards models were used to identify panels of biomarkers 
predictive of the risk of developing cognitive impairment (conversion from CDR 0 to 
CDR>0). Analyte measurements were converted to standard Z-scores to allow for 
comparison of hazard ratios between the different analytes. Variables with p<.15 in the 
univariate Cox analyses were considered for inclusion in multivariate models; variables 
were retained in the final model if p<.05. Because many of the analytes, including 
calbindin, demonstrated age and gender affects, both variables were entered into the 
multivariate models. However, as gender did not appear to contribute to the models (A, 
C), it was not included in the final panels (B, D). Although calbindin and tau both 
demonstrated p<.05 in the univariate analyses, the significant correlation between the 
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two (r=0.476, p<0.0001) prohibited inclusion of both variables in the multivariate model. 
Therefore, a separate multivariate model that included tau was evaluated (C, D). The 
higher HR of calbindin than of tau, and the higher overall model HR (4.704>3.610) and 









































The number of individuals affected by AD is projected to increase dramatically 
over the coming decades, barring the development of successful treatments. Although a 
large number of compounds have been tested as potential therapeutics, clinical trials 
have been largely unsuccessful, in part, because they have targeted study subjects who 
already have dementia. Clinicopathological studies have made it increasingly clear there 
exists a ‘preclinical’ or ‘presymptomatic’ stage during which the pathological changes 
associated with AD begin ~10-15 years before the synaptic and neuronal loss that 
accompany dementia onset. Thus, to prevent neurodegeneration and the resulting 
cognitive impairment, disease-modifying treatments will need to be applied early in the 
disease process (preclinically). Currently, ‘possible’ or ‘probable’ AD is diagnosed by 
clinical examination. However, clinical examination cannot identify preclinical AD, and in 
nonspecialized settings, has limited accuracy for mild disease stages. Additionally, 
clinical examination cannot identify individuals at risk of developing future cognitive 
impairment or predict the rate of cognitive decline. Thus, there is an urgent need for 
biomarkers of AD. CSF Aβ42 and tau are perhaps the two most promising biomarkers 
identified to date. We hypothesize that there are additional CSF biomarkers that can 
complement Aβ42 and tau, improving upon their diagnostic and prognostic accuracy. 
This thesis reflects my work to identify novel biomarkers for AD that may be useful in 
such capacities. 
We first utilized an unbiased proteomics approach (2D-DIGE LC-MS/MS) to 
identify CSF proteins increased or decreased in mild dementia (CDR 1, N=24) relative to 
cognitive normalcy (CDR 0, N=24). From this proteomic analysis, we identified 47 
proteins as differing significantly in abundance between CDR 0 and CDR 1 groups. Most 
of these 47 candidate biomarkers could be placed into structural and/or functional 
categories associated with accepted neuropathophysiological changes in AD, 
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suggesting that many of these changes are represented by alterations in the CSF 
proteome. Unsupervised clustering analyses of this 2D-DIGE data, performed without 
the influence of CSF Aβ42, tau, p-tau and APOE genotype, suggested that these 
biomarker candidates collectively showed utility for discriminating groups with and 
without mild dementia. We then went on to validate these findings by measuring a 
subset (11) of the identified candidate biomarkers by ELISA in the original discovery 
sample set. Six of the candidates (NrCAM, YKL-40, chromogranin A, carnosinase I, 
transthyretin, cystatin C) showed  differences in mean concentration between the 
original AD (CDR 1) and control (CDR 0) groups, and were thus subsequently evaluated 
in a larger independent sample set (N=292) that included CDR 0, CDR 0.5 (very mild 
dementia), and CDR 1 groups. In this larger independent sample set, CDR 0 and 
CDR>0 groups showed significant differences in mean concentrations of YKL-40, 
carnosinase I, tau, p-tau181 and Aβ42; CDR 1 and CDR <1 groups showed differences 
in carnosinase I, chromogranin A, NrCAM, tau, p-tau181 and Aβ42.  ROC analyses 
using a stepwise logistic regression model yielded optimal biomarker panels to 
distinguish CDR 0 from CDR>0 (tau, YKL-40, NrCAM) and CDR 1 from CDR<1 (tau, 
chromogranin A, carnosinase I). These analyses suggested that these four candidate 
biomarkers (YKL-40, NrCAM, chromogranin A, carnosinase I) could improve the ability 
of tau to classify individuals into CDR 0, CDR 0.5, and CDR 1 groups. Additionally, 
drawing on previous work from our lab and from other groups, with these four novel 
biomarkers and CSF Aβ42 and tau, we were able to provide a framework for 
categorizing six clinicopathological stages: normal cognition without amyloid plaques, 
normal cognition with amyloid plaques (preclinical AD), normal cognition at increased 
risk to develop dementia (converters), very mild dementia (CDR 0.5), very mild dementia 
at increased risk for progression, and mild dementia (CDR 1). This biomarker-based 
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classification of six disease stages ranging from cognitively normal to mild dementia 
represents an important contribution to the field, as most studies have focused only on 
distinguishing those with AD (and often in the later stages) or those with MCI (analogous 
to a CDR 0.5) from cognitively normal individuals. Additionally, this small panel of CSF 
biomarkers may be useful to guide enrollment into and maximize the efficiency of clinical 
trials by classifying subjects into precise disease stages, identifying those at risk of 
progression, and providing study endpoints based on biomarker-defined stage 
transitions, rather than measures of cognitive decline. 
One of the most promising candidate biomarkers to emerge from this 2D-DIGE 
study, in terms of novelty and fold-change, was YKL-40, a secreted glycoprotein of 
poorly understood function. Consistent with our 2D-DIGE findings, YKL-40 was 
significantly increased by ELISA in CDR 0.5 CSF of the discovery cohort, and CDR 0.5 
and CDR 1 CSF of the larger validation cohort. To continue our study of this novel 
biomarker, we measured YKL-40 levels in plasma samples of the validation cohort, 
along with levels in a small cohort of FTLD and PSP CSF samples.  Plasma YKL-40 
levels displayed a pattern of elevation in the CDR 0.5 and 1 groups similar to that 
observed for CSF, and plasma and CSF levels correlated modestly. CSF YKL-40 levels 
trended higher in the FTLD and lower in the PSP groups relative to the AD group. Thus, 
this study demonstrated the promise of CSF YKL-40 as a biomarker for very early stage 
AD (CDR 0.5) and, although not covering the complete differential diagnosis for mild 
dementia, suggested that CSF YKL-40 may be useful in distinguishing AD from some 
other forms of neurodegenerative disease. Importantly, this study also demonstrated the 
potential utility of YKL-40, coupled with Aβ42, to predict cognitive decline. The CSF YKL-
40/Aβ42 ratio displayed predictive value comparable to that of the best current CSF 
measures, tau/Aβ42 and p-tau181/Aβ42. This finding is particularly notable because, 
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whereas CSF tau is derived principally from neurons, based on our 
immunohistochemical analysis of human AD brain, YKL-40 appears to be secreted 
predominantly from astrocytes. To our knowledge, YKL-40 is the first astrocyte-derived 
marker shown to have such prognostic potential. CSF YKL-40/Aβ42 also showed 
promise in predicting progression of dementia from CDR 0.5 to CDR>0.5; however, 
tau/Aβ42 and p-tau181/Aβ42 appear to show greater utility in this regard. Unfortunately, 
plasma YKL-40 did not demonstrate similar prognostic utility. The finding of YKL-40 
immunoreactivity predominantly within astrocytes surrounding amyloid plaques 
suggested a role for YKL-40 in the neuroinflammatory response to Aβ deposition. 
Increasing evidence suggests that, in addition to the formation of amyloid plaques and 
neurofibrillary tangles, brain inflammation may be considered a third key mechanism 
contributing to disease pathogenesis, and consequently, another potential target for 
therapeutics. One may speculate that perhaps neuroinflammation in response to amyloid 
deposits accelerates the rate of synaptic and neuronal loss or dysfunction. These 
different but interrelated processes may respond differently to disease-modifying 
therapies. Therefore, a marker of inflammation in the brain such as YKL-40 may be 
helpful in monitoring disease progression or response to treatment. The identification of 
a biomarker for AD that predicts prognosis and that marks a process different than Aβ42 
or tau is a novel finding that could benefit the field.   
The 2D-DIGE study presented in this work represents an expansion/validation of 
a previous similar proteomics experiment utilizing 2D-DIGE on a smaller scale. To follow 
up on several candidate biomarkers identified in that study, we evaluated the levels of 
ACT, ATIII, ZAG, and AGT by ELISA in a larger, independent CSF sample set (N=138). 
However, levels of these four proteins were not found to differ between CDR 0 and 
CDR>0 groups. In spite of these seemingly negative findings, these proteins may still 
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have potential as biomarkers for AD. It is important to note that these four proteins were 
first identified as differing significantly in abundance between AD and control groups by 
2D-DIGE, a technique sensitive to concentration changes of minor protein isoforms and 
post-translational modifications which may not substantially alter global concentrations of 
a ‘parent’ protein. As these four proteins are known to have different isoforms, a 
thorough evaluation of their potential as biomarkers for AD would appear to require the 
design of ELISAs targeting specific post-translational modifications or specific ‘sub-
species’ of interest. 
A relatively unexplored source for novel biomarkers of AD is the low molecular 
weight components of CSF, or the CSF peptidome. To address this, we developed a 
protocol for the extraction and identification of peptides from CSF using Hypercarb 
chromatography material in a tip format and LC-MS/MS, and applied it to a CDR 0, CDR 
1, and mixed/pooled clinical sample. Quantification of a subset of the peptides detected 
in these samples revealed differences in abundance among pooled, CDR 1, and CDR 0 
CSF, albeit with a limited sample number. Additionally, recovery of internal standard 
BSA peptides was not statistically significantly different between sample runs, 
demonstrating the reproducibility of the extraction and LC-MS method. The future 
application of this low molecular weight protocol to larger numbers of AD and control 
CSF samples may identify many novel candidate biomarkers for AD; moreover, this 
protocol for extracting and identifying CSF peptides could be applied to studies of other 
neurodegenerative diseases as well.  
Finally, to complement the unbiased approaches we used to identify novel 
biomarkers for AD, in collaboration with Pfizer we utilized a targeted proteomics 
approach. In this study, a large number of CSF samples (N=333) from well-characterized 
MCI/very early stage-AD (CDR>0) and cognitively normal (CDR 0) individuals were 
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chosen for protein profiling using a commercially available multiplexed immunoassay 
platform that measured the levels of 190 proteins belonging to a wide variety of 
functional classes. From this analysis, the levels of 37 proteins were found to differ 
between CDR 0 and CDR>0 participants by age and gender-adjusted analysis of 
covariance. ROC analysis revealed that small combinations of a subset of these markers 
(cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF, GRO-α, fibrinogen, 
FAS, and eotaxin-3) could enhance the ability of the best-performing of the traditional 
biomarkers, the tau/Aβ42 ratio, to discriminate CDR 0.5 and 1 from CDR 0 participants. 
Using alternative statistical strategies more amenable to the analysis of larger 
combinations of markers, multiple machine learning algorithms likewise showed that the 
novel biomarkers improved upon the diagnostic performance of the traditional 
biomarkers (Aβ42, tau, p-tau181). Importantly, nearly all of the markers found to best 
discriminate CDR 0 from CDR 0.5 and 1 participants in the more targeted ROC analyses 
were also identified as the top predictors in the machine learning models that contain a 
built-in importance statistic, reconfirming the potential of these proteins as biomarkers for 
early-stage AD. We next used Cox proportional hazards models to evaluate the ability of 
the analytes to predict risk of developing cognitive impairment (conversion from CDR 0 
to CDR>0) and to determine the best combination of biomarkers for use in this regard. 
We demonstrated that an optimal panel of markers consisted of calbindin, Aβ42, and 
age, and that this panel had predictive value comparable to, if not better than, a second 
panel consisting of tau, Aβ42, and age (the significant correlation between calbindin and 
tau prohibited the inclusion of both variables in the same multivariate model). 
These studies have identified a number of novel candidate biomarkers that 
improve upon the ability of the best identified biomarkers to date to discriminate very 
mildly/mildly demented from cognitively normal participants (NrCAM, chromogranin A, 
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carnosinase I, YKL-40, cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, 
MIF, GRO-α, fibrinogen, FAS, and eotaxin-3). These studies have also identified two 
novel biomarkers (YKL-40 and calbindin) with significant prognostic potential. Although 
the mean concentrations of these candidate biomarkers differed between clinical groups, 
as with all biomarkers identified to date, considerable overlap in values was observed 
between the groups. This issue of overlapping values suggests that any biomarker alone 
will be insufficient for classifying subjects, and that a panel of complementary biomarkers 
will be necessary to achieve adequate sensitivity and specificity. Thus, it will be 
important in future studies to assess each candidate biomarker’s value in diagnosis in 
additional independent sample sets and when combined with other existing biomarkers 
or imaging tools. It is worth mentioning, however, that even with overlap between 
groups, a biomarker that shows significant differences between groups may have great 
value for clinical trial design and enrollment. By enrolling only subjects with lower or 
higher values of a particular biomarker and excluding potential subjects with 
intermediate or ‘overlap’ values, one might provide greater diagnostic certainty than is 
possible through clinical diagnosis alone. Biomarkers panels such as the ones proposed 
here may also allow clinical trials to evaluate stage-specific responses to treatment. 
Furthermore, as most of these biomarkers reflect underlying pathological changes in real 
time, the use of biomarkers as surrogate endpoints in clinical trials may allow for the 
monitoring of clinically imperceptible neuropathological changes, potentially decreasing 
study duration. The ability of these candidate biomarkers to discriminate AD from other 
causes of dementia needs to be examined as well. Indeed, plans are already underway 
to obtain CSF from other conditions for such an analysis. Many of these proteins have 
not been investigated in relation to AD, and their possible roles in the disease 
pathophysiology will be of interest in future studies.  
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Chapter 7. Conclusions and Future Directions 
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